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INTRODUCTION
Adult idiopathic nephrotic syndrome
Nephrotic syndrome is caused by diseases that disrupt the normal permselectivity of the 
glomerular filtration barrier. It is clinically defined as proteinuria >3.5 grams per 24 hours 
plus hypo-albuminemia and edema (1). Potential complications include renal failure, bacterial 
infections and venous or arterial thrombosis. The term idiopathic nephrotic syndrome (iNS) 
has been used to describe nephrotic syndrome caused by glomerular disorders without evidence 
of inflammation or abnormal protein deposition, and no underlying systemic disorders. The 
histopathological diagnosis guides further work-up and treatment of adult patients with iNS, 
and therefore a kidney biopsy should be obtained whenever possible. Three main histological 
patterns of glomerular injury are associated with iNS: minimal change disease (MCD), focal 
segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). A common finding 
among the respective patterns is diffuse effacement of the podocyte foot processes, suggesting a 
pivotal role of podocyte damage in the pathogenesis of iNS.
Minimal change disease
MCD is the most common cause of iNS in children. In adults, it accounts for 15-20% of cases 
with iNS. On kidney biopsy, there is no evidence of sclerosis, inflammation, or immune deposits. 
Glomerular changes consist of podocyte foot process effacement, only notable in electron 
microscopy. 
The pathogenesis of MCD remains unresolved. In 1974 Shalhoub proposed that the cause of MCD 
was related to T cell abnormalities, which resulted in the secretion of a circulating permeability 
factor that damages podocytes (2). The evidence supporting a role for T cells in the development 
of MCD included the association with non-Hodgkin lymphoma and atopy, the development of a 
remission after measles infection and induction of remission by immunosuppressive agents that 
inhibited T cell function (described below). The concept of a permeability factor produced by T 
cells was fostered by studies showing that injection of supernatants of cultured peripheral blood 
mononuclear cells, T cells or T cell hybridomas from patients with MCD in relapse induced 
proteinuria and foot process effacement in rats (3). Despite extensive research, the putative 
permeability factor responsible for MCD has not been identified. Candidates included an 
unidentified anionic 150 kDa protein, altered isoforms of plasma hemopexin, and several cytokines 
(4). However, no candidate has been definitively validated as the causative factor. Of note, a 
potential role of B cells in the pathogenesis of MCD was supported by studies demonstrating 
efficacy of B cell-depleting agent rituximab (5, 6). It has been speculated that rituximab may act 
through effects on T cell properties (7, 8). Alternatively, the putative mechanism may involve a 
direct effect on podocytes (9).  
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MCD is characterized by heavy proteinuria. The onset of nephrotic syndrome may be accompanied 
by acute kidney injury, sometimes necessitating temporary renal replacement therapy. High-dose 
oral prednisone is commonly used as first-line treatment (1). This treatment strategy is mainly 
based on data obtained in children with iNS. It is well established that childhood-onset iNS, 
typically associated with MCD on kidney biopsy, responds to high-dose prednisone therapy with 
complete remission of proteinuria being attained in the majority of patients after 4 weeks of 
treatment (10, 11). Only two small randomized controlled trials have compared the efficacy of 
prednisone to symptomatic treatment in adult-onset MCD. These studies showed that prednisone 
generally reduced proteinuria to levels <1g/24 hours within two months (12, 13). After two 
years of follow-up, most patients who received symptomatic treatment also reached proteinuria 
<1 gram/24h. However, a significant number of these patients needed rescue treatment with 
prednisone because of disease-related complications. Observational studies in adult-onset 
MCD have suggested that up to 16 weeks of high-dose prednisone may be needed to induce 
complete proteinuria remission (14-16). Presenting characteristics of adult-onset MCD have not 
been well described. An increased risk of acute kidney injury has been reported, but definitions 
varied among studies (14-16). In addition, little is known with regard to relapse patterns and 
efficacy of second-line agents. Guidelines have suggested treatment with cyclophosphamide and 
cyclosporine, which is again largely based on studies performed in children (17-19). Finally, long-
term complications and outcome of adult-onset MCD have been poorly defined.  
Focal segmental glomerulosclerosis
FSGS was first described in an autopsy series of patients with suspected iNS who died of infection 
or uremia (20). The FSGS lesion was defined as a sclerotic segment of the glomerular tuft, and was 
preferentially localized in juxtamedullary glomeruli. Over the years, “idiopathic FSGS” became 
a broader term for a diversity of sclerotic and non-sclerotic morphological lesions observed in 
kidney biopsies of patients with iNS. Other conditions associated with podocyte damage might 
display similar lesions and were collectively termed “secondary FSGS” (21). Mutations in 
podocyte-associated genes have been clearly identified as potential causes of FSGS. Patients with 
adult-onset familial FSGS mostly have autosomal dominant inheritance, caused by mutations 
in TRPC6, ACTN4, INF2, ANLN or other yet unidentified genes (22-25). In many cases, these 
patients have proteinuria without full nephrotic syndrome. It has been reported that genetic 
causes are rare in adults with sporadic FSGS (26-28). An exception may be the young adults (aged 
18-25 years) with steroid-resistant FSGS who were recently shown to have a single-gene cause in 
>20% of cases (29). Patients with genetic FSGS are resistant to corticosteroid treatment but may 
have partial response to cyclosporine in some cases (30-32). The response to cyclosporine may be 
related to direct podocyte-stabilizing effects of the drug (33).     
The pathogenesis of idiopathic FSGS likely involves one or more circulating factors that cause 
podocyte dysfunction and proteinuria. The best evidence for the existence of permeability factors 
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in patients with idiopathic FSGS are the high incidence of proteinuria recurrence early after 
kidney transplantation, and the induction of proteinuria remission by plasma exchange or immune 
absorption (34, 35). Experimental evidence also supports the existence of permeability factors. 
Serum from a patient with recurrent FSGS induced proteinuria in rats (36). Further research was 
stimulated by the development of an in vitro model using osmotic swelling of isolated glomeruli 
as parameter of glomerular permeability (37). This model provided compelling experimental 
evidence for the presence of circulating permeability factors, because (i) plasma from patients 
with documented recurrent FSGS but not controls increased glomerular albumin permeability, 
(ii) there was a clear relationship between serum permeability activity and the risk of recurrent 
FSGS after transplantation, and (iii) the reduction of proteinuria by plasmapheresis was paralleled 
by a decrease in the permeability activity in serum, and the permeability activity could be 
detected in the plasmapheresis fluid. In subsequent studies the glomerular permeability model 
was used in experiments directed at enrichment of the causative factor by various techniques (38). 
In a preliminary report cardiotrophin-like cytokine 1 was presented as the responsible factor (39). 
Unfortunately, this has not been followed by a published manuscript, and the finding has not 
been replicated or validated.
Recently, investigators have also tried to identify permeability factors using more hypothesis-
driven approaches, based on increasing knowledge of podocyte molecular biology. This has led 
to the claim that the soluble urokinase plasminogen activator receptor (suPAR) was a cause of 
FSGS (40). 
In the absence of validated disease-specific biomarkers, proteinuria and renal function at 
presentation remain important predictors of outcome in FSGS. Massive proteinuria at presentation 
(>10 gram per day) is associated with progression to end-stage renal disease within years (41). 
Conversely, long-term renal outcome is excellent in patients who enter complete proteinuria 
remission, and is also improved when partial remission is achieved (42). Immunosuppressive 
treatment offers the best chance to reach proteinuria remission. Prednisone is still considered 
first line therapy based on observational studies showing remission rates averaging 50%. Of 
note, median time to remission was 3-4 months, and treatment should be continued for up to 
6 months before defining non-responsiveness (43, 44). Patients with FSGS who relapse after 
prednisone-induced remission are treated as patients with MCD. Treatment of steroid-resistant 
FSGS is challenging. Two randomized controlled trials support efficacy of cyclosporine with low-
dose steroids. Overall 60-70% of patients responded mostly with partial remissions before 26 
weeks, but approximately 60% of these patients had relapsed by 72 weeks. Relapse occurred 
especially after treatment withdrawal (45, 46). One of the trials compared cyclosporine with 
mycophenolate and dexamethasone and found remission rates of 45% and 33% at 52 weeks, 
respectively. The difference was not significant, potentially because the study was underpowered 
(46). Given these poor results, clinicians should carefully weigh the benefit of proteinuria remission 
against potential treatment-related toxicity before proceeding with further immunosuppressive 
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treatment in patients with steroid-resistant FSGS. One of the most feared problems in the care 
of these patients is the high risk of disease recurrence after kidney transplantation. Although 
plasmapheresis therapy is effective, many patients do not respond with persistent remission. 
Membranous nephropathy
MN is the most common cause of adult-onset iNS in Caucasian adults (47). On kidney biopsy, 
MN is characterized by subepithelial deposits along the basement membrane. In early disease 
stages these deposits can only be identified by immunofluorescence microscopy and electron 
microscopy. In advanced stages the deposits form spike-like protrusions of the basement 
membrane visible on light microscopy. The presence of immune deposits in MN suggested that 
the disease was mediated by an immune response against constituents of the glomerular capillary 
filter. Already in 1959 an experimental model of MN was established by the immunization of 
rats with kidney extracts. Injury was caused by antibodies that were directed against podocyte-
associated megalin (48). Fifty years later, the phospholipase A2 receptor (PLA2R) expressed by 
podocytes was identified as a major antigenic target in patients with MN (49). Antibodies against 
PLA2R were specifically associated with idiopathic MN, and not with established secondary 
forms of MN. Furthermore, presence of antibodies correlated with disease activity (50). The 
discovery of PLA2R antibodies has proven that idiopathic MN is in fact an auto-immune disease 
of the podocyte. 
Without therapy nearly 50% of patients with MN will enter remission, whereas the other half will 
develop progressive disease (51). Three randomized controlled trials have proven that a combination 
of cytotoxic agents (cyclophosphamide or chlorambucil) and corticosteroids results in improved 
renal outcome compared to standard anti-proteinuric treatment (52-54). However, two trials 
included patients with well-preserved renal function who might have reached remission without 
immunosuppressive treatment. A restrictive treatment strategy that limited immunosuppressive 
drugs to patients with high risk of renal failure resulted in similar remission rates and good 
renal outcome (55, 56). Using this strategy, patients may have persistent nephrotic syndrome for 
several years. Moreover, second-line treatment with calcineurin inhibitors or rituximab may be 
more difficult or less effective in patients with established renal insufficiency. Ideally, treatment 
should be started early in patients who will otherwise progress to end-stage renal disease. Two 
models for the prediction of disease progression have been developed over the years. One model 
was based on the identification of tubulo-interstitial damage as a predictor of progression (57). 
Alpha-1-microglobulin and beta-2-microglobulin are urinary markers of tubulo-interstitial 
dysfunction and have been validated as early noninvasive markers of progression (51). The other 
model was based on repeated measurement of creatinine clearance and sustained proteinuria over 
a period of at least 6 months (58). Both models had similar prognostic accuracy with areas under 
the receiver operating characteristics curve of approximately 0.80 (59).   
Introduction and outline of the thesis  |  13 
1
OUTLINE OF THE THESIS
Aim of the thesis was to investigate prognosis, biomarkers and outcome in patients with iNS, 
with an emphasis on the adult population. 
According to the literature 15-52% of patients with FSGS who receive a first kidney transplant 
develop post-transplant disease recurrence. This wide variation in reported recurrence risk suggests 
that different inclusion criteria may have been used. Several clinical characteristics associated 
with post-transplant disease recurrence have been reported. Among these characteristics are rapid 
progression to end-stage renal disease, a young recipient age, and previous bilateral nephrectomy. 
These characteristics have not been validated, and their contribution to the risk of recurrence in 
individual patients has not been established. In Chapter 2, we describe a retrospective study of 
all patients with biopsy-proven FSGS who received a kidney transplant in our center to identify 
risk factors for recurrent FSGS. We used strict criteria to differentiate patients with idiopathic 
and secondary FSGS. In addition, we analyzed other clinical characteristics associated with 
recurrence risk.
In 2004, a pathological classification was introduced to standardize the morphological description 
of FSGS (60). The classification described five mutually exclusive variants, defined as collapsing, 
cellular, tip, perihilar, and not otherwise specified. The clinical usefulness of the classification 
was supported by confirmation of the morphological variants as independent predictors of 
outcome in idiopathic FSGS (61, 62). It has been hypothesized that the morphological variants 
reflect different underlying etiological factors in idiopathic FSGS. In Chapter 3 we tested this 
hypothesis by comparing FSGS morphological lesions in native kidneys and kidney grafts of 
patients with FSGS who develop post-transplant disease recurrence. In addition, we studied the 
evolution of the glomerular lesions in repeated biopsies.
The identification of suPAR as a potential new permeability factor and diagnostic marker in FSGS 
was welcomed as a scientific breakthrough and received great attention (40, 63). The same group 
of investigators had previously demonstrated that the membrane-bound urokinase plasminogen 
activator receptor (uPAR) on podocytes is involved in the development of proteinuria and 
FSGS through activation of β3-integrin signaling (64). Further studies addressed the inferred 
hypothesis that suPAR was involved in the pathogenesis of proteinuria (40). Indeed, animal 
studies demonstrated that suPAR caused proteinuria, while in vitro studies showed that sera from 
post-transplant recurrent FSGS patients increased β3-integrin activation. The latter was blocked 
by antibodies against uPAR and a β3-integrin inhibitor. The pathogenic role of suPAR in FSGS 
was further supported by human data, demonstrating significantly increased serum suPAR 
levels in FSGS patients compared to healthy and disease controls. From these experiments, it 
was concluded that suPAR was a circulating factor causing FSGS. However, the experimental 
models could not be validated, and the clinical studies were biased. In Chapter 4, we tested 
serum suPAR concentration as a diagnostic marker of idiopathic FSGS, and as a marker of post-
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transplant FSGS recurrence. In Chapter 5, we compared serum suPAR levels in patients with 
idiopathic FSGS to controls across different chronic kidney disease stages to identify potential 
estimated glomerular filtration rate-specific levels of suPAR diagnostic for idiopathic FSGS. In 
Chapter 6, we reviewed the established role of suPAR in experimental and human diseases, 
and specifically addressed problems with regard to its assigned role in FSGS. In Chapter 7 we 
reviewed the historical and present approaches to the search for circulating permeability factors 
in MCD and FSGS. In addition, we defined criteria for the validation of new permeability factors. 
Although MCD is a cause of iNS in a significant number of adults, few studies have addressed 
its clinical course, complications and outcome. We performed a retrospective study of MCD 
including a large cohort of patients treated in 10 Dutch centers (Chapter 8).
The choice when and how to start immunosuppressive treatment in patients with MN remains 
an area of debate. In Chapter 9 we summarized the evidence supporting various forms of 
immunosuppressive treatment in MN and proposed an individualized treatment strategy. As 
outlined above, current models predict progressive renal failure in MN with reasonable accuracy. 
It has been shown that repeated measurement of alpha-1-microglobulin during follow-up 
improves outcome prediction (51). Kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-
associated lipocalin (NGAL) are considered early and specific urinary markers of tubular 
damage. We hypothesized that measurement of these early markers might allow improved risk 
stratification in MN. We measured KIM-1 and NGAL in a cohort of patients with MN. The 
results are presented in Chapter 10.  
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ABSTRACT
Background: Focal segmental glomerulosclerosis (FSGS) is a frequent cause of end-stage renal 
disease. Renal transplantation in patients with FSGS is often complicated by disease recurrence, 
which is associated with poor outcome. There are no tests that reliably predict recurrence of FSGS 
after transplantation. The aim of this study was to evaluate if clinical criteria can identify patients 
at high risk for recurrent disease. 
Methods: We retrospectively studied 94 patients who received a first renal transplant at a median 
age of 37 years (range 5-69 years). Patients were assigned to one of three groups: familial or 
genetic FSGS (group I; n=18), secondary FSGS (group II; n=10) and idiopathic FSGS (group 
III; n=66). Pre-transplant clinical characteristics were analyzed to determine predictors of a 
recurrence after transplantation. 
Results: FSGS only recurred in patients with idiopathic FSGS (group III; 42%). Patients with 
a recurrence had a significantly lower serum albumin, higher 24-hour proteinuria and higher 
estimated glomerular filtration rate at diagnosis. Serum albumin at diagnosis was the only 
independent predictor of a recurrence in patients with idiopathic FSGS. Patients with recurrent 
FSGS had more acute rejection episodes (54% vs. 27%, P =0.02) and lower five-year graft survival 
compared to patients without a recurrence (50 vs. 82%, P <0.01). 
Conclusions: Clinical criteria allow identification of patients at high risk of recurrent FSGS 
after renal transplantation. This information can be used in the counseling and management of 
patients with FSGS. 
Prediction of post-transplant FSGS recurrence by clinical criteria  |  21 
2
BACKGROUND
Focal segmental glomerulosclerosis (FSGS) is a histological diagnosis and not a single disease 
entity. FSGS can occur at any age and presenting features include a variable degree of proteinuria, 
microscopic hematuria, hypertension and decreased glomerular filtration rate. While numerous 
causes for FSGS have been identified, still most patients are diagnosed with idiopathic FSGS 
(1, 2). Progression to end-stage renal disease (ESRD) is common, especially in patients with 
decreased glomerular filtration rate or nephrotic range proteinuria at presentation (1). In case of 
ESRD, renal transplantation is usually the treatment of choice. After renal transplantation, FSGS 
is reported to recur in 15-52% of first grafts (3-10). Significant proteinuria often progressing to 
nephrotic range proteinuria in the first days after transplantation heralds a recurrence in virtually 
all patients (11). Graft biopsy may either disclose normal glomeruli or typical FSGS lesions on 
light microscopy, and effacement of the epithelial foot processes on electron microscopy (12, 13). 
Without treatment, recurrent FSGS leads to early graft failure in more than 50% of patients (14, 
15). There is strong evidence that a circulating permeability factor is responsible for glomerular 
injury in many patients with recurrent FSGS after transplantation (16, 17). The suggestion of a 
circulating permeability factor has led to the use of plasma exchange for the treatment of recurrent 
FSGS. When initiated early after onset of proteinuria, plasma exchange can induce a remission of 
proteinuria and portends a better prognosis (18, 19). Therefore, accurate identification of patients 
at risk for recurrent FSGS is an important issue. 
We report a retrospective analysis of all patients with FSGS, who received a first renal transplant 
in our center. The purpose of the study was to define clinical criteria which would allow to 
identify patients at high risk for recurrent disease during pre-transplant counseling. 
METHODS
We identified all patients with FSGS who received a first renal transplant in our center in the 
period 1968-2009. Patients were included if the diagnosis of FSGS was confirmed on a native 
renal biopsy or if they had otherwise unexplained proteinuria and a first-degree relative with 
biopsy-proven FSGS. Patients with FSGS lesions secondary to other glomerular diseases including 
IgA nephropathy, membranous nephropathy and Alport disease were excluded.
For the purpose of the study, the medical records and pathology reports were reviewed. The 
Hospital Research Ethics Committee deemed formal committee review of the study unnecessary. 
Data collection was performed according to the Dutch Code of Conduct for Health Research.
Patients were assigned to one of three groups: Group I: patients with a first-degree relative with 
FSGS and/or identified gene mutations that cause FSGS. Group II: patients with secondary FSGS 
based on previously published criteria (with exclusion of cases assigned to group I) (1). Group III: 
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patients without evidence of genetic or secondary FSGS. This group is referred to as idiopathic 
FSGS. Assignment to a group was done without knowledge of transplantation outcome.
Definitions
Date of onset of FSGS in native kidneys was defined as date of first presentation. Date of diagnosis 
was recorded as biopsy date. Glomerular filtration rate was estimated with the abbreviated 
MDRD study equation in adults and the Schwartz formula in children (age < 16 years) (20, 
21). Definite recurrence of FSGS was defined as the occurrence of progressive proteinuria after 
transplantation, with 1) evidence of FSGS on light microscopy or 2) normal appearing glomeruli 
on light microscopy, but foot process effacement on electron microscopy. A probable recurrence 
was defined as proteinuria with normal glomeruli on light microscopy and no electron microscopy 
performed. Acute antibody mediated rejection has been described as a possible cause of early 
heavy post-transplant proteinuria (22). Any histologic signs of antibody-mediated rejection were 
therefore recorded. Delayed graft function was defined as need for dialysis within the first week 
after transplantation.
Statistical analysis
Values were expressed as median with range or mean ± SD. Statistical differences between groups 
were assessed with Chi-square or Fisher exact test, unpaired Student’s t test or Mann Whitney 
U test, where appropriate. We used a binary probit model to identify independent predictors 
of recurrent FSGS (23). To improve the validity of multivariate data analyses, 100 data sets 
were created with imputed values for albumin, 24-hour proteinuria and estimated glomerular 
filtration rate (eGFR) using Stata’s ice procedure (24). Ordinary least squares regression analysis 
was used to impute missing values. This model included age, gender, eGFR, proteinuria, serum 
albumin, and recurrence after transplantation (25). The association between predictor and 
imputed variables were assumed to be linear, no interactions were included as effect modification 
was deemed unlikely to be present in the final analysis. Kaplan–Meier curves and log-rank tests 
were used for description and comparison of graft survival. A two-sided P-value <0.05 was 
considered as the level of statistical significance for all tests. The analyses were performed with 
the use of SPSS 16.0 for Windows (SPSS inc, Chicago, IL, USA) and Stata 10 for Windows (Stata 
Corporation, Texas, USA). 
RESULTS
Baseline characteristics
We identified 94 patients with FSGS who received a first renal transplant. In 92 patients, the 
diagnosis was proven by renal biopsy. In addition, in two patients the diagnosis FSGS was based 
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on the presence of proteinuria and the family history of a first-degree relative with biopsy-proven 
FSGS. Baseline characteristics are shown in Table 1. Eighty-five patients were native Dutch. The 
remaining patients were Turkish (n=3), Moroccan (n=1), Dutch Antillian (n=1), Sri Lankan (n=1), 
Indonesian (n=1), Iranian (n=1) and Somalian (n=1). Thirty-two patients were younger than 16 
years at onset of FSGS. Eighteen patients were diagnosed with familial/genetic FSGS (group I). 
Mutations were identified in four of them. One patient had a three-allelic mutation (compound 
heterozygous mutations in the NPHS2-gene and one mutation in the NPHS1-gene), two related 
patients had homozygous mutations in the NPHS2-gene and one patient had a mutation in the 
WT1-gene. A secondary cause was identified in 10 patients (group II): renal agenesis (n=3), 
traumatic kidney injury (n=1), hypoplasia of one kidney (n=1), reflux nephropathy (n=2), chronic 
pyelonephritis (n=1), a history of intravenous heroin abuse (n=1), and Hajdu-Cheney syndrome 
(n=1) (26). Idiopathic FSGS was diagnosed in 66 patients (group III). 
A diagnosis of FSGS was made at a median of 6.0 years (0.3-36.9 years) before renal transplantation. 
Patients were on dialysis for a median of 1.4 years (0-9.3 years) before transplantation. Bilateral 
nephrectomy was performed before transplantation in six patients, all were children. Four patients 
underwent pre-emptive renal transplantation. 
Recurrence after renal transplantation
FSGS recurred in 28 patients (30%; Table 1). Twenty-four patients had a definite recurrence 
of FSGS and four patients had a probable recurrence. Typical FSGS lesions were seen in light 
microscopy in biopsies of 11 patients. In none of the patients there was evidence of acute transplant 
glomerulopathy. Peritubular capillary C4d staining was performed in biopsies of six patients 
with a recurrence, and all were negative. Three probable recurrences occurred within the first 
month after transplantation, and all had nephrotic range proteinuria. All recurrences occurred in 
patients with idiopathic FSGS (group III; P <0.01). Median amount of proteinuria at the time of 
graft biopsy in patients with a recurrence was 5.0 g/24 hours (interquartile range 3.6-6.9 g/24 
hours). The median time to recurrence was 6 days (0-2082 days) after transplantation. In two 
patients the diagnosis of recurrence was made more than six months after renal transplantation. 
The first patient, a 32-year old woman, had a probable recurrence more than five years after 
transplantation after cyclosporine monotherapy was replaced by azathioprine and prednisone 
because of cyclosporine toxicity. Shortly thereafter massive proteinuria occurred. Initiation 
of plasma exchange led to a remission of proteinuria, however prolonged plasma exchange 
was necessary to sustain the remission of proteinuria. The other late recurrence was a definite 
recurrence which occurred four years after transplantation in an 18 year-old patient. No inciting 
event was found. He was treated with ACE-inhibitors and had only slight proteinuria and a 
reasonable graft function after a follow-up of 17 years. 
24  |  Chapter 2
T
ab
le
 1
. B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
of
 p
at
ie
nt
s 
w
it
h 
FS
G
S 
an
d 
co
m
pa
ri
so
n 
of
 b
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
be
tw
ee
n 
pa
ti
en
ts
 w
it
h 
an
d 
w
it
ho
ut
 F
SG
S 
re
cu
rr
en
ce
To
ta
l p
op
ul
at
io
n 
(n
=
94
)
R
ec
ur
re
nc
e
(n
=
28
)
N
o 
re
cu
rr
en
ce
(n
=
66
)
P
-v
al
ue
 (d
if
fe
re
nc
e 
re
cu
rr
en
ce
 
vs
. n
o 
re
cu
rr
en
ce
 g
ro
up
)
Se
x 
(M
/F
)
51
/4
3 
16
/1
2
35
/3
1
0.
82
A
ge
 a
t 
on
se
t 
(y
r)
26
 (1
-6
1)
19
 (4
-5
7)
26
 (1
-6
1)
0.
63
A
ge
 a
t 
di
ag
no
si
s 
(y
r)
*
28
 (2
-6
2)
23
 (5
-5
7)
29
 (2
-6
2)
0.
25
Se
ru
m
 a
lb
um
in
 a
t 
di
ag
no
si
s 
(g
/L
)
27
 ±
 1
1
(n
=
60
)
20
 ±
 9
(n
=
20
)
31
 ±
 1
0
(n
=
 4
0)
<
0.
01
24
-h
ou
r 
pr
ot
ei
n 
ex
re
ti
on
 (g
)
8.
0 
±
 7
.3
(n
=
42
)
11
.7
 ±
 8
.8
(n
=
15
)
5.
9 
±
 5
.5
(n
=
27
)
0.
01
eG
FR
 a
t 
di
ag
no
si
s†
 (m
L/
m
in
/1
.7
3m
2 )
81
 ±
 5
3
(n
=
63
)
10
4 
±
 5
0
(n
=
21
)
69
 ±
 5
1
(n
=
42
)
0.
01
C
au
se
 o
f F
SG
S
F
am
il
ia
l/
ge
ne
ti
c F
SG
S 
(g
ro
up
 I
)
18
 (1
9%
)
0
18
<
0.
01
Se
co
nd
ar
y 
F
SG
S 
(g
ro
up
 I
I)
10
 (1
1%
)
0
10
Id
io
pa
th
ic
 F
SG
S 
(g
ro
up
 I
II
)
66
 (7
0%
)
28
38
B
il
at
er
al
 n
ep
hr
ec
to
m
y 
be
fo
re
 t
ra
ns
pl
an
ta
ti
on
 
6
1
5
0.
67
In
te
rv
al
 o
ns
et
 t
o 
di
ag
no
si
s*
 (y
r)
0.
5 
(0
-3
1)
0.
3 
(0
-6
.9
)
0.
8 
(0
-3
1.
0)
0.
07
In
te
rv
al
 d
ia
gn
os
is
 t
o 
E
SR
D
 (y
r)
3.
9 
(0
.1
-3
2.
4)
4.
9 
(0
.1
-1
6.
8)
3.
7 
(0
.1
-3
2.
4)
0.
96
In
te
rv
al
 E
SR
D
 t
o 
tr
an
sp
la
nt
at
io
n
1.
4 
(0
-9
.3
)
1.
2 
(0
-4
.7
)
1.
4 
(0
-9
.3
)
0.
53
A
ge
 a
t 
tr
an
sp
la
nt
at
io
n 
(y
r)
37
 (5
-6
9)
32
 (1
0-
62
)
38
 (5
-6
9)
0.
17
D
on
or
D
ec
ea
se
d
75
24
51
0.
57
Li
vi
ng
 u
nr
el
at
ed
7
1
6
Li
vi
ng
 r
el
at
ed
12
3
9
D
on
or
 a
ge
 (y
r)
35
.5
 (0
-6
8)
36
.5
 (5
-6
4)
35
.5
 (0
-6
8)
0.
91
N
um
be
r 
of
 H
LA
 m
is
m
at
ch
es
2.
0 
±
 1
.2
2.
0 
±
 1
.2
2.
0 
±
 1
.2
0.
77
In
it
ia
l 
im
m
un
os
up
pr
es
si
ve
 
re
gi
m
en
P
 +
 C
sA
54
18
36
0.
38
P
 +
 A
za
11
5
6
P
 +
 C
sA
 +
 M
M
F
13
2
11
P
 +
 t
ac
ro
 +
 M
M
F
14
3
11
D
ac
l +
 t
ac
ro
 +
 M
M
F
2
0
2
D
at
a 
ar
e 
gi
ve
n 
as
 n
(%
), 
m
ea
ns
 ±
 S
D
 o
r 
m
ed
ia
n 
(r
an
ge
).
*a
ge
 a
t d
ia
gn
os
is
 is
 b
as
ed
 o
n 
bi
op
sy
 d
at
e.
 T
w
o 
pa
ti
en
ts
 w
it
h 
fa
m
il
ia
l F
SG
S 
w
er
e 
no
t b
io
ps
ie
d.
 F
or
 th
es
e 
pa
ti
en
ts
, a
ge
 a
t d
ia
gn
os
is
 e
qu
al
s a
ge
 o
f fi
rs
t p
re
se
nt
at
io
n
†e
G
FR
 w
as
 c
al
cu
la
te
d 
w
it
h 
th
e 
ab
br
ev
ia
te
d 
M
D
R
D
 s
tu
dy
 e
qu
at
io
n 
in
 a
du
lt
s 
an
d 
w
it
h 
Sc
hw
ar
tz
’ f
or
m
ul
a 
in
 c
hi
ld
re
n
P,
 p
re
dn
is
on
e;
 C
sA
, 
cy
cl
os
po
ri
ne
; 
A
za
, 
az
at
hi
op
ri
ne
; 
M
M
F,
 m
yc
op
he
no
la
te
 m
of
et
il
; 
Ta
cr
o,
 t
ac
ro
li
m
us
; 
D
ac
l, 
da
cl
iz
um
ab
; 
eG
FR
, 
es
ti
m
at
ed
 g
lo
m
er
ul
ar
 
fil
tr
at
io
n 
ra
te
; E
SR
D
, e
nd
-s
ta
ge
 r
en
al
 d
is
ea
se
.
Prediction of post-transplant FSGS recurrence by clinical criteria  |  25 
2
Compared to patients without a recurrence, delayed graft function occurred more often in patients 
with recurrent FSGS, although this difference did not reach statistical significance (25% vs. 12%, 
P =0.13). Patients with recurrent FSGS had significantly more biopsy-proven acute rejection 
episodes (54% vs. 27%, P =0.02). There were no significant differences in HLA-mismatches 
and immunosuppressive regimens. Graft survival at five years was significantly lower in patients 
with recurrent FSGS compared to patients without a recurrence (50% vs. 82%; P <0.01). Plasma 
exchange for the treatment of recurrent FSGS was introduced in 1994. We have previously shown 
an improved outcome in patients treated with plasma exchange compared to historical controls 
(18). In the current study nine out of 28 patients with recurrences were treated with plasma 
exchange. 
Clinical prediction of recurrent FSGS
To determine clinical factors associated with FSGS recurrence, we compared baseline characteristics 
of patients in group III with and without a recurrence of FSGS (Table 2). Patients with familial 
or secondary FSGS were excluded because a recurrence did not occur in these patient groups. 
Patients with a recurrence had a significantly lower serum albumin, higher 24-hour proteinuria 
and higher eGFR at diagnosis (Table 2). They also had a shorter interval between presentation 
and renal biopsy than patients without a recurrence. The interval between first renal biopsy and 
ESRD did not differ significantly between patients with and without a recurrence, nor did age at 
diagnosis and donor age.
Serum albumin, eGFR and 24-hour proteinuria were analyzed as predictors in the binary probit 
model. Because there was significant multicollinearity between albumin and 24-hour proteinuria, 
these parameters were analyzed separately with eGFR. In the complete case analysis of eGFR and 
serum albumin (n=39), serum albumin was an independent predictor with a relative risk of 
0.93 per incremental g/L (95% confidence interval 0.88-0.98). In the complete case analysis of 
eGFR and 24-hour proteinuria (n=26), 24-hour proteinuria was a significant predictor with a 
relative risk of 1.36 per incremental g/24 hours (95% confidence interval 1.05-1.77). eGFR was 
a significant but weak predictor in the complete case analysis. After imputation serum albumin 
was the only independent predictor of a recurrence with a relative risk 0.92 per incremental g/L 
(95% confidence interval 0.88-0.96). 
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Table 2. Demographic and transplant-related factors, and laboratory results at diagnosis in patients with 
idiopathic FSGS (group III) with and without a recurrence
Recurrence No recurrence P-value
n 28 38
Sex (M/F) 16/12 24/14 0.80
Age at presentation (yr) 19 (4-57) 28 (1-61) 0.45
Age at diagnosis (yr) 23 (5-57) 34 (2-61) 0.13
Body mass index at diagnosis in patients >16 years 
(n=48)
24.6 ± 3.6
(n=12)
25.0 ± 3.5
(n=26)
0.76
eGFR at diagnosis (mL/min/1.73m2) 104 ± 50
(n=21) 
53 ± 22
(n=22)
<0.01
Serum albumin at diagnosis (g/L) 20 ± 9 
(n=20)
33 ± 10
(n=24)
<0.01
24-hour protein excretion (g) 11.7 ± 8.8
(n=15)
4.6 ± 2.7
(n=14)
<0.01
Interval onset to diagnosis (yr) 0.3 (0-6.9) 1.0 (0-22) <0.01
Interval diagnosis to ESRD (yr) 4.9 (0.1-16.8) 3.7 (0.2-32.4) 0.96
Interval ESRD to transplantation (yr) 1.2 (0-4.7) 1.5 (0-9.3) 0.34
Age at transplantation (yr) 32 (10-62) 44 (5-68) 0.06
Donor age (yr) 36.5 (5-64) 38 (0-68) 0.60
Number of HLA mismatches 2.0 ± 1.2 2.1 ± 1.2 0.81
Donor source (n) Deceased 24 27 0.35
Living unrelated 1 4
Living related 3 7
Baseline immunosuppressive 
regimen (n)
P, CsA 18 23 0.64
P, Aza 5 4
P, CsA, MMF 2 2
P, tacro, MMF 3 8
Dacl, tacro, MMF 0 1
Data are given as n(%), means ±SD or median (range).
P, prednisone; CsA, cyclosporine; Aza, azathioprine; MMF, mycophenolate mofetil; Tacro, tacrolimus; Dacl, 
daclizumab; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
The percentage of recurrences by serum albumin level at diagnosis in the idiopathic FSGS group 
is shown in Table 3. The ROC curve for the predictive value of serum albumin at diagnosis for 
FSGS recurrence is shown in Figure 1.
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Table 3. Recurrence rates in patients with idiopathic FSGS according to serum albumin concentration at 
diagnosis
Serum albumin (g/L) Number of cases Patients with recurrences (%)
>35 12 0
25-35 14 6 (43%)
<25 18 14 (78%)
Missing 22 8 (36%)
Figure 1. ROC curve of the predictive value of serum albumin at diagnosis for focal segmental 
glomerulosclerosis (FSGS) recurrence after renal transplantation.
AUC 0.87 (0.75-0.97); P <0.0001
DISCUSSION
Many factors have been associated with recurrence of FSGS after renal transplantation, including 
a young age at diagnosis, a rapid progression to ESRD, loss of a previous renal graft from 
recurrent disease, and prior bilateral nephrectomy (3, 4, 6, 15, 27). Except for recurrence in 
a previous graft none of these factors is highly predictive in an individual patient (28). Since 
recurrent FSGS has been associated with a circulating plasma factor, in vitro determination of 
plasma factor(s) that induce permeability to albumin in isolated glomeruli has also been used to 
predict recurrence (6, 16). Although initial reports showed good correlations between in vitro 
tests and recurrent disease in renal grafts, later studies reported less robust correlations and less 
specificity (29). Recently, Wei et al. have described the soluble urokinase plasminogen activator 
receptor (suPAR) as a circulating factor that may cause FSGS (17). They reported that higher 
concentrations of suPAR before transplantation are associated with an increased risk for recurrence 
after transplantation. However, there was a large degree of overlap between pre-transplant suPAR 
in patients with recurrent and non-recurrent FSGS. We have recently shown that suPAR is not 
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a specific marker for idiopathic FSGS (30). In the absence of a reliable diagnostic test that can 
predict FSGS recurrence after transplantation, we evaluated whether clinical criteria can improve 
pre-transplant risk assessment.
In our study FSGS recurred only in patients assigned to group III (idiopathic FSGS). In this group 
recurrence rate was 42%. The lower recurrence rate reported in many studies may be related to 
inclusion of patients with secondary/genetic FSGS (3-5, 9). Except for patients with congenital 
nephrotic syndrome (NPSH1) in which anti-nephrin antibodies may be involved, FSGS rarely 
recurs in patients with genetic FSGS (31, 32). With the identification of mutations in podocyte-
associated genes it has become apparent that an increasing number of patients originally thought 
to have idiopathic FSGS, actually have a form of genetic FSGS (2). In children with FSGS, genetic 
testing strategy in our center has involved sequential testing for all mutations known at the 
time. Most children in this cohort received a transplant before any FSGS-associated mutations 
were identified. In adult-onset sporadic FSGS, most of the currently known FSGS-associated 
mutations are rare (33). Still, we cannot exclude the possibility that some patients assigned to our 
group III in fact had an unidentified gene mutation.
In the early phase of recurrent FSGS after transplantation, glomeruli often appear normal on 
light microscopy, but display diffuse foot process effacement on electron microscopy. We used a 
definition of a probable recurrence if glomeruli appeared normal but electron microscopy was not 
performed. Nevertheless, recurrent FSGS was in fact the most likely diagnosis in these cases, as all 
patients had nephrotic-range proteinuria. Moreover, previous studies have used similar definitions 
(13). Although acute antibody-mediated rejection can cause post-transplant proteinuria, we 
consider this an unlikely event. There was no evidence of acute transplant glomerulopathy in 
light microscopy, and in available biopsies C4d stainings were negative.  
Risk factor analysis using a binary probit model identified serum albumin at diagnosis as an 
independent predictor of recurrence. In patients with idiopathic FSGS (group III) and a serum 
albumin <25 g/L at diagnosis recurrence rate was high (78%), whereas FSGS did not recur in 
patients with a normal serum albumin (>35 g/L) at diagnosis. This finding supports the present 
notion among many clinicians that a more severe nephrotic syndrome in patients with FSGS is 
associated with a higher recurrence risk. To our knowledge, this is the first study to demonstrate 
the predictive value of serum albumin at diagnosis in recurrent FSGS. This is likely due to the 
fact that previous studies have never reported pre-transplant serum albumin. 
Admittedly, serum albumin was not available in 22 patients with idiopathic FSGS which may 
have biased results. To account for these missing values, we used imputed values in the binary 
probit model. It has been shown that a properly performed multiple imputation gives less biased 
results compared to traditional complete case analysis (34). Recurrence after transplantation was 
used as a predictor variable because multiple imputation with the outcome has been shown to 
yield more valid results (25). 
Previously, Praga et al. showed that a normal serum albumin was suggestive of FSGS secondary 
to hyperfiltration in patients with FSGS in their native kidneys and nephrotic range proteinuria. 
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Hyperfiltration in these patients was due to severe obesity (BMI ≥35 kg/m2), vesico-ureteral 
reflux, or renal mass reduction. In our study, none of the children were obese, and none of the 
adult patients in the idiopathic FSGS group had a body mass index over 35 kg/m2. Moreover, 
patients with reflux or renal mass reduction were assigned to group II. Nevertheless, it is possible 
that at least some of the patients in group III, specifically those with a normal serum albumin 
and nephrotic range proteinuria at diagnosis, had glomerular hyperfiltration that would not be 
expected to recur in the renal transplant. Because we were unable to identify an underlying 
secondary cause with certainty, we assigned these patients to group III (idiopathic FSGS). In daily 
clinical practice these patients would also be diagnosed with idiopathic FSGS.
In the past, living related donor transplantations have often been avoided in patients with FSGS, 
because of fear that recurrent FSGS in the renal allograft would lead to premature graft loss. 
However, this fear has become less justified since therapeutic plasma exchange has been shown 
to improve outcome in patients with recurrent FSGS. Moreover, data from the USRDS study 
revealed that living related donor transplantation has no association with graft loss from recurrent 
FSGS (35). Rather, living related donor transplant is associated with a graft survival advantage 
for living donor kidneys over deceased donor kidneys. Furthermore, as confirmed by our study, 
the rate of recurrence among recipients of living or deceased donor kidneys is similar (5, 9, 14, 
36-38).  
The immunosuppressive regimen did not influence the risk of recurrent disease in our study. 
In particular, the use of cyclosporine was not associated with a decreased recurrence rate. In 
children, there is limited evidence that recurrent FSGS can be successfully treated with high-
dose intravenous or oral cyclosporin (39, 40). However, cyclosporine does not appear to prevent 
recurrence in the transplant when given as part of the initial immunosuppressive regimen (38, 
41, 42).
A rapid clinical course to ESRD, a previously reported risk factor for recurrence, did not 
influence the recurrence rate in our study (4, 14, 15, 37). Several other studies also observed no 
differences between the rapidity of progression of the initial disease and recurrent disease (5, 7-9, 
38). Although speculative, differences in pre-transplant immunosuppressive therapy may help 
explain the discrepancy between the above-mentioned studies. Pardon et al. and Hickson et al. 
showed that recurrent disease occurred more often in patients treated with cyclosporine before 
transplantation, whereas time to ESRD did not influence recurrence rate (7, 8). Although these 
patients eventually developed ESRD, cyclosporine may have slowed progression by reducing 
proteinuria. As recently shown, cyclosporine can reduce proteinuria due to a direct effect on 
podocyte function, which appears to be related to a stabilization of the actin cytoskeleton in 
podocytes (43). In contrast, these patients may progress rapidly to ESRD if not treated with 
cyclosporine.
Several investigators have identified bilateral nephrectomy before transplantation as a risk factor 
for recurrence (4, 27). This may reflect a more aggressive disease with a higher propensity to 
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recur. In our study, we were not able to confirm this finding because bilateral nephrectomy was 
only performed in six patients. We only advise nephrectomy in patients with ESRD and severe, 
persistent nephrotic syndrome refractory to medical treatment. 
Recurrent FSGS was associated with decreased graft survival: within five years, half of the patients 
with recurrent FSGS lost their renal graft compared to only 18% of patients without recurrent 
FSGS. It is important to note that most patients included in our cohort were transplanted in the 
era before plasma exchange was applied as treatment of FSGS recurrence. Others and we have 
shown that sustained remissions resulting in better renal survival can be attained after treatment 
with plasma exchange (18, 19, 41). The higher incidence of acute rejection episodes in patients 
with FSGS recurrence may also have contributed to their decreased graft survival. In addition 
to acute rejections, delayed graft function also appeared to occur more often in patients with 
recurrent FSGS, although this difference was not statistically significant. It is not clear how 
FSGS recurrence, delayed graft function, and acute rejection are intertwined. Kim et al. reported 
that both recurrence of FSGS and delayed graft function were independently associated with an 
increased incidence of acute rejection in patients with ESRD due to FSGS (44). Furthermore, 
there was an increased rate of early graft dysfunction in their FSGS patients, which was assumed 
to be a consequence of immediate recurrence. In our study, the increased number of acute rejection 
episodes may be due to a higher surveillance rate. Patients with an FSGS recurrence had a mean 
of 1.5 renal graft biopsies per patient in the first year after transplantation, whereas the patients 
without a recurrence had only 0.5 biopsies.  
CONCLUSIONS
Clinical criteria can identify a group of patients at high risk for recurrent FSGS after renal 
transplantation. Serum albumin at diagnosis predicts recurrence rate with a 78% risk of recurrence 
in patients with serum albumin concentration <25 g/L. Admittedly our study is limited by the 
retrospective design and missing data. Prospective studies are needed to confirm our findings. 
Nevertheless, our data can already be used to provide better counseling of patients with FSGS 
before renal transplantation. High-risk patients should be closely monitored for proteinuria, 
especially in the first weeks after transplantation, to enable early initiation of plasma exchange. 
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ABSTRACT
Background: The Columbia pathological classification was developed to standardize the 
description of focal segmental glomerulosclerosis (FSGS) morphology. The classification consisted 
of five mutually exclusive variants defined as collapsing (COL), tip (TIP), cellular (CELL), 
perihilar (PH), and not otherwise specified (NOS). We tested the hypothesis that the FSGS 
variants represent different etiologies by comparing native kidney and post-transplant recurrent 
FSGS morphology in the same patients. In addition, we examined potential transitions in FSGS 
morphology over time. 
Methods: patients with FSGS recurrence in our center were identified from the transplant 
database. Patients with two or more kidney biopsy specimens available for revision, including 
at least one kidney graft biopsy were included. All available samples were revised according to 
the Columbia classification. Specimens with no defining FSGS lesions were classified as minimal 
lesions (ML). 
Results: We included 16 patients with FSGS in their native kidney, who had post-transplant 
proteinuria recurrence in 23 grafts. All variants except CELL were observed in the native 
kidneys. Graft biopsies obtained within one month after transplantation revealed ML without 
exception. Native kidney and post-transplant morphology was discordant in 76% of cases. If ML 
was regarded as an intermediate stage, the proportion with discordance was 5/9 (55%). Sixteen 
morphological transitions were seen in repeat biopsies, including 10 from ML to an FSGS variant. 
TIP appeared as an early FSGS lesion, whereas COL and NOS were seen in later stages.
Conclusion: the morphological variants appear to reflect different stages in the evolution of 
lesions rather than different etiologies.  
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BACKGROUND
Focal segmental glomerulosclerosis (FSGS) is the description of a histopathological pattern 
of injury defined by the formation of segmental scars, involving some but not all glomeruli. 
FSGS may occur without a known cause (idiopathic FSGS), or may be secondary to a variety 
of pathological processes that induce structural and functional adaptations, resulting in 
segmental glomerular scarring (1). FSGS is associated with proteinuria, which is often in the 
nephrotic range or accompanied by full nephrotic syndrome. The lesions of FSGS have been 
better defined by a working group of kidney pathologists who convened at Columbia University 
to achieve a standardized approach to the pathologic classification of FSGS. This resulted in 
the Columbia classification of FSGS, which defines five mutually exclusive light microscopic 
variants: the collapsing variant (COL; collapse of the glomerular tuft associated with epithelial 
cell hypertrophy and hyperplasia), the tip variant (TIP; lesions located at the urinary pole), the 
cellular variant (CELL; characterized by endocapillary hypercellularity), the perihilar variant (PH; 
lesions predominantly localized at the vascular pole), and finally FSGS not otherwise specified 
(NOS) when none of the previous definitions apply. Because different glomerular lesions may 
be seen in one biopsy, a hierarchy was proposed to allow exclusive definition of one variant. 
The classification is purely based on morphology, and the working group admitted that it was 
unclear if the variants reflected pathogenic differences (2). Subsequent studies found differences 
in clinical characteristics and kidney survival between patients with different morphological 
variants, supporting the clinical usefulness of the Columbia classification (3-5). Furthermore, 
the expression of podocyte markers differed between COL and other variants (6). However, these 
findings do not provide sufficient evidence that the variants are separate clinical entities. For 
example, TIP lesions have been observed in both steroid sensitive nephrotic syndrome with 
preserved renal function and steroid resistant nephrotic syndrome with progression towards end-
stage renal disease (7-9). 
A significant proportion of patients with idiopathic FSGS who progress to end-stage renal disease 
develop disease recurrence after transplantation, which is typically characterized by early-onset 
nephrotic proteinuria (10). There is strong evidence that post-transplant recurrent FSGS is 
caused by a glomerular permeability factor, which can be removed by plasmapheresis or immune 
absorption (11). Several permeability factors have been proposed (12, 13). 
If the morphological FSGS variants reflect different etiologies, this would be supported by 
consistency of morphological variants in pre- and post-transplant biopsies of patients with 
FSGS who experience disease recurrence after transplantation. Several groups have studied FSGS 
morphological variants in native and graft biopsies. These studies have yielded conflicting results 
with regard to concordance of FSGS variants (14-16). We investigated the concordance between 
FSGS variants in the native kidney and kidney graft in patients treated in our center. Furthermore, 
we investigated if morphological transitions occurred in repeat biopsies. 
38  |  Chapter 3
METHODS
Patients with biopsy-proven FSGS in the native kidney who received a kidney graft in our center 
between 1968 and 2012 were identified from the transplant database. We reviewed the medical 
records for evidence of post-transplant FSGS defined by the development of nephrotic proteinuria 
(≥3.0 g/24 hours or 3.0 g/10 mmol creatinine), in the absence of other explanatory glomerular 
abnormalities such as transplant glomerulopathy or de novo glomerulonephritis. Electron 
microscopy was not routinely performed, but available results were recorded. Patients with two 
or more available specimens, including at least one kidney graft biopsy were included. Review 
of light microscopy was performed by a nephropathologist (E.J.S.) who was unaware of clinical 
details. Morphological evaluation of FSGS lesions was according to the Columbia classification 
(2). Specimens containing only normal appearing glomeruli on light microscopy were classified 
as minimal lesions (ML). We compared the morphology observed in repeat biopsies, as well as the 
morphology in native and graft biopsies in individual patients. The variant in the initial native 
kidney biopsy was considered the defining variant in the comparison between native kidney 
and allograft. Biopsies were performed on clinical indication, and included onset or relapse of 
proteinuria, decline in glomerular filtration rate, delayed graft function, or treatment failure. We 
have reported improved graft survival in patients with post-transplant FSGS since plasmapheresis 
was instituted for its treatment in 1994 (17). In recent years, nephrotic proteinuria early after 
transplantation prompted immediate plasmapheresis without initial biopsy confirmation (18). 
In these patients, a kidney biopsy was obtained at the time of proteinuria relapse, treatment 
resistance, or worsening kidney function. Timing and response to plasmapheresis were recorded 
to evaluate a potential influence on histological findings. Partial remission was defined as a ≥50% 
reduction to levels ≤2 gram/24 hours (or ≤2 gram/10 mmol creatinine), and complete remission 
was defined as a decrease in proteinuria to ≤0.2 gram/24 hours (or ≤0.2 gram/10 mmol creatinine), 
in the presence of stable serum creatinine. 
 
RESULTS
From the transplant database and medical records, we identified 30 patients who were eligible 
for the study. Twelve patients were excluded because less than two specimens or no graft biopsy 
was available for revision. Two patients were excluded because transplant glomerulopathy was 
observed on revision of one or more graft biopsies. Thus, we included 16 patients with idiopathic 
FSGS, who had developed post-transplant proteinuria in 23 grafts. Nephrotic proteinuria usually 
recurred within one week after transplantation (Table 1). 
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Table 1. Clinical characteristics of patients with FSGS and post-transplant proteinuria recurrence 
Characteristic
Gender (Male/Female) 10/6
Age at first native kidney biopsy (years) 19 (8 - 57)
Interval between first native kidney biopsy and ESRD (years) 3.6 (0.3 - 16.8)
Age at first kidney transplantation (years) 22 (10 - 62)
Time to onset of nephrotic range proteinuria in the graft * (days) 6 (0 - 935)
Time to first graft biopsy * (days) 64 (0 - 965)
ESRD: end-stage kidney disease. Data are expressed as median (range)
* Data were recorded for first graft biopsy with available tissue for revision
From the 16 patients included in the study, 72 kidney specimens had been obtained for 
pathological examination. Eight specimens were not available for revision. Thus, we revised 21 
specimens from 13 native kidneys and 43 specimens from 21 kidney allografts (Supplementary 
Table). Fifty-three tissue samples were obtained by surgical or percutaneous needle biopsy, and 
11 were obtained from nephrectomy specimens. Electron microscopy had been performed in 31 
specimens (43%) and all disclosed diffuse foot process effacement. 
 
Concordance of morphological variants between native kidney and allograft kidney
Thirteen patients who received 17 allograft kidneys had at least one native kidney and one 
allograft specimen available for revision. Morphology was concordant in 4/17 cases (24%; Figure 
1). ML was initially observed in 13 grafts. Thus, many cases of discordance between native and 
transplant morphology were based on the finding of ML in the initial allograft biopsy. However, 
even if ML was considered as an intermediate before development of an FSGS variant, concordance 
between native and allograft kidney FSGS morphology was only present in 4/9 cases (44%) with 
FSGS variants in the native and allograft kidneys (Supplementary Table). 
Figure 1. Comparison of first morphological pattern observed in the native kidney and first pattern observed 
in the kidney allografts of thirteen patients. Comparisons with morphological patterns in all grafts are 
depicted.
COL, collapsing variant; ML, minimal lesion; NOS, not otherwise specified variant; PH, perihilar variant; 
TIP, tip variant
40  |  Chapter 3
Evolution of morphological variants 
Repeat biopsies were available in 24 cases (8 native; 16 grafts). Morphological transitions in repeat 
biopsies are depicted in Figure 2. In the native kidneys, we observed morphological transitions in 
five patients, including two with progression from ML to an FSGS variant. Concordance was seen 
in one patient with COL and one with PH variant, respectively. 
Time course of morphological lesions found in the kidney grafts is shown in Table 2. In the 
first month after onset of nephrotic proteinuria all samples had ML morphology. However, the 
prevalence of ML morphology progressively decreased over time.
Table 2. Time course in relation to FSGS morphological variants observed in the transplant kidney specimens 
Case 
number
Transplant 
number
Months after onset of nephrotic proteinuria in the transplant kidney
<1 1-3 3-12 >12
1 1 COL
2 ML COL
2 1 ML; ML
3 1 ML
4 2 ML ML; TIP; TIP; COL
5 1 ML
6 2 ML COL
7 1 ML TIP; TIP
8 1 ML COL
2 ML NOS
9 1 NOS
2 ML; ML; ML
10 1 COL COL
2 ML
11 1 ML TIP; ML
12 1 ML COL
13 1 ML ML
14 2 ML COL
15 1 ML TIP
2 COL COL
16 1 ML ML
ML morphology (%) 100 45 33 13
COL, collapsing variant; ML, minimal lesions; NOS, not otherwise specified variant; PH, perihilar variant; 
TIP, tip variant
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In one kidney graft, two morphological transitions were observed (ML, TIP and COL, respectively). 
There were 10 transitions from ML to an FSGS variant. Only one transition between FSGS 
variants was observed (TIP to COL). 
Figure 2. Morphological transitions in serial specimens from native or transplant kidneys. The numbers 
indicate how many times a morphological transition was observed, and the arrows indicate the direction of 
the transition. 
COL, collapsing variant; ML, minimal lesion; NOS, not otherwise specified variant; PH, perihilar variant; 
TIP, tip variant
Evolution of morphological variants in relation to proteinuria outcome after plasmapheresis 
Plasmapheresis was performed as treatment for post-transplant FSGS in 10 grafts (from nine 
patients). Complete remission was attained in three cases, partial remission in four, and no 
remission in three (Supplementary Table). Prolonged or repeated courses of plasmapheresis 
were often needed to maintain proteinuria remission. All three patients who reached complete 
remission had long-term preserved graft function. Six repeat biopsies were performed because of 
proteinuria relapse, which disclosed ML in five cases and a tip lesion in one case. 
Patients who did not reach complete remission lost their grafts. Four patients had partial 
remissions on plasmapheresis treatment. In two patients with prolonged partial remission 
evolution from ML to TIP variant was observed, followed by COL or TIP in the nephrectomy 
specimen. Plasmapheresis-resistant cases were characterized by transition from ML to COL or 
NOS variant in subsequent specimens. 
DISCUSSION
In this study, concordant morphology between the initial native kidney and allograft sample was 
observed in only 4/17 (24%) cases. The number was 4/9 (45%) if ML histology was regarded as 
an intermediate before development of an FSGS morphological variant. In addition, we observed 
many morphological transitions in serial biopsy specimens. To our knowledge, three previous 
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studies have addressed FSGS morphologic lesions before and after transplantation. Ijpelaar et al. 
included 19 patients (21 grafts) with post-transplant FSGS recurrence in a multi-center study 
(14). The authors reported concordance between native and transplant morphology in 15/21 
cases (81%), including four cases with ML as an intermediate in the kidney grafts. Of note, the 
morphological variant in the last kidney sample obtained was considered the defining variant. 
The last kidney sample was often obtained in the setting of advanced disease (e.g. nephrectomy 
sample), or >1 year after proteinuria recurred in the graft. In nine cases FSGS NOS was found 
in both native kidney and allograft. Since all lesions may progress to FSGS NOS in late disease 
stages (2, 19), this partially explains the high reported concordance rate. Canaud et al. reported 
histological findings in 42 patients with FSGS in the native kidney and post-transplant proteinuria 
recurrence (15). In the native kidneys, few repeat biopsies were performed, and no morphological 
transitions of FSGS variants were seen. Similar to the findings reported in the present study, ML 
was observed at onset of post-transplant proteinuria. Patients who had persistent or relapsing 
proteinuria after transplantation developed FSGS lesions. Only 4/24 (17%) kidney grafts with 
FSGS lesions had the same morphological variant as observed in the native kidneys. Schachter 
et al. studied 15 patients with post-transplant FSGS recurrence (16). It was noticed that three 
patients who had the COL variant on native kidney biopsy also had COL morphology in at least 
one kidney graft sample. Overall, similar FSGS morphology was present in 5/9 (56%) cases that 
allowed a comparison. 
We combined data from the cited studies with our results to compare native and transplant FSGS 
morphology in a large number of patients. The first FSGS variant observed was considered the 
defining variant, and biopsies with ML were disregarded. Using these criteria, 23/60 (38%) of 
allograft kidneys had FSGS morphological variants that were in agreement with native kidney 
histology (Figure 3). Combining studies, morphological transitions observed in repeat biopsies of 
native kidneys and kidney grafts were also investigated (Supplementary Figures 1 and 2). Similar 
patterns in the morphological evolution were observed. ML was most frequently observed in the 
first biopsy, especially in kidney grafts. Subsequent biopsies revealed various FSGS variants. TIP 
and CELL variants were followed by COL or NOS on repeat biopsy. However, the reverse order 
was not observed. 
Based on the combined observations from four studies, it seems unlikely that the FSGS 
morphological variants represent separate etiologic factors. Rather, we propose that the respective 
variants reflect the level of severity and chronicity of lesions (Figure 4). 
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Figure 3. Concordance between native and transplant focal segmental glomerulosclerosis (FSGS) 
morphological variants in three studies (14-16), and the present study. The first FSGS morphological variant 
that was observed was the defining variant in both native and allograft kidneys.
Figure 4. Schematic illustration of the hypothetical concept that morphological appearance of focal 
segmental glomerulosclerosis (FSGS) represents activity and chronicity of the disease process. Mild podocyte 
injury causes minimal abnormalities on light microscopy, reminiscent of minimal change disease. Beyond a 
critical threshold, FSGS lesions develop. Tip lesions are frequent if podocyte injury is limited and collapsing 
lesions occur if podocyte injury is severe. If podocyte injury stops, sclerosis may be limited. On the other 
hand, an ongoing process or repeated episodes of podocyte injury cause sclerotic lesions (FSGS NOS).
Samples obtained early after the onset of post-transplant proteinuria do not contain FSGS lesions 
(ML histology, Table 2). Successful treatment may prevent the development of FSGS lesions. 
Patients who attained a complete remission on plasmapheresis had foot process effacement at the 
time of proteinuria relapse, but did not have FSGS lesions in later biopsies (except a single TIP 
lesion). This concept is supported by the observation that podocyte foot process effacement can be 
restored by retransplantation of the kidney into another recipient who does not carry the responsible 
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glomerular permeability factor (20). In our study, TIP lesions were early stage FSGS lesions that 
occurred in patients who had no or incomplete proteinuria remission. Previously, Howie et al. 
have identified glomerular tip lesions as the earliest stage of FSGS (8). The COL variant has been 
described as a separate entity characterized by severe treatment-resistant nephrotic syndrome 
with rapid progression (21). However, results of pooled studies demonstrate that 6/13 patients 
with COL variant in their native kidney had a different FSGS variant after transplantation (Figure 
3). Animal models have provided evidence that collapsing glomerulopathy results from rapid 
and extensive podocyte loss, followed by recruitment of parietal epithelial cells to the denuded 
basement membrane (22, 23). The role of parietal epithelial cells in collapsing lesions was 
recently confirmed in human biopsy studies (24, 25). This concept may explain the observation 
of the COL variant early after transplantation (Table 2). In our study, COL was preceded by ML 
or TIP variant, but not by NOS, and COL was not followed by other variants except NOS (Figure 
2). This suggests that the collapsing lesion is characterized by severity but not chronicity (Figure 
4). By definition, a single collapsing lesion can define the COL variant in a biopsy. This may 
have contributed to observation of NOS followed by COL in previous studies (Supplementary 
Figures). Moreover, the NOS variant includes any type of FSGS that does not fulfill the criteria 
for other variants, and is thus heterogeneous from a morphological point of view.
Our findings support and extend results of a repeat biopsy study performed in native kidney 
FSGS. In repeat samples from 24 patients, these investigators observed 11 transitions including 
9 from other types to the NOS variant (26). 
The PH variant has been associated with maladaptive responses following hyperfiltration, which 
occurs in the setting of obesity and low birth weight, for example (27, 28). Typically, there 
is proteinuria without full nephrotic syndrome, and incomplete foot process effacement. These 
forms of FSGS are not associated with recurrence after transplantation. In our experience, 25% of 
patients with the PH variant did present with full nephrotic syndrome (4). Here, we confirm that 
the PH variant may also be seen in patients who develop post-transplant proteinuria recurrence. 
The CELL variant was not seen in our study. Previous studies have also reported a low or 
absent prevalence of the CELL variant (3-5, 29). Moreover, the interobserver agreement among 
pathologists was the lowest for this variant (30). It has therefore been proposed to abandon the 
CELL variant in future studies (31).
Our observations lend support to the podocyte depletion hypothesis, which states that progressive 
quantitative loss of podocytes sequentially results in mesangial expansion, followed by adhesions 
to Bowman’s capsule, focal sclerosis, and global sclerosis (32). Accordingly, prevention of 
podocyte loss by removal of a noxious factor may arrest or mitigate progression of lesions. Recent 
findings even suggest that podocyte loss is the driving mechanism of progression in all glomerular 
diseases (33). However, it should be noted that parietal epithelial cells are also key players in the 
morphological development of idiopathic FSGS that recurs after transplantation (34, 35).
We acknowledge that our study has limitations. The progression of lesions could not be 
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systematically evaluated, because protocol biopsies were not obtained. Furthermore, some biopsy 
specimens were not available for revision. The morphological course may have been influenced 
by other factors such as calcineurin inhibitor toxicity or unidentified viral infection, especially in 
allograft kidneys (36, 37).
In conclusion, the TIP, COL, NOS and PH morphological variants of FSGS were all associated 
with potential nephrotic proteinuria recurrence after transplantation. However, the morphological 
variants recurred in a different pattern in the majority of cases. Thus, our findings did not support 
the hypothesis that the morphological variants reflect separate etiological factors. The study of 
serial biopsies suggested that the TIP variant reflects early FSGS, whereas COL variant was a 
feature of severe podocyte injury. NOS and COL variants were seen in advanced stages of FSGS. 
Successful treatment prevented the progression of lesions. 
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Supplementary Figure 1. Evolution of focal segmental glomerulosclerosis morphological lesions in native 
kidneys as reported in three studies (14, 15), as well as the present study. Dotted lines connect findings in 
subsequent biopsies from the same patient.
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Supplementary Figure 2. Evolution of focal segmental glomerulosclerosis morphological lesions in 
allograft kidneys as reported in three previous studies (14-16), and the present study. Dotted lines connect 
findings in subsequent biopsies from the same patient. 
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INTRODUCTION
A recent study by Wei et al. suggested that serum measurement of the soluble urokinase 
plasminogen activator receptor (suPAR) could have diagnostic value in patients with idiopathic 
nephrotic syndrome (1). Serum suPAR concentrations were elevated in patients with idiopathic 
focal segmental glomerulosclerosis (FSGS) and not in patients with other glomerular diseases. 
The authors proposed that serum suPAR levels ≥3000 pg/mL were specific for idiopathic FSGS. 
Even higher serum suPAR levels were measured in pre-transplant sera of patients with FSGS 
who were on hemodialysis and developed FSGS recurrence after transplantation. However, the 
study did not include appropriate controls. In addition, serum albumin was normal or unknown 
in many of the patients with suspected idiopathic FSGS. The absence of hypo-albuminemia 
despite heavy proteinuria suggests FSGS due to hyperfiltration rather than idiopathic FSGS 
(2). It is also unknown whether suPAR is associated with the response to corticosteroids. Thus, 
the data presented by Wei et al. were potentially biased. The aim of this study was to evaluate 
serum suPAR as a biomarker for predicting the diagnosis in patients with idiopathic nephrotic 
syndrome, the response to corticosteroid treatment, and the risk of FSGS recurrence after kidney 
transplantation. 
METHODS
We measured suPAR concentrations in stored serum samples of adult patients with idiopathic 
FSGS (n=11), secondary FSGS (hyperfiltration n=3, familial n=2), and minimal change disease 
(MCD; n=7). At the time of suPAR measurement, patients had variable stages of chronic kidney 
disease (CKD) but were not on dialysis. The response to corticosteroid treatment had been 
established.  
In addition, we measured serum suPAR concentrations in eight chronic hemodialysis patients. 
Three patients had a history of biopsy-proven FSGS in their native kidney and recurrent FSGS 
in one or two kidney allografts, and five controls had non-FSGS CKD. None of the patients had 
active infection or systemic malignancy. All measurements of suPAR were performed with the 
Quantikine Human suPAR Immunoassay (R&D Systems).
RESULTS 
Median serum suPAR concentration was not different between idiopathic FSGS (2392 pg/
mL), secondary FSGS (2716 pg/mL) and MCD (2482 pg/mL) nor did it predict corticosteroid 
responsiveness in patients with idiopathic FSGS/MCD (Figure 1). We found a significant negative 
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correlation between suPAR and estimated glomerular filtration rate (eGFR) calculated with the 
six-variable MDRD formula (Figure 2). 
Figure 1. Serum soluble urokinase plasminogen activator receptor (suPAR) concentrations in patients with 
idiopathic focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and secondary FSGS. 
Median suPAR concentration is indicated by the horizontal line.
Δ= steroid-sensitive (complete remission), = steroid-resistant (no remission),  = no immunosuppressive 
therapy. 
Figure 2. Correlation analysis of serum soluble urokinase plasminogen activator receptor (suPAR) 
concentrations with estimated glomerular filtration rate (eGFR; calculated with the six-variable MDRD 
formula). Spearman’s rho -0.46, P =0.03
In the patients on hemodialysis, all serum samples had suPAR concentrations >3000 pg/mL. 
There was no difference between patients with a history of post-transplant FSGS recurrence and 
controls (Figure 3).
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patients with a history of post-transplant focal segmental glomerulosclerosis (FSGS) recurrence and controls. 
Median suPAR concentration is indicated with the horizontal line.
CONCLUSION
Serum suPAR concentration was not a specific marker for idiopathic FSGS and it did not reliably 
predict response to treatment. In patients on hemodialysis, measurement of suPAR was not 
helpful in the identification of patients with a high risk of post-transplant FSGS recurrence. Our 
findings strongly suggest that serum suPAR concentrations are dependent on eGFR. 
Although our data indicate that for the individual patient suPAR is not a reliable marker, the 
small size of our study does not allow definite conclusions on the role of suPAR in FSGS. A larger 
study is needed to clarify this issue, as well as the correlation between suPAR and eGFR.
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ABSTRACT
The soluble urokinase plasminogen activator receptor (suPAR) promotes proteinuria and induces 
focal segmental glomerulosclerosis (FSGS)-like lesions in mice. A serum suPAR concentration cut-
off of 3000 pg/mL has been proposed as clinical biomarker for patients with FSGS. Interestingly, 
several studies in patients with glomerulopathy demonstrated an inverse correlation between 
the estimated glomerular filtration rate (eGFR) and suPAR. As patients with FSGS present at 
different eGFRs, we studied the relationship between eGFR and suPAR in a cohort of 476 non-
FSGS patients and 54 patients with biopsy-proven idiopathic FSGS. In the non-FSGS patients, 
eGFR was the strongest determinant of suPAR. The proposed cut-off for suPAR in FSGS patients 
was exceeded in 17%, 39% and 88% in patients withs eGFR of more than 60, 45-60 and 30-45 
ml/min/1.73 m², respectively. In patients with eGFR of <30 ml/min/1.73 m², suPAR exceeded 
the cut-off in 95% of patients. Levels of suPAR in patients with idiopathic FSGS overlapped 
with non-FSGS controls and for any given eGFR did not discriminate FSGS cases from non-
FSGS controls. In the overall cohort, there was a negative association between idiopathic FSGS 
and suPAR, and idiopathic FSGS was not an independent predictor of suPAR concentration 
over 3000 pg/mL. Thus, this study does not support an absolute, eGFR-independent, suPAR 
concentration cut-off as a biomarker for underlying FSGS pathology and questions the validity of 
relative, eGFR-dependent suPAR cut-off values.
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INTRODUCTION
Idiopathic focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome 
in both children and adults, and despite intensive treatment it will progress to end-stage kidney 
disease in 40% of affected patients. FSGS frequently recurs after transplantation, and recurrences 
have been associated with decreased allograft survival. The pathogenesis of FSGS is incompletely 
resolved; however, evidence suggests that it involves immune cell dysfunction, secretion 
of a circulating factor and podocyte maladaptation. The existence of a circulating vascular 
permeability factor has been postulated based on rapid recurrence of proteinuria following kidney 
transplantation (1, 2), the occurrence of a transient nephrotic syndrome in a newborn to a women 
affected by FSGS (3), the beneficial effect of immunoadsorption and/or plasma exchange (4) and 
the ability of FSGS patient serum to induce albuminuria in rats (5). In a recent publication, 
Wei et al. provide ample evidence that serum soluble urokinase plasminogen activator receptor 
(suPAR) is a circulating factor that may cause FSGS (6). 
The urokinase plasminogen activator receptor (uPAR; encoded by PLAUR), apart from 
being the cellular receptor for urokinase, is a versatile receptor affecting migration, adhesion, 
differentiation and proliferation through intracellular signaling (7). uPAR consists of three 
internally disulphide-bonded domains (D1,D2, and D3) anchored to the cell surface by a 
glycosyl phosphatidylinositol bridge. suPAR is released from the plasma membrane by cleavage 
of the glycosyl phosphatidylinositol anchor (7). Induction of podocyte uPAR signaling leads 
to foot process effacement and proteinuria via the activation of β3 integrin (8). In a similar 
fashion, circulating suPAR also activates podocyte β3 integrin, causing foot process effacement, 
proteinuria and FSGS-like glomerulopathy. suPAR-induced glomerular disease can be blocked by 
neutralizing suPAR antibodies (6). 
In the original report, suPAR was elevated in patients with FSGS, but not in patients with 
minimal change disease, membranous nephropathy, or preeclampsia (6). The highest serum 
suPAR levels were found in sera from patients with FSGS who developed post-transplant 
proteinuria recurrence. Using a suPAR cut-off value of 3000 pg/mL, circulating suPAR levels 
were elevated in 84.3% and 55.3% of patients in two patient cohorts of biopsy-proven FSGS, 
compared with 6% of controls (P <0.0001). These studies suggest the potential role of suPAR 
as an independent biomarker of FSGS (9). Multivariate analysis revealed an inverse correlation of 
suPAR to estimated glomerular filtration rate (eGFR), in agreement with several single center 
reports (10-13). A similar association has been observed in patients admitted to the intensive care 
unit (14). This may be attributed to reduced clearance of suPAR and/or overproduction. 
The relative importance of kidney function to suPAR concentrations in chronic kidney disease 
(CKD) patients has not been investigated in depth. We therefore studied suPAR concentrations 
in a large cohort of patients with non-FSGS CKD (the Leuven mild-to-moderate CKD cohort) 
to study the relationship between eGFR and suPAR concentrations. In addition, we evaluated 
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suPAR levels in patients with biopsy-proven idiopathic FSGS to test the validity of suPAR as an 
FSGS biomarker.
PATIENTS AND METHODS
The Leuven mild-to-moderate CKD study (clinicaltrials.gov NCT00441623) is a prospective 
cohort to study uremic retention solutes, including protein-bound uremic solutes (15). Prevalent 
CKD patients, followed at the nephrology outpatient clinic of the University Hospitals Leuven, 
18 year of age or older, were eligible for inclusion. Data on baseline demographics and cause of 
kidney disease were collected at time of informed consent. The study was performed according 
to the Declaration of Helsinki and approved by the ethics committee of the University Hospitals 
Leuven. Informed consent was obtained from all patients. We enriched the number of patients 
with biopsy-proven primary FSGS taking samples from the Leuven renal research Biobank. 
Approval for measurement of suPAR on samples of the Leuven renal research Biobank was 
granted by the medical ethics committee of the University Hospitals Leuven.
In Radboud University Medical Center, patients with proteinuria are evaluated using a standard 
protocol (16). In brief, patients are seen after an overnight fast. Blood pressure and body weight 
are measured and serum and urine are collected for clinical laboratory tests. In addition, aliquots 
of serum and urine are stored at -70°C for research on prognostic factors. The local medical ethics 
committee has given approval for the protocol and collection of follow-up data from patients. All 
patients have given written informed consent. For the current study, we selected stored serum 
samples obtained from 39 patients with FSGS, including 11 patients with previously reported 
suPAR levels (10). Patients aged ≥18 years with biopsy-proven idiopathic FSGS were included. 
Patients were classified as idiopathic FSGS based on the following criteria: all patients had nephrotic 
syndrome (serum albumin ≤30 g/L, proteinuria ≥3.5 g/24 hours). Secondary causes of FSGS 
(hereditary, HIV, drugs, adaptive structural-functional responses mediated by hyperfiltration, 
malignancy, other glomerular diseases) were excluded by detailed diagnostic work-up, including 
medical history and family history, physical examination, kidney imaging, and kidney pathology, 
including electron microscopy studies. In the absence of a positive family history, genetic testing 
was not routinely performed, as currently known FSGS-associated mutations are rare in adults 
with isolated FSGS (17). Outcome was defined by response to steroid treatment. Patients with 
steroid-sensitive FSGS had at least 50% reduction in peak proteinuria and attained subnephrotic 
levels (<3.5 g/24 hours) on steroid treatment (18). Patients with steroid-resistant FSGS did not 
meet criteria for steroid-sensitive FSGS after 16 weeks of high-dose steroid therapy (prednisone 
dose equivalent of 1 mg/kg/day). Serum suPAR has been proposed as a risk marker for post-
transplant FSGS recurrence (6). As recurrence typically occurs in steroid-resistant patients (19), 
we performed additional analyses in this subgroup. 
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Creatinine was measured using an isotope dilution mass spectometry-traceable method. eGFR 
was calculated using the CKD-EPI equation (20). In both centers, measurement of suPAR was 
performed using the Human uPAR Quantikine enzyme-linked immune sorbent kit (DUP00, 
R&D systems). All samples were measured twice, and the mean suPAR concentrations were used. 
Reproducibility of the assay was excellent, with the mean coefficient of variation in individual 
patients of 2.43%.
Data are expressed as mean (standard deviation) for normally distributed variables or median 
(interquartile range) for non-normally distributed variables. Differences were tested using 
parametric analysis of variance, Kruskal-Wallis test, or χ2 test as appropriate. For multivariate 
analysis, we used a stepwise approach, with P
include
 <0.20 en P
exclude
 >0.05. All statistical analyses 
were performed using SAS (version 9.2, the SAS institute, Cary, NC).
RESULTS
We determined suPAR concentrations in 476 patients (Table 1) with known non-FSGS CKD 
(controls), and in 54 patients with biopsy-proven FSGS (cases: 44 active disease, 10 remission), 
using the human uPAR enzyme-linked immune sorbent assay (R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany). Compared with control patients, patients with FSGS were younger and 
had higher eGFR. suPAR concentrations were similar between FSGS cases and CKD controls. 
We first studied explanatory variables for suPAR concentrations in non-FSGS CKD patients 
(controls). As suPAR concentrations showed a non-normal distribution, suPAR concentrations 
were log-transformed for linear regression analyses. In multivariate analysis, suPAR concentrations 
were higher in females (P =0.003). A direct association was observed with age (P <0.0001) and 
C-reactive protein (P =0.0009), whereas albumin (P <0.0001) and the eGFR (P <0.0001) were 
inversely associated, with the latter having the highest partial coefficient of determination (R²). In 
multivariate analysis, proteinuria was not an independent determinant of suPAR concentrations 
(Table 2).
As eGFR was the strongest determinant, we stratified suPAR according to eGFR (Figure 1a). 
The percentage of patients with suPAR concentrations exceeding the proposed cut-off for FSGS 
of 3000 pg/mL rises significantly from 17% in those with eGFR of >60 mL/min/1.73 m² to 39 
and 88% for those with eGFR of 45-60 and 30-45 mL/min/1.73 m², respectively. In patients 
with eGFR of <30 mL/min/1.73 m², suPAR concentrations exceeded the proposed cut-off in 
95% of patients. 
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Figure 1. Circulating soluble urokinase plasminogen activator receptor (suPAR) in patients with 
chronic kidney disease (CKD).
(a) suPAR concentrations according to strata of estimated glomerular filtration rate (eGFR). (b-d) suPAR 
concentrations plotted as a function of the eGFR for non-focal segmental glomerulosclerosis (FSGS) controls 
(black dots), patients with active FSGS (red dots), and FSGS in remission (green dots). Data are plotted for 
all patients (a,b), for patients with 24-hour proteinuria more than 1 gram (c), and for patients with 24- hour 
proteinuria exceeding 3 grams (d).
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As patients with FSGS present at different eGFRs, we then plotted biopsy-proven FSGS patients 
and non-FSGS CKD controls on suPAR per eGFR graphs, irrespective of proteinuria (Figure 
1b), those with 24-hour proteinuria exceeding 1 gram (Figure 1c) and only those with 24-hour 
proteinuria exceeding 3 grams (Figure 1d). On these graphs, FSGS cases are interspersed with 
non-FSGS controls and, for any given eGFR, are not identifiable by higher suPAR concentrations, 
questioning the use of any suPAR cut-off value to be used as biomarker for FSGS. We compared 
patient with steroid-resistant and steroid-sensitive idiopathic FSGS (Table 3). suPAR levels were 
equal, providing additional evidence that suPAR does not distinguish between steroid-sensitive 
and steroid-resistant FSGS. Finally, we performed multivariate analysis in the overall cohort, 
combining data of FSGS cases with active disease and non-FSGS controls to study determinants 
of suPAR (Table 4). In multivariable analysis, with suPAR as the continuous parameter, primary 
FSGS was negatively associated with suPAR concentrations (P =0.04). Furthermore, in the 
analysis with dichotomized suPAR values, FSGS was not an independent determinant (P =1.0) of 
suPAR concentrations above the proposed 3000 pg/mL cut-off.
Table 3. Steroid-resistant and steroid-sensitive FSGS in the Nijmegen cohort
Variable Steroid-resistant Steroid-sensitive P
Patients (n)* 15 23
Age (years) 50 (22–62) 47 (34–58) 0.6
Sex (male/female) 12/3 17/6 1.0
Serum creatinine (mg/dL) 1.39 (0.87–3.09) 1.03 (0.86–1.69) 0.1
eGFR (mL/min/1.73 m²) 62.0 (20.0–114.7) 74.7 (40.1–101.5) 0.6
Serum albumin (g/L) 23 (13–27) 22 (20–26) 0.2
Proteinuria (g/g creatinine) 9.5 (6.8–14.1) 10.4 (6.2–17.4) 0.4
suPAR (pg/mL) 3713 (2614–4204) 3489 (2392–4503) 0.9
eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; suPAR, soluble 
urokinase plasminogen activator receptor.
Data expressed as median (interquartile range). 
* Steroid responsiveness could not be determined in one patient with recently diagnosed FSGS.
Table 4. Variables related to suPAR concentrations in the overall study
                  suPAR concentration suPAR >3000 pg/mL
Variable β P β P
Age 0.005 <0.0001 0.005 <0.0001
Sex 0.09 0.0003 0.09 0.003
eGFR -0.008 <0.0001 -0.008 <0.0001
CRP 0.045 0.0006 0.033 0.04
Albumin -0.018 <0.0001 -0.013 0.0006
FSGS -0.18 0.04 0.00 1.0
Model R² 0.50 Model R²                       0.44
CRP, c-reactive protein; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; 
suPAR, soluble urokinase plasminogen activator receptor. 
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DISCUSSION
The current study questions the value of suPAR as a clinical biomarker for FSGS. We demonstrate 
that eGFR is a potent determinant of suPAR. Consequently, suPAR concentrations exceed the 
proposed threshold of 3000 pg/mL in the large majority of patients with advanced CKD. The 
causes for the accumulation of suPAR in patients at reduced glomerular filtration are incompletely 
understood. Urinary excretion of suPAR has been demonstrated. suPAR is a circulating protein 
ranging from 20 to 50 kDa, depending on the degree of glycosylation and proteolytic cleavage 
(6, 7). As the molecular weight cut-off for glomerular filtration is thought to be around 30–50 
kDa (21), loss of glomerular filtration is expected to result in rising suPAR concentrations (22). 
To what extent glycosylation affects glomerular filtration of suPAR is unclear. The degree of 
suPAR glycosylation in patients with CKD has not been studied to date. In addition, the tubular 
handling - that is, whether and to what extent suPAR is absorbed by the tubuli - remains to be 
studied. 
Renal handling may not even explain the observed wide dispersion in serum concentrations, 
especially in patients with low eGFR (Figure 1a). Contrary to the published cohorts of FSGS 
patients, we did observe a direct gradual relationship with C-reactive protein, pointing toward 
a role for inflammation. Our multivariate model only predicted slightly more than half of the 
variance in suPAR concentrations, indicating a role for as yet unidentified determinants.
A key question is whether accumulation of suPAR in patients with progressive CKD is of clinical 
relevance. Ample evidence suggests that suPAR affects the podocyte through integrin signaling. 
Given the versatile roles of uPAR as a signaling orchestrator, it is tempting to speculate that 
the accumulation of suPAR is in the causal chain of extrarenal manifestations of CKD. Clinical 
or experimental data to support a pathophysiological role of suPAR in CKD have not been 
published to date. 
Although the number of patients with primary FSGS was considerably lower than that of control 
non-FSGS patients, the cohort is still of reasonable size, and it is unlikely that clinically relevant 
differences will be observed in larger studies. In any case, in future studies, control patients 
should be selected not solely based on histopathological diagnosis but should also be matched for 
demographic and biochemical parameters including the eGFR.
In conclusion, our study does not support the use of any absolute – that is, eGFR-independent - 
suPAR concentration cut-off as a biomarker for FSGS. Our data, moreover, question the validity 
of relative – that is, eGFR-dependent - suPAR cut-off values. 
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ABSTRACT
The urokinase plasminogen activator receptor (uPAR) has important functions in cell migration. 
uPAR can be shed from the cell membrane resulting in soluble uPAR (suPAR). Further 
cleavage gives rise to shorter fragments with largely unknown functions. Recent studies have 
demonstrated that both overexpression of uPAR on podocytes and administration of suPAR cause 
proteinuria in mice. The common pathogenic mechanism involves the activation of podocyte 
β3-integrin. Increased activation of β3-integrin is also observed in patients with focal segmental 
glomerulosclerosis (FSGS). These observations were the basis for the hypothesis that suPAR 
may be the circulating factor causing FSGS. A recent study fostered this idea by demonstrating 
increased suPAR levels in the serum of patients with FSGS and reporting an association with 
recurrence after transplantation and response to plasmapheresis. However, this study was heavily 
biased, and subsequent studies have given conflicting results. Although the experimental work 
is very suggestive, at present there is no proof that any known human suPAR fragment causes 
FSGS in humans. We therefore suggest that the measurement of suPAR using currently available 
assays has absolutely no value at the present time in decision-making in routine clinical practice.
Serum suPAR in patients with FSGS: trash or treasure  |  71 
6
INTRODUCTION
Focal segmental glomerulosclerosis (FSGS) is a common histologic finding in children and adults 
with nephrotic syndrome (1, 2). Podocyte damage plays a pivotal role in the development of 
proteinuria (3). Well-known causes of podocyte injury and FSGS include gene mutations, viral 
infections, and drugs (4). However, in most patients with nephrotic syndrome and FSGS the 
underlying cause is unknown, a condition also defined as idiopathic FSGS. It is now well-accepted 
that the pathogenesis of idiopathic FSGS involves a circulating factor that disturbs podocyte 
function and increases glomerular permeability. This concept of a circulating permeability factor 
as a cause of idiopathic FSGS is supported by experimental and clinical evidence (summarized in 
Table 1) (5-11). 
Although the existence of a permeability factor is not disputed, the search for a causative 
permeability factor has thus far been unsuccessful. Recently, Wei et al. have proposed soluble 
urokinase plasminogen activator receptor (suPAR) as a circulating factor causing FSGS (12). In 
this review, we briefly summarize the structure and function of uPAR and the relevance of the 
cellular actions of soluble and membrane-bound uPAR for the development of proteinuria. We 
discuss the evidence that suPAR is a cause of idiopathic FSGS, and whether measurement of 
suPAR is of value in current clinical practice. 
Table 1. Clinical and experimental evidence for a circulating factor in the pathogenesis of FSGS and its 
post-transplant recurrence
Serum from patients with idiopathic FSGS increases glomerular albumin permeability in vitro (5)
Serum from patients with post-transplant FSGS recurrence induces proteinuria in rats (6, 7) 
Proteinuria recurs within days after kidney transplantation in many patients with native kidney FSGS (8)
Plasmapheresis and immune absorption induces proteinuria remission in post-transplant FSGS (9)
A newborn child from a mother with FSGS had transient proteinuria (10)
Reimplantation of a kidney allograft with FSGS recurrence in another patient resulted in proteinuria 
remission (11)
FSGS, focal segmental glomerulosclerosis
Structure and function of uPAR
In healthy tissues, the expression of the membrane-bound uPAR is limited (13). However, 
uPAR is strongly expressed by many different cell types during physiologic and pathologic 
tissue remodelling. For example, it is expressed in osteoclasts during bone resorption and in 
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macrophages, vascular smooth muscle cells and endothelial cells during the formation of the 
atherosclerotic plaque (14, 15). uPAR also has a role in the migration of activated T lymphocytes, 
monocytes and neutrophils to sites of inflammation (16-18). Furthermore, the overexpression of 
uPAR in malignancies reflects the migratory and invasive features of cancer cells and is associated 
with disease progression (19). 
Structurally, uPAR is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein 
(20). It consists of three homologous domains (DI, DII, and DIII), each of approximately 90 
amino acids which are encoded by separate exon sets of the Plaur-gene (21). Binding to GPI 
at the DIII domain attaches uPAR to the cell membrane (Figure 1) (22, 23). The molecular 
mass of non-glycosylated uPAR is approximately 35 kDa, whereas glycosylated uPAR has a 
molecular mass of approximately 60 kDa (20). uPAR was initially characterized as a cofactor 
for plasminogen activation by its ligand urokinase plasminogen activator (uPA or urokinase) 
(22). Vitronectin was identified as a second ligand of uPAR (24). The crystal structure of uPAR 
allows simultaneous binding of uPA at its central concave surface and vitronectin at the linker 
region between DI and DII on the outer surface (25). Furthermore, the uPA-uPAR interaction 
promotes vitronectin binding, possibly as a result of uPAR clustering in lipid raft portions of the 
cell membrane, which are platforms for cell signaling (26). Interactions with its ligands appear to 
be relevant for uPAR-mediated cell signaling. Being surface anchored, uPAR needs to associate 
with transmembrane proteins to influence intracellular processes. Integrins are one of several 
groups of transmembrane proteins which fulfill this function (27). These heterodimer receptor 
proteins have a long extracellular and a short intracellular domain (28). Integrins link the actin 
cytoskeleton to the extracellular matrix by inside-out and outside-in signaling properties (28). 
The interaction between uPAR and integrins appears to be vitronectin-dependent, although the 
exact mechanism is not elucidated (29, 30). 
Cleavage of uPAR from the cell membrane is catalyzed by various enzymes and can occur both at 
the GPI –anchor and at the linker region between DI and DII (31). The suPAR resulting from 
cleavage may thus consist of domains DI-II-III (suPAR
I-III
), DII-III (suPAR
II-III
), or DI (suPAR
I
) 
(Figure 1). Only suPAR
I-III
 is able to bind vitronectin and uPA (32) and due to its ligand-binding 
ability, it may be able to interact with integrins and influence intracellular processes. The role of 
the splice variants is only partly known. There is evidence that suPAR
II-III
 has specific properties: 
when cleaved at a specific site in the linker region, a chemotactic sequence is exposed that 
stimulates monocyte migration through interaction with the G-coupled formyl peptide receptor-
like 1 (33-35). In conclusion, suPAR appears to be more than mere “trash shed from the cell 
surface” as formulated by Thunø et al. (36). 
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Figure 1. The urokinase plasminogen activator receptor (uPAR) is bound to the membrane by a 
glycosylphosphatidylinositol (GPI)-anchor. Cleavage of the GPI-anchor results in formation of soluble 
uPAR (suPAR). Both uPAR and suPAR can be cleaved in the protease-sensitive linker region between 
the D1 and D2 domains in a reaction catalyzed by the ligand urokinase (uPA). Cleavage results in a D1 
and a D2D3-fragment, which can either be bound to the membrane or soluble. Reprinted from Blasi and 
Carmeliet (23) and used with permission from the publisher (MacMillan Publishers Ltd).
Animal models and podocyte studies link uPAR and suPAR to human proteinuria and FSGS 
Xu et al. were among the first to describe a role of uPAR in glomerular injury (37). In a rat 
model of proliferative glomerulonephritis, they observed strong uPAR expression in glomerular 
endothelial, mesangial and epithelial cells. There were also numerous glomerular fibrin deposits. 
Although these authors primarily considered a role for uPAR-uPA in the degradation of fibrin 
deposits, they recognized that uPAR may also be involved in podocyte effacement and detachment 
from the glomerular basement membrane. 
Proteinuria is characterized by podocyte foot process effacement. The morphological changes 
in podocytes in proteinuric diseases are reminiscent of the migratory features of cancer cells. 
This observation stimulated Wei et al. to study the potential role of uPAR in proteinuria (38). 
In this study they demonstrated increased Plaur mRNA in glomeruli of patients with FSGS 
and diabetic lesions. In the lipopolysaccharide and puromycin aminonucleoside nephrosis mouse 
models of proteinuria, uPAR expression was primarily located at the podocyte cell membrane, 
and the expression of uPAR and vitronectin were co-localized in podocytes. Plaur knockout (and 
thus uPAR-negative) mice were protected from proteinuria after lipopolysaccharide injection, 
but this effect was restored after Plaur gene reconstitution. It was already known at this time 
that podocyte α3β1-integrin is crucial for podocyte foot process development (39), and that both 
α3β1-integrin and αvβ3-integrin are present at the base of podocytes and in the slit diaphragm 
(39, 40). Based on these data, and the well-known interaction between uPAR/vitronectin and 
integrins, the aim of subsequent experiments was to identify a role for integrins in podocyte 
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uPAR signaling. In podocyte cultures and murine models, uPAR was shown to cause vitronectin-
dependent αvβ3-integrin activation (38). Subsequent integrin-mediated activation of the small 
GTPases Rac and Cdc42 resulted in reorganization of the actin cytoskeleton and caused proteinuria 
in mice. A modified form of uPAR that was not able to bind α3β1-integrin did not prevent 
lipopolysaccharide-induced proteinuria in mice, suggesting that uPAR did not interact with 
α3β1-integrin in the development of proteinuria. A further study identified activated nuclear 
factor of activated T cells, cytoplasmic 1 (NFATc1), as a mediator of uPAR expression and β3-
integrin activation in podocytes (41). Interestingly, cyclosporine interrupted NFATc1:uPAR:β3-
integrin signaling and proteinuria in a T cell-independent manner. 
Subsequent studies addressed the question of whether not only membrane-bound podocyte uPAR, 
but also circulating suPAR could be implicated in the pathogenesis of proteinuria (12). High-
dose recombinant mouse suPAR
I-III
 induced proteinuria in Plaur knockout mice. A kidney from 
a Plaur knockout mouse that was transplanted in a wild-type mouse developed proteinuria after 
lipopolysaccharide-induced suPAR production, indicating that circulating suPAR may activate 
β3-integrin independent of uPAR. Furthermore, proteinuria and FSGS-like lesions developed 
in wild-type mice after planting a suPAR
I-II
 producing plasmid in their skin. Interestingly, 
these non-proteinuric mice already had suPAR levels of approximately 3000 pg/mL at baseline 
before activation of the plasmid by electroporation. After the initiation of recombinant suPAR 
expression by the plasmid, a sharp rise in urinary suPAR excretion was seen, along with a rise of 
blood suPAR up to 5000 pg/mL. A plasmid with a point mutation in the DII-domain that did 
not bind to β3-integrin was also expressed and did not induce proteinuria. Taken altogether, the 
results of these experiments provide evidence that whole domain suPAR
I-III
, as well as shorter 
fragments can cause proteinuria in mice. Additional in vitro studies were performed to study 
the possible role of suPAR in human FSGS. Sera from patients with FSGS who were treated for 
post-transplant disease recurrence were used for this purpose. Increased activation of β3-integrin 
was observed when differentiated podocytes were exposed to sera from patients with recurrent 
FSGS. Podocyte β3-integrin activation was reduced when using sera from patients with complete 
proteinuria remission after plasmapheresis, and it was blocked by antibodies against uPAR and 
a β3-integrin inhibitor. Increased β3-integrin activation was also observed in the glomeruli of 
patients with idiopathic FSGS in their native or transplant kidney, compared to controls with 
minimal change disease or membranous nephropathy. Of note, long before these studies, Kemeny 
et al. already described enhanced podocyte β3-integrin staining along with loss of podocyte α3-
integrin and α5-integrin staining in the biopsy of a patient with recurrent FSGS (42). A decrease 
of serum suPAR and β3-integrin activation after plasmapheresis was associated with complete 
proteinuria remission.
These experimental studies formed the basis for the hypothesis that suPAR may be the circulating 
factor causing human FSGS (Figure 2). However, even these studies should be interpreted with 
caution and do not prove that suPAR is the circulating permeability factor in humans. It is unclear 
if intact suPAR or a fragment of suPAR is most relevant. The pivotal work of Savin et al. showed 
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that the permeability factor resided in a 30- to 50-kDa plasma fraction, but this information has 
not lead to the identification of a causative factor (43). Still, it is consistent with the molecular 
mass of intact deglycosylated suPAR or glycosylated suPAR fragments. If suPAR depends on 
vitronectin for the interaction with β3-integrin, suPAR
I
 and suPAR
II-III
 are unlikely FSGS factors, 
because they do not bind to vitronectin efficiently (32). Crucial vitronectin-binding epitopes have 
been identified in domains I and II (29). This theoretically includes the protein product of the 
plasmid used in the mouse experiments performed by Wei et al. as a candidate for vitronectin 
binding. mRNA encoding this fragment has been identified in mice, but the corresponding 
protein was not detected in vivo (44, 45). In western blots the size of the predominant fragment 
in the sera of FSGS patients was 22 kDa, which may represent this fragment, although there has 
been no formal identification (12). Interpretation of the experiments with cultured podocytes 
is also equivocal. Other factors can activate β3-integrin. Bitzan et al. recently confirmed that 
podocyte β3-integrin could be activated by plasma from patients with FSGS recurrence. However, 
this activation could be reversed by blocking tumour necrosis factor-alpha (46). Wei et al. used 
antibodies against uPAR (12), and the studies thus do not allow exclusion of the possibility 
that the reduction of β3-integrin activation was mediated by blocking membrane bound uPAR. 
Interestingly, tumour necrosis factor-alpha is critical for uPAR-expression, at least on platelets 
(47). 
 
Figure 2. Schematic representation of the presumed mechanism whereby the soluble urokinase plasminogen 
activator receptor (suPAR) causes foot process effacement and proteinuria. Question marks reflect areas of 
uncertainty. Left: normal podocytes with inactive αvβ3-integrin. Middle: pathogenic suPAR molecules 
originate from an unknown source and have an undefined structure; they activate podocyte αvβ3-integrin 
either via direct binding or interaction with vitronectin (Vn). Right: activated αvβ3-integrin causes 
intracellular Rac and Cdc42 activation, resulting in actin cytoskeleton rearrangement and foot process 
effacement. GBM, glomerular basement membrane.
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Circulating suPAR is a prognostic marker in many non-proteinuric human diseases
In healthy adults, mean serum and plasma suPAR concentrations of approximately 2000 pg/mL 
have been reported using commercially available assays, with a maximum level of 4000 pg/mL 
(48, 49). Higher serum or plasma suPAR levels have been demonstrated in patients with various 
diseases, such as cancer, sepsis, liver disease, and atherosclerosis (49-52). In these studies, patients 
with stage III lung cancer had mean serum suPAR levels of 3416 pg/mL, and patients with sepsis 
who did not survive even had median serum suPAR concentrations of 14060 pg/mL (49, 50). 
There was a wide range of suPAR values. In patients with systemic lupus erythematosus, suPAR 
level is correlated with disease activity (53). The overall conclusion of these studies is that suPAR 
level cannot be used as a marker of a specific disease. It is shown that an increased concentration 
of serum/plasma suPAR predicts an adverse outcome in many different diseases.
The assays used in these studies use antibodies against full-length suPAR
I-III
, which may detect 
both intact and spliced circulating suPAR. Specific assays have demonstrated the presence of 
all three forms of suPAR in plasma samples from patients with acquired immunodeficiency 
syndrome, lung cancer and colorectal cancer (54-56). For example, in patients with acquired 
immunodeficiency syndrome, mean plasma concentrations were 81 fmol/L for suPAR
I-III
 
(approximately 4000 pg/mL for a 50-kDa molecule), 144 fmol/ml for suPAR
II-III
 (approximately 
5000 pg/mL for 35-kDa molecule), and 89 fmol/mL for suPAR
I
 (approximately 1300 pg/mL 
for 15-kDa molecule). It is unclear if measurement of suPAR fragments provides additional 
information. 
Of note, the fact that increased levels of suPAR are observed in patients with various diseases in 
the absence of overt proteinuria suggests that the current assays are not specific for pathogenic 
(i.e. proteinuria causing) suPAR.     
Circulating suPAR levels in patients with FSGS
The interest in measuring serum suPAR was sparked by the study of Wei et al. (12). The 
investigators measured suPAR in patients and healthy controls using a commercially available 
assay (Quantikine human suPAR immunoassay; R&D diagnostics, Minneapolis, MN) and 
found increased serum suPAR levels in patients with FSGS as compared to patients with 
other glomerular diseases or healthy controls. A cut off value of 3000 pg/mL was considered 
optimal. Values above this threshold were observed in 45 out of 63 patients with “idiopathic” 
FSGS, in 4 out of 11 patients with membranous nephropathy, and in none of the patients with 
minimal change disease, preeclampsia, or healthy controls (12). The highest serum suPAR 
concentrations were found in sera of patients with FSGS who developed proteinuria recurrence 
after transplantation. These data and especially Figure 1 in the published article of Wei et al. (12), 
which illustrated the clear-cut differences in serum suPAR levels between patients with FSGS and 
controls groups, have been used as evidence that suPAR is the pathogenic circulating factor in 
FSGS which causes disease recurrence and that measurements of serum suPAR are useful in the 
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diagnosis and guidance of FSGS treatment. However, in our view the data are biased and should 
be interpreted more cautiously. In the western blotting assay of Wei et al. (12) the molecular 
weight of the predominant suPAR fragment in FSGS serum was 22 kDa. It is well known that 
proteins of this size pass the glomerular filter. Thus, serum levels of such proteins (e.g. kappa 
light chains) are inversely related to estimated glomerular filtration rate (eGFR). Furthermore, 
the association between elevated suPAR levels and atherosclerosis, which has been found in the 
general population and in patients with chronic kidney disease, should be taken into account (57, 
58). Indeed, we and others have reported an association between eGFR and serum suPAR levels 
(59-63). Wei et al. did not adjust for eGFR in their first study. In fact, the majority of patients with 
FSGS were dialysis dependent, whereas the disease controls were not. Moreover, most dialysis-
independent adult patients with FSGS had reduced eGFR, thus invalidating a comparison with 
minimal change disease and preeclampsia patients, who had normal renal function. Therefore, the 
patients with FSGS can only be compared to the patients with membranous nephropathy. If we 
use the cut off value of 3000 pg/mL increased values were seen in 10 out of 15 patients with FSGS 
and 4 out of 11 patients with membranous nephropathy, a non significant difference (P =0.23). 
There is one additional note of caution. It is well known that FSGS is a histological diagnosis, 
and not a disease entity. Clinical characteristics can be used to differentiate between secondary 
and idiopathic FSGS, and the best clinical marker is serum albumin (64). Patients with secondary 
FSGS usually have normal or slightly decreased serum albumin levels, whereas patients with 
idiopathic FSGS are hypo-albuminemic. In their study, Wei et al. included 12 adults with FSGS. 
In only three patients serum albumin values were available (33, 43, and 43 g/L, respectively), 
challenging the diagnosis “idiopathic” FSGS.
Subsequent studies of other investigators have provided additional information to suggest that 
measuring suPAR is not useful. We measured serum suPAR levels in 11 patients with idiopathic 
FSGS, 5 patients with secondary FSGS, and 7 patients with minimal change disease (Chapter 4). 
All cases were biopsy-proven, and all patients with idiopathic FSGS had a serum albumin <30 
g/L. Median serum suPAR levels were 2392 pg/mL (idiopathic FSGS), 2716 pg/mL (secondary 
FSGS), and 2482 pg/mL (minimal change disease), respectively (no significant difference). We 
found a relationship between suPAR levels and eGFR, and the highest level was observed in a 
patient with minimal change disease and acute kidney injury, who needed dialysis treatment. 
Admittedly, numbers were small, but our data indicated that measuring suPAR levels is not 
useful for the individual patient. Recent studies reported at the 2012 meeting of the American 
Society of Nephrology extended and confirmed our conclusions (Table 2) and also confirmed 
the relationship between suPAR levels and eGFR (59, 60). In these studies, no differences were 
observed in serum suPAR levels when patients with FSGS were compared with patients with IgA 
nephropathy, lupus nephritis, membranous nephropathy and chronic tubulointerstitial nephritis 
(60). Two pediatric studies reached conflicting results with regard to the specificity of suPAR 
elevation in FSGS patients (65, 66). However, neither study presented eGFR values. 
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Franco-Palacios et al. found comparable pretransplant suPAR levels of approximately 6000 pg/
mL in adult kidney allograft recipients with FSGS and IgA nephropathy, respectively (67). Pre-
transplant suPAR did not predict FSGS recurrence. 
In their most recent study, Wei et al. have measured serum suPAR levels in 70 patients who 
participated FSGS clinical trial sponsored by the National Institutes of Health and in 94 
patients from PodoNet (68). The authors concluded that their data support a role of suPAR 
in the pathogenesis of FSGS. However, also this study should be interpreted with caution and 
provides no definite answer. The authors clearly showed that serum suPAR levels are correlated 
with eGFR. Remarkably, the highest levels were observed in patients with a podocin mutation, 
which is in contrast with the observation that recurrences of FSGS occur most frequently in 
patients with non-genetic, idiopathic FSGS. In multiple regression analysis, lower suPAR levels 
were associated with mycophenolate mofetil (MMF) treatment. This finding was explained by an 
increase of suPAR in patients that were treated with cyclosporine and a non-significant decrease 
in patients on MMF therapy. The difference in suPAR levels can be attributed to the contrasting 
effects of the drugs on eGFR. Finally, the authors suggested that there was a correlation between 
the relative reduction of suPAR after 26 weeks of therapy and the reduction of proteinuria. This 
finding is contra-intuitive, since treatment with cyclosporine reduced proteinuria and increased 
suPAR, whereas treatment with MMF was slightly less effective in reducing proteinuria and did 
not alter suPAR levels. Moreover, if at all the effect of the relation is very weak, with a reported 
beta coefficient of 0.03 g/g per 10% change in suPAR. To illustrate the impact, a reduction of 
suPAR by 50% would thus lead to a reduction of proteinuria of 0.15 g/g. 
CONCLUSION
The results from the in vitro studies and mouse models suggest that membrane-bound uPAR 
on podocytes is involved in the development of proteinuria and FSGS, likely by activation of 
β3-integrin signaling (38). Experimental data suggest that suPAR also might cause proteinuria 
and FSGS (12). However, these findings cannot be easily translated to routine patient care. 
Measurement of suPAR with the assays currently available is of no proven clinical value in patients 
with FSGS. We cannot exclude that hitherto unidentified fragments of suPAR are involved in 
FSGS and therefore support further studies in this field. It is also possible that suPAR is one 
of multiple hits to the podocyte, which converge to a final common pathway of “idiopathic” 
FSGS. Potential new diagnostic tests should be systematically assessed in prospective clinical 
studies to determine their utility as a marker of disease, prognosis and response to therapy. Until 
new information becomes available, we do not recommend taking suPAR levels into account in 
decisions on patient care. 
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ABSTRACT
 
The term idiopathic nephrotic syndrome traditionally covers minimal change disease and focal 
segmental glomerulosclerosis (FSGS), now thought to be separate disease entities. Clinical 
and experimental evidence suggest that circulating permeability factors are involved in their 
pathogenesis. In the past four decades, many investigators have searched for the responsible 
factors, thus far with little success. The recent report of the soluble urokinase plasminogen 
activator receptor as a causative factor in FSGS has received much attention, but again the initially 
promising findings were not confirmed. We describe the history of the search for permeability 
factors, discuss the pitfalls that are likely responsible for the lack of success, and propose criteria 
that should be used in future studies when evaluating candidate permeability factors.  
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INTRODUCTION
The term idiopathic nephrotic syndrome (iNS) was used to describe a condition consisting of 
proteinuria, hypo-albuminemia and edema, caused by a glomerular disease characterized by the 
absence of distinctive glomerular abnormalities in conventional light microscopy. Nowadays, 
minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are considered 
main causes of iNS. Most experts consider these as separate disease entities, although this is still 
debated (1). Already in 1954 Gentili et al. hypothesized that iNS was caused by a circulating 
factor, based on rather daring experiments in which they administered plasma from infants with 
iNS to non-nephrotic children and observed a minimal increase in proteinuria (2). In 1974, 
Shalhoub suggested that iNS was mediated by (a) T cell dependent circulating factor(s) that 
would affect glomerular permeability (3). Since then many investigators have tried to identify 
putative permeability factors. Still, despite the development of many new research techniques, 
thus far the responsible factors have escaped identification, with soluble urokinase plasminogen 
activator receptor (suPAR) being the latest example of an unfulfilled prophecy (4). In this review 
we describe the history of the search for permeability factors in iNS, discuss potential pitfalls, and 
provide guidance for future studies. 
Permeability factors in iNS: a hypothesis
The best evidence for the existence of circulating permeability factors and their role in glomerular 
disease came from clinical observations in recurrent FSGS after kidney transplantation (5). In 
1972, Hoyer et al. presented the cases of two children and one young adult with iNS and no or 
minimal sclerotic lesions on initial kidney biopsy (6). Subsequent biopsies showed progressive 
sclerotic lesions. End-stage renal disease (ESRD) developed within 2-6 years, despite treatment 
with high-dose corticosteroids combined with other immunosuppressive drugs. After kidney 
transplantation, proteinuria recurred and kidney biopsy showed a similar histological pattern 
and no evidence of rejection. Additional evidence for a permeability factor was derived from 
studies reporting remission of proteinuria by plasma exchange or immunoadsorption, especially if 
instituted early in the course of recurrent disease (7-9). Moreover, serum or plasma from patients 
with recurrent FSGS induced proteinuria in rats and increased albumin permeability in isolated 
glomeruli (10, 11). Case reports demonstrated transmission of FSGS from a mother to her child, 
and remission of proteinuria following implantation of a kidney with FSGS in recipients with 
other kidney diseases (12-14). In contrast, there is less clinical evidence for the existence of a 
circulating permeability factor in MCD. The idea that a permeability factor produced by T 
cells is responsible for MCD was based on combining several observations: i) the association 
with non-Hodgkin lymphoma and atopy, the onset of remission of MCD after measles infection 
and the induction of remission by immunosuppressive agents that inhibit T cell function 
(corticosteroids or cyclophosphamide) all suggested involvement of T cells; ii) the absence of 
T cells or immunoglobulins in kidney biopsies; iii) the discovery of lymphokines, biologically 
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active products of lymphocytes present in plasma (3, 15, 16). Evidence for a circulating factor was 
also supported by a single case report of proteinuria remission after transplantation of two kidneys 
from a donor with biopsy proven active MCD (17).
The search for permeability factors 
Many investigators have evaluated the role of circulating permeability factors in iNS. When 
comparing literature data, it is obvious that different models have been used to identify the 
factor, with most authors using only one model (18). Moreover, few studies have validated their 
results. Also patient populations have been divergent. It is evident that strict criteria are needed 
to evaluate the pathogenic and causative role of a putative disease-causing permeability factor. In 
the 19th century Koch proposed a set of criteria to judge the pathogenic role of micro-organisms 
as cause of disease (19). Johnson et al. adapted these criteria to be applicable to the studies of the 
pathobiology of growth factors in glomerular disease (20). Such criteria are also needed in the 
search for glomerular permeability factors (GPFs) (21). Table 1 summarizes the conditions that 
should be met before a permeability factor can be considered the pathogenic culprit. 
Table 1. Conditions that should be met before a permeability factor can be considered pathogenic
Criteria to establish the causality 
of a putative permeability factor
Requirements Comments
I. The permeability factor must 
have biologic effects in vitro 
and in vivo, and be confirmed in 
validation studies 
−	 Development of a suitable model, 
e.g. an animal model, cell 
culture, or permeability assay
−	 Validation of the model by 
different research groups or by 
using more than one model
Response to a permeability factor  
depends on expression of the target 
molecule in an experimental model. Thus 
response may differ between animal and 
human models 
II. Identification of the 
permeability factor in well-
phenotyped patients but not 
in appropriate controls and 
validation in independent 
patient cohorts
−	 Use of biomaterial from well-
phenotyped patients and 
appropriate healthy and disease 
controls
−	 Validation of the specificity of 
the permeability factor in an 
independent patient cohort, 
preferably in a multicenter study
Good phenotyping requires
exclusion of patients with
secondary FSGS. This also
includes use of serum
albumin and amount of
proteinuria to diagnose FSGS
secondary to glomerular
hyperfiltration (89, 90)
Controls should be matched for 
confounders such as eGFR, amount of 
proteinuria, treatment
III. Temporal relation of the 
permeability factor with disease 
activity and remission
−	 Collection of multiple samples 
per patient during follow-up
−	 Adequate follow-up data
Follow-up data should include 
information on treatment response and 
proteinuria outcome, independent of 
blood pressure changes 
IV. Specific removal or 
inhibition of the permeability 
factor in vivo blocks the biologic 
effect
−	 Specificity of a method used 
to remove or inhibit the 
permeability factor should be 
demonstrated
Plasmapheresis is a rather crude method 
and removes many proteins. Thus, 
plasmapheresis can be used to obtain 
information relevant for item III, but 
cannot be used as condition to fulfil the 
requirement of this item (IV)
Adapted from references (19-21).
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Permeability factors in MCD
Vascular permeability factor (VPF)
Lagrue et al. were the first to systematically study the effect of potential plasma factors on vascular 
permeability using a defined model (22). Their investigations were stimulated by clinical 
observations and the experimental observation that a human lymphocyte product termed “skin 
reactive factor” increased permeability in guinea pig skin capillaries (6, 23). Therefore, Lagrue et al. 
used isolated lymphocytes from patients with different histological types of nephrotic syndrome 
and healthy controls (Table 2). Cell culture supernatants were injected into guinea pig skin, 
followed by immediate intravenous injection of a blue dye. Vascular permeability was measured 
as the surface of blue dye at the skin injection site. Culture medium derived from lymphocytes 
of nephrotic patients resulted in significantly higher permeability compared with controls. 
Culture of lymphocytes in serum, as well as lymphocyte stimulation with concanavalin A (Con 
A) or phytohemagglutinin (PHA) increased the response. It was concluded that lymphocytes 
from nephrotic patients produced a vascular permeability factor (VPF) that may be related to 
increased glomerular vascular permeability and the mechanism of proteinuria. Although Lagrue 
et al. are credited for being the first to document the presence of a permeability factor in MCD, 
their pivotal study actually showed that VPF was present in most but not all patients with 
nephrotic syndrome and certainly was not unique to MCD. Still, their work formed the basis for 
following studies, mainly conducted in MCD (24). These studies reported that VPF bioactivity 
corresponded with disease activity and remission, and was inhibited by cyclosporine (25, 26). 
Remarkably, plasma from patients with active MCD inhibited VPF production, but had no direct 
blocking effect on its activity (25). Matsumoto et al. studied the effect of several cytokines on 
VPF, and found that IL-4, IL-10, IL-13 and TGF-β had blocking effects, whereas IL-12 and IL-15 
stimulated its release (27-31)
Physicochemical characteristics of the VPF were investigated using culture medium of cells 
obtained from an unspecified group of patients with nephrotic syndrome (32). Using Sephadex 
column chromatography and isoelectric focusing, VPF activity was identified in a fraction with a 
molecular weight (MW) of 12 kDa, and an isoelectric point of 6.4, respectively. Furthermore, it 
was established that VPF activity mainly resided in T lymphocytes, and specifically in the CD4+ 
fraction (25, 33, 34). IL-2 is produced by T lymphocytes, and can induce a vascular leakage 
syndrome, but was shown to be distinct from VPF (35). The exact composition of VPF remains 
unknown to date. Measurement of VPF is a complex technique and has never been standardized. 
Of note, VPF is not specific for MCD/FSGS, but also common in other glomerular diseases and 
not all studies confirmed elevated VPF activity in MCD versus healthy controls (22, 36-38). More 
importantly, there is no direct evidence that the VPF causes proteinuria or even has an effect on 
the glomerular capillary wall permeability (21, 39, 40). In fact, lymphocytes of patients with IgA 
nephropathy and mild proteinuria released more VPF than lymphocytes of patients with MCD 
and heavy proteinuria (37).
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Glomerular permeability factor (GPF)
The limitations of the guinea pig skin model and the possible discrepancies between vascular 
and glomerular permeability prompted experiments in which Con A-stimulated lymphocyte 
culture supernatants were administered to rats, and glomerular histology and/or proteinuria 
were used as markers of glomerular permeability (41). A transient increase in proteinuria along 
with rat podocyte foot process effacement was elicited by cell culture supernatant of patients 
with MCD, but not of healthy or nephrotic controls. Another study also suggested the presence 
of a glomerular permeability factor (GPF) in MCD using a reduction in anionic sites in the 
glomerular basement membrane of rat kidney as read-out (40). Several authors demonstrated that 
GPF activity was present in some patients with FSGS and investigated the relationship between 
VPF and GPF in MCD (40, 42, 43). Clearly, VPF and GPF were not similar, as VPF activity was 
observed in the absence of GPF (Table 3) (40, 43).
Koyama et al. were able to construct stable T cell hybridomas, derived from T cells from patients 
with MCD (44). GPF was identified by the ability of hybridoma supernatants to induce proteinuria 
and podocyte foot process effacement when injected intravenously in rats (Table 3). The putative 
GPF was present in fractions with a MW in the range of 60-160 kDa. Unfortunately, in spite 
of the continuous production of supernatant, the T cell hybridomas have not resulted in the 
characterization of the GPF (21). 
Bakker et al. found a vasoactive plasma fraction with a MW of 80-100 kDa that affected glomerular 
sialoglycoproteins in patients with MCD (45, 46). The responsible protein was identified as 
hemopexin, a 80-85 kDa abundant heme-scavenging plasma protein (47). When purified human 
or recombinant hemopexin was infused into rats, it induced reversible proteinuria accompanied by 
podocyte foot process effacement (48, 49). Hemopexin induced nephrin-dependent cytoskeletal 
rearrangement in cultured podocytes, and increased albumin passage across monolayers of 
glomerular endothelial cells, possibly by affecting its glycocalyx (50). In MCD in relapse, lower 
titers of hemopexin but with enhanced protease activity were observed compared to MCD in 
remission and disease controls, including FSGS (49). It was suggested that various isoforms of 
hemopexin exist and that in normal conditions circulating hemopexin is inactive but that in 
certain conditions it can become activated and act as serine protease (51). These observations thus 
far have not been validated. The studies also point to some important methodological issues: i) 
it may not be sufficient to evaluate merely protein levels and ii) the factor may not only affect 
podocytes but also may alter permeability by changing the endothelial cell layer.
In view of the varying sizes reported for the permeability factor, research has also focused on 
cytokines. Especially IL-8 and IL-13 have been suggested. IL-13 has been shown to stimulate 
podocyte protein trafficking and proteolysis in vitro (52). Overexpression of IL-13 in rats induced 
a MCD-like nephropathy (53). However, it is unknown if such high IL-13 levels can be present 
in human MCD (54). A pathogenic role for IL-8 in glomerular permeability was suggested 
because serum levels were increased in MCD in relapse compared to MCD in remission and 
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disease controls and because IL-8 affected the metabolism of glomerular basement membrane 
compounds in vitro (55). However, rat podocytes incubated in vitro with high concentrations of 
human IL-8 did not show any alteration in permeability, heparin sulphate proteoglycan gene 
expression or heparan sulphate synthesis (56).
FSGS permeability factor
Experimental models to study permeability factors in recurrent FSGS have used serum rather than 
cell culture supernatants. Sera from a single patient were shown to induce proteinuria in rats, but 
histological effects were not investigated (11). Savin et al. presented an in vitro model to measure 
the effect of the FSGS permeability factor (10). This model used isolated rat glomeruli, incubated 
in isotonic bovine serum albumin. The diameter of the glomeruli and glomerular volume changes 
were measured after changing the medium to one containing a lower bovine serum albumin 
concentration. The resulting oncotic pressure gradient caused swelling of glomeruli if glomerular 
permeability was maintained. Pre-incubation of isolated glomeruli in serum of patients with 
recurrent FSGS compared to healthy controls resulted in less glomerular swelling, explained by 
loss of glomerular permeability and thus dissipation of the oncotic gradient. Permeability to 
albumin (Palb) was expressed as 1 minus the ratio of glomerular volume difference established 
by patient serum to control serum. In patients with FSGS, increasing Palb was associated with 
increasing risk of post-transplant proteinuria. A Palb cut-off of 0.50 predicted recurrence with 
a sensitivity of 60% and specificity of 95%. Compared with patients with post-transplant FSGS 
recurrence, Palb was also lower in patients with steroid-sensitive nephrotic syndrome and post-
transplant membranous nephropathy. A clinical response to plasmapheresis coincided with a 
decrease in Palb. The fraction with Palb activity precipitated in 70-80% ammonium sulphate 
solution, inconsistent with immunoglobulin. It appeared to have a molecular mass of 50 kDa, 
and was bound by protein A. The latter is consistent with a report of proteinuria remission after 
protein A column ex vivo adsorption (8). In rats, infusion of the purified 30-50 kDa fraction with 
high Palb activity caused increased proteinuria (57). 
The predictive value of albumin permeability for post-transplant FSGS recurrence has been 
investigated by only two other groups with equivocal results. In a cohort of 32 children with 
FSGS, a pre-transplant Palb value >0.6 predicted post-transplant proteinuria recurrence with 
a sensitivity of 73% and specificity of 80% (58). Godfrin et al. used a very similar model, but 
measured permeability to albumin using electric impedance (59). Compared with a control group 
of 63 patients with ESKD due to various causes, 80 patients with FSGS had significantly higher 
albumin permeability. However, some patients with membranous nephropathy had similar 
high values, and pre-transplant albumin permeability did not predict proteinuria recurrence in 
patients with FSGS. 
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Several investigators have tried to apply the findings to patients with native kidney FSGS. Palb 
>0.5 was present in 42% of children with iNS (60). However, Palb did not discriminate between 
steroid-responsive and steroid-resistant patients. In adult patients with FSGS, Palb was <0.5 in 
the majority of patients, and there was no good correlation between change in Palb and treatment-
induced changes in proteinuria (61).
Savin et al. hypothesized that the FSGS permeability factor interacts with sugars of the podocyte 
glycocalyx, which may be prevented by the monosaccharide galactose (62). Indeed, galactose had 
strong affinity for the plasma fraction <30 kDa with high Palb in FSGS patient plasma. Oral 
galactose caused a decrease in Palb in a patient with plasmapheresis-resistant post-transplant 
FSGS. There was no effect on proteinuria, which was attributed to irreversible glomerular damage. 
Proteomic analysis of the galactose-affinity fraction with high Palb suggested that cardiotrophin-
like cytokine 1 was the culprit (63). Unfortunately, these preliminary findings, reported more 
than 5 years ago, still await further confirmation. Of note, after 1999 there are no reports of 
investigators who have validated the model used by Savin et al. We were unable to reproduce 
the findings, and observed large variations when using isolated glomeruli as model (unpublished 
observations).
Other investigators have used podocyte cell cultures as model to study the presence of putative 
permeability factors in the serum or plasma of patients with FSGS. Read-out parameters have 
varied, and included a change in podocyte cell shape, or altered expression of podocyte specific 
proteins such as nephrin and podocin. Most studies have only been published in abstract form, 
and have not been validated. In a recent study, Harris et al. demonstrated increased protease 
activated receptor 1-mediated phosphorylation of the vasodilator stimulated protein (VASP) 
in response to FSGS plasma in human conditionally immortalized podocytes, suggesting that 
circulating proteases could be involved (64). However, which protease(s) would be responsible 
has yet to be determined. 
The suPAR as a permeability factor in FSGS 
In the above-mentioned studies the search for a causative circulating permeability factor in FSGS 
was guided by models that were used as biomarkers for the activity of the factor. Total serum, 
plasma, or fractions thereof were used in an “untargeted” approach toward the identification of 
the putative factor. In recent studies investigators have used a more targeted approach, based on 
more detailed knowledge of podocyte pathobiology. Using such an approach, suPAR was recently 
proposed as a candidate protein, and received much attention. The membrane-bound urokinase 
plasminogen activator receptor (uPAR) is a three-domain glycoprotein with a MW of 35-60 
kDa, depending on its degree of glycosylation (65). Proteolytic cleavage at the membrane anchor 
and the linker region between domains 1 and 2 results in different circulating (soluble) forms of 
uPAR. Originally identified as the receptor for urokinase, uPAR also interacts with transcellular 
receptors such as integrins (66). The uPAR-integrin interaction causes a motile cell phenotype 
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seen in circumstances such as inflammation and neoplasia. A similar observation of increased 
podocyte motility in proteinuric diseases stimulated research into the role of uPAR in FSGS. Wei 
et al. studied uPAR in the lipopolysaccharide (LPS) mouse model of proteinuria and in podocyte 
cultures (67). In the respective models, increased podocyte uPAR expression resulted in foot 
process effacement and actin cytoskeleton rearrangement, likely by activation of αvβ3-integrin. 
Subsequent studies addressed the inferred hypothesis that circulating suPAR is a circulating 
factor causing FSGS. We discuss these studies and show how too early optimism could have been 
prevented by applying the criteria as proposed in Table 1.
I. The permeability factor must have biologic effects in vitro and in vivo, and be 
confirmed in validation studies 
Wei et al. showed that sera from patients with post-transplant FSGS recurrence activated podocyte 
αvβ3-integrin, which was demonstrated with the β3-integrin specific antibody AP5 (68). 
Antibodies against uPAR blocked the effect on AP5. From these studies, it cannot be determined 
if uPAR or suPAR interacted with αvβ3-integrin. In fact, other pathways such as TNF-α may 
also be involved (69).  
To ascertain the relevance of suPAR, studies were conducted in vivo in uPAR-null mice. These 
mice developed dose-dependent proteinuria after injection of a chimeric full-domain murine 
suPAR linked to a human IgG1-Fc. The investigators evaluated the effects of a fragment of 
suPAR, produced by a plasmid and containing domains 1 and 2 in wild-type mice. These mice 
developed proteinuria and early FSGS lesions. A recent study by Cathelin et al. failed to validate 
the role of intact suPAR (70). These investigators showed that the same suPAR chimera as used 
by Wei et al. failed to cause proteinuria in wild-type mice despite glomerular suPAR deposition. 
Additional negative findings regarding the pathogenic role of suPAR in a similar mouse model 
were reported by Spinale et al. (71). Thus, studies with intact suPAR have failed criterion I. 
Fragments of suPAR may play a role, however these findings need further confirmation and 
validation. 
II. Identification of the permeability factor in well-phenotyped patients but not in 
appropriate controls and validation in independent patient cohorts
Wei et al. reported increased serum suPAR concentrations in patients with FSGS versus controls 
with or without glomerular disease. The highest values were found in patients who developed post-
transplant FSGS recurrence. Based on their initial data, serum suPAR concentrations of 3000 pg/
mL measured by a commercial assay were proposed as a diagnostic cut-off value. In a subsequent 
study, suPAR levels >3000 pg/mL were confirmed in 84% of FSGS patients from the NIH-FSGS 
Clinical Trial, and in 55% from the PodoNet consortium, respectively (72). By contrast, only 6% 
of controls had elevated suPAR levels. Although these findings were used as strong supportive 
evidence, the studies do not fulfil criterion II. Many patients that were included in the seminal 
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studies were not well phenotyped. In fact, a closer look at the individual patient data showed 
that the studies included patients with secondary FSGS as well as patients with hereditary FSGS, 
conditions that are not associated with recurrent disease after transplantation. Moreover, the 
controls patients were not matched for critical parameters such as estimated glomerular filtration 
rate (eGFR). We found an inverse correlation between suPAR and eGFR in a small group of 
patients with idiopathic and secondary FSGS, and MCD, and serum suPAR concentration did not 
distinguish between respective patient groups (73). When comparing suPAR concentrations in 
patients with idiopathic FSGS with eGFR-matched controls from the Leuven mild-to-moderate 
CKD study, suPAR was not higher in patients with FSGS (74). Cohorts from Japan, India, and 
the United States also failed to demonstrate elevated suPAR in patients with FSGS compared 
to other glomerular diseases, and confirmed the negative correlation between eGFR and suPAR 
(71, 75, 76). Even in FSGS patients with ESRD who had developed post-transplant disease 
recurrence, we and others did not find elevated suPAR compared to non-FSGS controls (77, 78). 
In conclusion, criterion II is not fulfilled, and the role of intact suPAR in recurrent FSGS remains 
unproven. Importantly, the investigators who first introduced the commercial R&D assay in 
FSGS research have recently suggested that a specific form of suPAR unrecognized by this ELISA 
is involved in FSGS (79). Clearly, new assays will need to be developed, which should be validated 
in independent cohorts.
III. Temporal relation of the permeability factor with disease activity and remission
Few studies have performed serial measurement of suPAR in different disease states. In a 
subgroup analysis from the NIH-FSGS Clinical Trial, there was a correlation between decrease 
in proteinuria and suPAR (72). On the other hand, Sinha et al. found no relationship between 
suPAR and disease state in patients with FSGS and MCD (76). In the setting of post-transplant 
FSGS recurrence, Wei et al. found a pronounced decrease in serum suPAR in two patients who 
responded to plasmapheresis, compared to stable levels or slightly decreasing suPAR in two 
patients who did not respond (68). Of note, corresponding eGFR values during follow-up were 
not reported. Morath et al. demonstrated that suPAR was reduced by both plasmapheresis and 
immunoadsorption (80). In addition, there was a clear relationship between amount of proteinuria 
and AP5 activation by serum on podocytes. However, plasmapheresis and immunoadsorption are 
not specific for removal of suPAR, and the authors admitted that the effect may have been related 
to other substances. Remarkably, a recent study showed that protein A column immunoadsorption 
also induced proteinuria remission, but did not remove suPAR (81). 
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IV. Specific removal or inhibition of the permeability factor in vivo blocks the biologic 
effect
No studies with suPAR have been done. Researchers are developing specific methods for the 
removal or inhibition of suPAR, and have alluded to a trial of specific suPAR removing in patients 
with FSGS. This would indeed be a strong proof of principle, and provide relief for patients who 
long for improved and less toxic treatment. 
The search for permeability factors: future perspectives 
The history of the search for a GPF is a learning experience. It is evident that circulating factors 
must be present. The search for the responsible factor has been difficult, and thus far the causative 
factor has escaped identification. We expect that causative factors will be identified in the very 
near future, due to the major advances in technology. However, there are certain caveats that 
should be taken into account.
1. We propose that collaborative efforts are needed to ascertain the validity of findings 
and define disease causality. We suggest that the criteria as illustrated in Table 1 could 
give guidance, and emphasize the need for appropriate patient phenotyping, the use of 
appropriate controls, and validation studies.
2. When searching for the permeability factor, one must bear in mind that there may be 
more than one factor. It is evident that multiple candidate proteins have been proposed 
(Table 4). Interestingly, the activity of the permeability factor has resided in plasma 
fractions with divergent MW (Table 4). One simple explanation could be the existence 
of multiple factors.
3. Increased permeability may not be caused by the presence of a causative permeability 
factor, but related to the absence of an inhibitor. Already in 1976 Moorthy et al. described 
a factor in sera of patients with MCD in relapse that could inhibit the mitogenic response 
of PHA-stimulated lymphocytes (82). However, the relevance remained uncertain 
since other groups have reported inhibition of lymphokines (macrophage migration 
inhibitor factor) not associated with iNS and an inhibitory effect on lymphocytes by sera 
from patients with FSGS and membranous nephropathy (83, 84). The group of Savin 
demonstrated that normal serum from a variety of species contains (a) factor(s) that 
block the increase in Palb by FSGS serum in vitro (85). These blocking factors may exert 
their protective effects by competing with the binding of the permeability factor to 
glomerular cells. Alternatively, normal components of serum may bind or enzymatically 
degrade the permeability factor, with several apoliproteins (Apo J, Apo L, Apo E
2
 and 
E
4
, and a fragment of Apo-IV) being proposed as relevant substances (86-88)
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Table 4. Putative permeability factors in MCD and FSGS.
Putative permeability 
factors
Molecular 
weight
Comments
MCD
GPF-NOS (22)
Hemopexin (23)
IL-13 (24)
60-160 kDa
80-85 kDa
16 kDa
Obtained from T cell hybridoma made from patients with MCD
Induced proteinuria when injected into rats
Permeability factor has not been further characterized
Both recombinant and human hemopexin induced reversible 
proteinuria accompanied by FPE in rats
Decreased serum hemopexin with increased protease activity in 
MCD in relapse
Induced nephrin-dependent cytoskeletal rearrangements 
and increased albumin permeability across monolayers of 
glomerular endothelial cells
No validation studies have been performed
Increased expression of mRNA and cytoplasmic IL-13 in CD4+/
CD8+ T cells from children with SSNS
Stimulated podocyte protein trafficking and proteolysis in vitro
Overexpression of IL-13 in rats induced MCD- like disease
No clinical studies 
FSGS
CLC-1 (25)
suPAR (14)
22-25 kDa
20-50 kDa
Increased glomerular permeability
Decreased nephrin expression in cultured podocytes
Antibody to CLC-1 reversed the permeability effect of FSGS sera
Concentrations up to 100 times higher in recurrent FSGS
Results are preliminary, only published in abstract form 
Activated podocyte β3 integrin, resulting in reorganization of the 
actin cytoskeleton of podocytes
High dose recombinant mouse suPAR induced proteinuria, 
increased podocyte β3 integrin activity and foot process 
effacement in mice lacking the gene for uPAR but not in wild 
type mice
Experimental data were not supported by clinical data: 
−	 When adjusted for renal function suPAR levels did not 
differentiate between FSGS and other kidney diseases
−	 No correlation between serum suPAR and degree of 
proteinuria
−	 Higher serum or plasma levels of suPAR were also reported 
in patients with cancer, sepsis, atherosclerosis and PNH 
without FSGS
FSGS, focal segmental glomerulosclerosis; GPF-NOS, glomerular permeability factor not otherwise 
specified; MCD, minimal change disease; PNH, paroxysmal nocturnal hematuria; CLC-1, cardiotrophin-
like cytokine-1; SSNS, steroid-sensitive nephrotic syndrome; (s)uPAR, (soluble) urokinase plasminogen 
activator receptor 
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ABSTRACT
Background: Few studies have examined treatment and outcome of nephrotic syndrome due to 
adult-onset minimal change disease (MCD). We retrospectively studied 125 patients with adult-
onset MCD who were treated in 10 centres. 
Methods: Patients were identified from the pathology records. Presenting characteristics, 
duration of initial treatment and proteinuria response, relapse patterns, complications and long-
term outcome were studied. 
Results: Corticosteroids were given as initial treatment in 105 (84%) patients, and resulted 
in remission in 92. Seven patients (6%) initially received cyclophosphamide with or without 
corticosteroids, and all attained remissions. Thirteen patients (10%) reached remissions without 
immunosuppressive treatment. Relapses were observed in 57 (62%) patients who responded to 
corticosteroid treatment. Second-line cyclophosphamide resulted in stable remission in 57% of 
patients with relapsing MCD. Acute kidney injury was observed in 50 (40%) patients according 
to RIFLE criteria. Recovery of renal function occurred almost without exception. Arterial or 
venous thrombosis occurred in 11 patients (9%). At the last follow-up, 113 (90%) patients 
were in remission and had preserved renal function. Three patients with nephrotic syndrome 
unresponsive to treatment progressed to end-stage renal disease, which was associated with focal 
segmental glomerulosclerosis lesions on repeat biopsy. 
Conclusions: The large majority of patients with adult-onset MCD were treated with 
corticosteroids and reached remissions, but many experienced relapses. Cyclophosphamide 
resulted in stable remission in many patients with relapses. Significant morbidity was observed 
due to acute kidney injury and other complications. Progression to end-stage renal disease 
occurred in few patients and was explained by focal segmental glomerulosclerosis.
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INTRODUCTION
Minimal change disease (MCD) is the most common cause of the nephrotic syndrome in children 
(1). In adults, MCD accounts for 15-20% of patients with nephrotic syndrome (2). There is no 
evidence from randomized controlled trials to support the efficacy of any treatment modality 
in adults with MCD (3). Based on extrapolation from randomized studies in children and 
observational studies in adults, corticosteroids (CS) are the cornerstone of therapy (reviewed in 
(4)). However, adults differ from children in being less responsive to CS and more likely to 
present with acute kidney injury (5-9). In the present study we retrospectively reviewed 125 
patients with adult-onset MCD treated in 10 Dutch hospitals. Specific questions relate to 1) 
response to initial CS therapy, and specifically the relation between dose and duration of initial CS 
treatment and (time to) relapse 2) prevalence and factors associated with spontaneous remissions 
which we have frequently observed, 3) disease course and response to second-line treatment in 
patients with relapsing MCD, 4) the course, severity and outcome of acute kidney injury, 5) other 
disease- and treatment-related complications, and 6) long-term outcome. 
PATIENTS AND METHODS
Study design and patient selection
From the pathology registries we identified all adult patients (age ≥ 16 years at biopsy) diagnosed 
with minimal change disease between 1 January 1985 and 1 September 2011 at the Radboud 
University Medical Center and nine participating regional hospitals. We reviewed the complete 
pathology reports. Histological criteria included normal appearing glomeruli on light microscopy 
and negative immunofluorescence staining. Exclusion criteria were absence of nephrotic syndrome 
and associated underlying conditions (10). 
Medical records were reviewed for clinical data from presentation until last follow-up. 
Demographics, presenting characteristics, laboratory parameters, dosage, duration, and response 
to medical treatments, relapses, and adverse events were recorded. All patients with follow-up of 
at least 6 months were included, as well as patients who died within 6 months. 
Definitions
Nephrotic syndrome was defined as proteinuria of ≥3.5 g/24 hours and a serum albumin 
concentration of ≤30 g/L. Complete remission (CR) was defined as proteinuria <0.2 g/24 hours or 
<0.2 g/10mmol creatinine, with progressively increasing serum albumin. Partial remission (PR) 
was defined as reduction of proteinuria to 0.2-2.0 g/24 hours or 0.2-2.0 g/10mmol creatinine, 
with a stable serum creatinine (≤25% increase from baseline). Relapse was defined by an increase 
in urinary protein excretion to ≥3.5 g/24 hours or ≥3.5 g/10 mmol creatinine in patients who 
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had at least attained a partial remission. Time to remission was calculated from initiation of 
immunosuppressive therapy to the first day on which remission was observed, and from biopsy in 
patients who did not receive immunosuppressive therapy. Frequent relapse was defined as two or 
more relapses within 6 months. CS dependence was defined as two relapses during CS treatment 
or within 2 weeks after completing CS treatment. CS resistance was defined as failure to attain 
a remission after 16 weeks CS therapy. Spontaneous remission indicates that it occurred without 
immunosuppressive treatment.
Acute kidney injury was defined according to the RIFLE criteria (11). Because serum creatinine 
before onset of the nephrotic syndrome was usually not available, p5 of age- and gender-based 
reference values were used to estimate baseline estimated glomerular filtration rate (eGFR) and 
corresponding serum creatinine values (12). Hypertension was defined as two repeated systolic 
blood pressure measurements of ≥140 mmHg or two diastolic blood pressure measurements of 
≥90 mmHg or use of blood pressure lowering agents (13).
Treatment
Spontaneous remissions may occur in adult-onset MCD (14, 15). Therefore, an initial period 
of observation was given for a minority of patients with acceptable symptoms. Prednisone was 
initiated at a dose of 1 mg/kg daily with a maximum of 80 mg or 2 mg/kg on alternate days with 
a maximum of 125 mg. Tapering was based on improvement of symptoms and proteinuria. In 
general, initial high-dose prednisone was maintained until remission, and slowly tapered with 
total treatment duration usually lasting 6 months or longer, depending on drug tolerance and 
individual experience (see results section). 
  
Statistical analyses
Continuous variables are expressed as means ± SD or median and range or interquartile range 
(IQR, 25° - 75° percentile) where appropriate. For comparison between groups Mann-Whitney 
U test was used for continuous data and Fisher’s exact test was used for categorical data. 
The Kaplan-Meier method and log-rank test were used for description and comparison of time to 
remission and time to relapse. A P-value <0.05 was considered statistically significant. 
RESULTS
Participants
From the pathology reports, we identified 180 adult patients diagnosed with MCD between 1985 
and 2011. Five patients were excluded because they had childhood-onset MCD. In these patients 
a kidney biopsy was performed because of persistent disease activity. Twenty-one patients did not 
have nephrotic syndrome, and two patients had an associated malignant disorder (lymphoma). 
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Twenty-seven patients had insufficient follow-up data. In the final analysis, we therefore included 
125 patients with adult-onset MCD. In 74 (59%) of the included patients the diagnosis was 
supported by electron microscopic studies showing diffuse effacement of podocyte foot processes, 
and no abnormalities of the glomerular basement membranes. 
Clinical characteristics at presentation are shown in Table 1. Three patients were of Turkish 
origin, five of Eastern Asian origin, and all others were Dutch Caucasian. Median duration of 
follow-up was 4.9 years (range 0.3-25.7 years, including one patient who died within 6 months 
after presentation). Kidney biopsy was performed at a median of 10 days (IQR 5-20 days) after 
presentation.
Table 1. Characteristics of patients with adult-onset MCD at presentation
Characteristic Values
n 125
Age (yr) 46 (range 16-82)
Gender (male/female) 52/73
Serum creatinine (µmol/L) 81 (70-113) 
eGFR (mL/min/1.73m2)† 81 (53-97)
Serum albumin (g/L) 20 (15-25)
24h urinary protein excretion (g) 9.6 (6.0-14.5)
Hypertension (%) 36.8
eGFR, estimated glomerular filtration rate. Data are expressed as median (interquartile range) unless stated 
otherwise.
† eGFR was estimated with the abbreviated Modification of Diet in Renal Disease formula
Initial treatment and outcome
The majority of patients (84%) received initial treatment with oral prednisone (Table 2), 
administered in a daily dose of 1 mg/kg (73%) or an alternate day dose of 2 mg/kg (27%). There 
were no significant differences in baseline variables between those who received daily or alternate 
day prednisone. Cumulative remission rates were 68% (52% CR / 16% PR) after 8 weeks, and 
88% (67% CR / 21% PR) after 16 weeks, respectively. Cumulative time to remission is shown 
in Figure 1a and Figure 1b. There were no significant differences in time to remission between 
patients who received daily or alternate day CS. In 40 patients, the date of first PR and CR 
coincided. CS were gradually tapered after a median of 7 weeks (IQR 4-10 weeks) over a period 
of 30 weeks (IQR 13-42 weeks). 
In seven patients (6%) the initial immunosuppressive therapy consisted of cyclophosphamide 
and prednisone (n =6) or cyclophosphamide alone (n =1). Median initial cyclophosphamide dose 
was 150 mg (range 50-150 mg). Compared to patients treated with CS, patients treated with 
cyclophosphamide had significantly more proteinuria (P =0.02) and a lower eGFR (P =0.02) at 
presentation. All patients treated with cyclophosphamide attained remissions.
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Figure 1. Cumulative remission rates during initial corticosteroid treatment
Partial remission (A); complete remission (B)
Spontaneous remission
Spontaneous remissions occurred in 13 patients (10%; Table 2). Compared to patients who 
received immunosuppressive treatment, these patients had less severe nephrotic syndrome at 
baseline. Median time to PR was 13 (IQR 4-51) weeks in untreated patients, compared to 4 (IQR 
2-7) weeks in patients who reached remissions on immunosuppressive therapy (P =0.06). Ten 
patients with spontaneous remissions had a progressive rise in serum albumin after biopsy, with 
eight reaching levels ≥30 g/L within 3 months, indicating clinical improvement. For comparison, 
we evaluated follow-up data of patients who were treated with CS after an initial symptomatic 
treatment of at least 2 months (n =12). In these patients, a progressive decline (n =5) or persistently 
low serum albumin <25 g/L (n =7) was observed during symptomatic treatment.  
 
Corticosteroid-resistant minimal change disease
Thirteen patients had CS resistant MCD (outlined in Supplementary Table). Eight patients 
reached remissions after prolonged therapy. A significant decrease in proteinuria during initial 
CS treatment often preceded a remission after additional therapy. Repeated biopsies were 
performed because of persistent proteinuria in four patients. In three patients, focal segmental 
glomerulosclerosis (FSGS) lesions were found. 
Relapsing minimal change disease 
Relapse free survival and time to first relapse are shown in Figure 2 and Table 2, respectively. 
Of 92 patients with initial CS-induced remissions, 35 (38%) did not experience relapse during 
follow-up. Forty-three of 57 patients who relapsed were treated with a repeated course of CS. 
All had remissions after a median of 4 weeks (IQR 2-8 weeks), and maintained high-dose CS 
for 5 weeks (IQR 2-11 weeks). These data are similar to the results of initial CS treatment 
(Table 2). Nineteen patients (44%) did not have further relapses after the second course of CS. 
Of the remaining 24 patients with further relapses, 16 developed CS dependent and 2 frequently 
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relapsing MCD. One additional patient who received a combination of cyclosporine and CS after 
the first relapse developed CS dependent MCD. 
Figure 2. Relapse free survival after initial corticosteroid-induced remission
Cyclophosphamide and cyclosporine were the main second-line drugs for relapsing MCD. Timing 
of treatment and clinical course in these patients are shown in Figure 3. Twenty-one patients with 
relapsing MCD (11 CS dependent, 1 frequently relapsing, and 9 relapsing) received 28 courses of 
cyclophosphamide. Median daily dose of cyclophosphamide was 150 mg (range 100-200mg), and 
median duration of treatment was 13 weeks (range 6-44 weeks). Cyclophosphamide was initially 
combined with CS in virtually all patients. Twelve patients (six CS dependent, six relapsing) 
successfully tapered CS and had stable remissions during follow-up (Figure 3). 
Seven patients (three CS dependent, one frequently relapsing, and three relapsing) with relapsing 
MCD after initial CS treatment received second-line cyclosporine. Four patients who received 
cyclosporine had previously received cyclophosphamide. Median maintenance dose of cyclosporine 
was 300 mg/day (range 150-400 mg/day). Median duration of cyclosporine treatment was 131 
weeks (range 28-543 weeks), and four patients were still on cyclosporine at last follow-up. Six 
patients received concurrent cyclosporine and CS. All patients had remissions during cyclosporine. 
Only one patient discontinued both cyclosporine and CS without further relapses. 
Only one patient with relapsing MCD received mycophenolate, and none received rituximab. 
Two relapses occurred in patients who were initially treated with cyclophosphamide. Both 
responded to repeated cyclophosphamide treatment, and did not experience further relapses.  
Two patients who had spontaneous remissions experienced a relapse, which again resolved without 
immunosuppressive treatment.
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Figure 3. Second-line cyclophosphamide and cyclosporine therapy in patients with relapsing MCD
|   relapse treated with corticosteroids
  relapse treated with cyclophosphamide
- - - relapse treated with cyclosporine
×  end of follow-up
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Acute kidney injury
Acute kidney injury was observed in 50 patients (40%). According to RIFLE classification, 
17 (14%) had Risk, 12 (10%) had Injury, 19 (15%) had Failure, and 2 (2%) had Loss. All 
acute kidney injury episodes except one occurred during the initial episode of MCD. Patients 
with acute kidney injury were older, more likely to be male and hypertensive, and had more 
proteinuria (Table 3). Eliciting factors for acute kidney injury involved initiation of non-steroidal 
anti-inflammatory drugs (n=4), a combination of non-steroidal anti-inflammatory drug use and 
duodenal ulcer perforation (n=1), haemorrhage after kidney biopsy (n=1), and contrast-medium 
administration for a diagnosis of pulmonary embolism (n=1). Median time to recovery of renal 
function was 6 weeks (IQR 3-12 weeks). Nine patients needed hemodialysis, all of them received 
CS. Haemodialysis was maintained for a median of 16 days (range 1-74 days). Eight had recovery 
of renal function, but one patient died of infectious complications during CS treatment while he 
was on haemodialysis. Post mortem examination revealed Pneumocystis jiroveci pneumonia, and 
disseminated bacterial abscesses. Remissions were reached in all other patients with acute kidney 
injury, except one who had FSGS lesions on a subsequent biopsy. Patients with Failure or Loss 
tended to have longer time to remission compared to other patients, but differences were not 
statistically significant. 
Table 3. Baseline parameters and outcome of patients with and without AKI
Characteristic No AKI AKI (any RIFLE class) P-value 
n (%) 75 (60) 50 (40)
Age at onset (yr) 41 (28–52) 55 (42–72) <0.001
Gender (male/female) 23 / 52 29 / 21 0.002
Hypertension (%) 19 (25) 27 (54) 0.001
Serum albumin (g/L) 21 (17–25) 18 (15-23) 0.06
24h urinary protein excretion (g) 7.5 (5.1–11.6) 12.4 (9.6-18.5)  <0.001
eGFR at last follow-up 
(n =121*)
88 (75–103)
(n =73)
76 (61–87)
(n =48)
<0.001
eGFR at last follow-up lower than p5 of 
reference value (%)
(n =121*)
6 (8) 9 (19) 0.10
Data are expressed as median (IQR) or n (%). 
*Three patients who progressed to end-stage renal function and one patient who died during AKI were 
excluded from the analysis
Long-term outcome
Clinical status at the end of follow-up is summarized in Table 4. In general, patients had good 
renal outcome. Three patients with CS resistant MCD had progressive renal failure. Repeated 
biopsies were performed on two of these patients, and revealed FSGS lesions (Supplementary 
Table). One additional patient who did not reach CR also had FSGS lesions on a repeated biopsy. 
At the last follow-up, previous acute kidney injury was associated with lower eGFR (Table 3). 
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However, the proportion of patients with eGFR below the p5 of the age- and gender-based 
reference value was not significantly different compared with patients who did not experience 
acute kidney injury. 
One patient described above died of infectious complications within 16 weeks after initiation 
of CS treatment. Four other patients died after achieving CR, and were no longer receiving 
treatment for MCD at the time of their deaths. Causes of death were small cell lung carcinoma 
(n =1; aged 80 years), breast cancer (n =1; aged 69 years), sudden cardiac arrest (n =1; aged 76 
years), and bladder carcinoma (n =1; aged 77 years), respectively. The patient with a bladder 
carcinoma had received two courses of cyclophosphamide given 4 and 2 years before death, 
respectively. The other patients who died had not received second-line treatment. 
Table 4. Clinical status at the end of follow-up by initial treatment and CS responsiveness
CS responsive CS resistant Cyclophosphamide No immunosuppression
CR 84 6 6 13
PR 1 2 1 -
Relapse 3 - - -
Active 
immunosuppressive 
treatment
26 - - -
Persistent NS - 1 - -
ESRD - 3 - -
Death 4 1 - -
Total 92 13 7 13
CR, complete remission; CS, corticosteroids; ESRD, end-stage renal disease; NS, nephrotic syndrome
Other complications
Several disease- and treatment-related adverse events occurred. Thrombotic events usually 
occurred early after first presentation or relapse, in the presence of severe nephrotic syndrome 
(Table 5). In one patient a lower extremity deep venous thrombosis was diagnosed after remission 
of nephrotic syndrome.
Particularly severe infectious complications occurred in a 35 year-old female with CS dependent 
MCD. She needed intensive care treatment twice during follow-up for spontaneous bacterial 
peritonitis and influenza pneumonia, respectively. All other complications are listed in Table 6. 
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Table 6. Other disease- and treatment-associated complications in patients with MCD 
Complication Number of patients
Upper respiratory infection 5
Bacterial pneumonia 5
Herpes zoster 3
Candida stomatitis 3
Staphylococcus aureus bacteremia 1
Campylobacter jenuni 1
Pneumocystis jiroveci pneumonia * 1
CS induced diabetes mellitus 9
Osteoporotic fracture 3
CS induced psychosis 2
Hemorrhagic duodenal ulcer 1
Hemorrhagic cystitis 1
Sudden cardiac arrest * 1
Bladder cancer * 1
Squamous cell cancer 1
Small cell lung cancer * 1
Breast cancer * 1
CS, corticosteroids
* Causes of death
DISCUSSION
We have pooled our results with four previous studies that have mainly included Caucasian 
patients with adult-onset MCD in order to obtain an overview of 400 cases (6-9), summarized 
in Table 7. It appears from these studies that adult-onset MCD may present at any age, and that 
there is a slight female preponderance. At presentation, the disease is typically characterized by 
heavy nephrotic syndrome, and most patients have a normal eGFR. Our study confirms that 
routine high-dose CS is an effective treatment, although CR is often delayed. Current guidelines 
suggest that initial high-dose CS should be maintained up to 16 weeks until CR is reached (16). 
At that time point, 70% of patients have CR (Table 7). Our data indicate that prolonged CS 
or other immunosuppressive treatment induced remissions in most patients with CS resistant 
MCD. Those with a clear proteinuria reduction after 16 weeks were most likely to benefit from 
additional treatment. Patients with persistent proteinuria and progressive renal disease usually 
had FSGS on repeated biopsy.
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Early randomized studies in adult-onset MCD have shown that spontaneous remissions eventually 
occur in >50% of patients (14, 15). We observed a spontaneous remission rate of 10%. A steady rise 
in serum albumin was observed in these patients. By contrast, patients who received CS treatment 
after an initial waiting period had a persistently low or progressively declining serum albumin. 
Patients with spontaneous remissions experienced few relapses. There were no thrombotic or 
infectious complications in patients who received no or delayed immunosuppressive treatment. 
We have seen similar spontaneous remission rates in patients with FSGS (17). We suggest that 
an initial period of symptomatic treatment is safe and beneficial in selected patients with a rising 
serum albumin.
Approximately 70% of patients will experience relapse after CS-induced remission, and 
most relapses occur within 2 years (Table 7). In our cohort, 68% of relapsing patients had a 
maximum of one relapse after initial CS. We observed less CS dependent or frequently relapsing 
MCD compared to previous reports (Table 7). The early use of cyclophosphamide may have 
contributed to the reduced relapse rates. Many patients had long-term stable remissions after 
cyclophosphamide treatment. Patients with CS dependent or frequently relapsing MCD had 
the highest risk of relapse after cyclophosphamide (50%). Infertility and long-term cancer risk 
after cyclophosphamide remain a cause of concern, and preclude the administration of repeated 
courses (18, 19). Rituximab may be a promising agent in patients with relapsing MCD. 
Observational studies have reported stable short-term remissions in 50-65% of patients after 
rituximab, including a minority of patients who had received previous alkylating agents (20, 21). 
Randomized controlled studies will be needed to evaluate the relative efficacy and safety profile 
of the respective agents (22). Patients with relapsing MCD may also reach stable remissions after 
prolonged (≥2 years) cyclosporine treatment (23-25). In this study, only one out of seven patients 
treated with cyclosporine discontinued treatment without further relapse. 
Acute kidney injury is a well-known complication of adult-onset MCD (7-9, 15, 26-30). 
Respective studies used variable definitions for acute kidney injury (Table 7). Using RIFLE 
criteria, we observed acute kidney injury in 40% of patients. We used age- and gender-specific 
baseline eGFR values, which are more accurate compared to the fixed eGFR of 75 mL/min/1.73m2 
as proposed in the Acute Dialysis Quality Initiative consensus definition (11, 31). Older age, male 
gender, hypertension, and a more severe nephrotic syndrome were associated with acute kidney 
injury in this study as well as in previous reports (9, 28, 29). Importantly, nine patients needed 
dialysis for a median of 16 days, with a maximum of several months. One of these patients died of 
complications, but all others had recovery of kidney function. An episode of acute kidney injury 
was associated with decreased eGFR at last follow-up. However, after correction for baseline 
characteristics the difference was not significant (Table 3). 
Other complications were both disease- and treatment-related. The list of complications reflects 
the unmet need for a more effective and less toxic treatment. Thrombosis occurred in 11 patients 
(9%), including mainly venous thrombo-embolic events. Most were diagnosed early after first onset 
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of nephrotic syndrome or relapse, suggesting a relationship with disease and not with treatment. 
The pooled incidence of venous thrombo-embolisms in patients with adult-onset MCD of 7% 
(Table 7) is comparable to the rates described in membranous nephropathy (32, 33). These data 
indicate that an individualized risk to benefit analysis of prophylactic anticoagulation in adult-
onset MCD is warranted. There were many infections, which may be related to the nephrotic state 
as well as immunosuppressive treatment. Typical complications of CS such as diabetes mellitus, 
osteoporosis, and psychosis were also observed. Finally, there was one death directly related to 
MCD and its treatment, and four late deaths due to malignancies or cardiovascular disease, which 
may be regarded as late complications.
We recognize some strengths and weaknesses of our study. Patients were included based on 
predefined clinical and histological criteria. Furthermore, patients were identified from the 
pathology registry. Moreover, both secondary and a tertiary referral centres participated. Therefore, 
the cohort reflects a representative group of patients with MCD. On the other hand, the exclusion 
of patients with insufficient follow-up data may have introduced bias. Kidney biopsies were 
not centrally revised, and electron microscopy was not uniformly performed. We can therefore 
not exclude the possibility of some misdiagnoses. For the same reason, we could not establish 
histological characteristics, which may be related to acute kidney injury or outcome. Finally, due 
to the retrospective and multicenter study design, there were differences in treatment protocols. 
This impairs an accurate comparison of the effectiveness and side effects of individual drugs.   
In conclusion, the majority of patients with adult-onset MCD reached remissions after CS 
treatment, sometimes followed by additional immunosuppressive drugs. Failure of treatment 
suggested FSGS. Remission occurred without immunosuppressive treatment in 10% of patients. 
Relapsing MCD responded well to repeated CS treatment, or second-line cyclophosphamide. 
According to RIFLE criteria, 40% of patients had acute kidney injury, including nine patients 
who needed dialysis. Recovery of kidney function was the rule. Despite good long-term outcome, 
life threatening and debilitating complications frequently occurred. Future studies should 
focus on the accurate identification of patients who can be safely withheld immunosuppressive 
treatment, effective and efficient CS dosage, and comparison of second-line agents for relapsing 
MCD.
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ABSTRACT
Idiopathic membranous nephropathy (MN) is the most common cause of the nephrotic syndrome 
in adults. In patients who present with nephrotic-range proteinuria the clinical course is variable, 
with 50% of patients developing end-stage renal disease after extended follow-up without therapy. 
We review the various immunosuppressive treatment modalities. The efficacy of alkylating agents 
is demonstrated in randomized trials, although side effects are a major drawback. Calcineurin 
inhibitors, rituximab and possibly adrenocorticotropic hormone are able to induce remission 
of proteinuria, which portends a good prognosis. However, the efficacy of these agents must be 
confirmed in randomized trials with adequate renal end points. Immunosuppressive treatment 
should be restricted to high-risk patients. The use of immunosuppressive therapy has improved 
outcome of patients with MN, with nowadays less than 10% of patients progressing to end-stage 
renal disease.
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INTRODUCTION
Idiopathic membranous nephropathy (MN) is the most common cause of the nephrotic syndrome 
in Caucasian adults (1, 2). In recent years our understanding of the pathogenesis of MN has 
greatly increased. It is now well established that MN is caused by binding of antibodies to 
antigens that are present on podocytes (3). The M-type phospholipase A
2
 receptor (PLA
2
R) was 
identified as the most important antigenic target, with antibodies against native PLA
2
R being 
present in approximately 70% of patients with MN (4, 5). MN should thus be considered an 
autoimmune disease.
The clinical course of MN is quite variable. In the older literature the rule of thirds is often 
mentioned: one third of patients with MN develops a spontaneous remission, one third of patients 
progresses to end-stage renal disease (ESRD), whereas the other third maintains persistent 
proteinuria. We already discussed that this rule of thirds was an artifact and created by studies 
with relatively short follow-up (6). When only evaluating studies with long-term follow-up there 
was evidence of a “rule of halves”: almost 50% of patients developed a spontaneous remission, the 
other 50% progressed.
In recent years this natural course of disease in untreated patients with MN has not changed 
significantly. We analyzed a cohort of 129 patients with MN, nephrotic syndrome and well-
preserved renal function who presented in the period from 1995 to 2009. During follow-up, 47% 
of patients had progressive loss of renal function whereas 51% developed a spontaneous remission 
of proteinuria (7).
In this review we will focus on immunosuppressive therapy in patients with MN. This should 
not be interpreted as skepticism of conservative therapy. On the contrary, it is important to use 
optimal conservative therapy in every patient with MN. Edema should be treated with sodium 
restriction and diuretics as needed (8). It is suggested that all patients should be treated with 
angiotensin converting enzyme-inhibitors or angiotensin receptor blockers, in view of their 
protective, antiproteinuric effects in patients with chronic proteinuric kidney diseases (8, 9). 
Admittedly, the role of these agents in improving outcome in patients with MN is not firmly 
established. The natural course of disease has not changed over the last three – four decades. 
Already two decades ago, Praga et al. noted that the angiotensin converting enzyme-inhibitor 
captopril did not affect proteinuria in nephrotic patients with MN (10). Finally, in observational 
studies the use of angiotensin converting enzyme-inhibitors and angiotensin receptor blockers did 
not affect renal outcome in multivariable analysis (6, 11). Treatment with cholesterol lowering 
drugs is advised in patients with longstanding proteinuria, in view of their increased risk of 
cardiovascular events and in line with recent evidence based on a randomized trial of cholesterol 
lowering in patients with chronic kidney disease (12). Patients with a nephrotic syndrome are 
at increased risk for thrombosis, and as confirmed recently the risk is highest in patients with 
MN (13, 14). Although there is no evidence, most authors advise to consider prophylactic anti-
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coagulant therapy in patients with serum albumin <20 g/L, especially if there is a history of 
thrombosis or immobilization.
Immunosuppressive therapy in idiopathic membranous nephropathy
Corticosteroids
Until 1979 MN was considered a slowly progressive disease and only uncontrolled studies 
suggested some benefit from prednisone treatment, as reviewed by du Buf-Vereijken et al. (6). In 
1979 the Collaborative Study group of the idiopathic Nephrotic Syndrome under the leadership 
of Cecil Coggins reported the results of the first randomized controlled trial in MN (15). This 
study included 72 patients. Thirty-four patients received immunosuppressive therapy consisting 
of high-dose alternate-day prednisone (125 mg every other day for 8 weeks). In the intervention 
group the rate of renal function deterioration was significantly reduced. This study was criticized 
because of the unlikely poor renal survival rate in the control group during the short period of 
follow-up (6), and two randomized controlled trials that followed showed that prednisone did not 
prevent deterioration of renal function (16, 17). Of note, these latter studies used prednisone for a 
short period or in a relatively low dose (either 125 to 150 mg of prednisone on alternate days for 8 
weeks or 45 mg/m2 on alternate days for 6 months), so that we cannot exclude a potential positive 
effect of prednisone administered for a longer period in a higher dose (6). Since such high-dose 
steroid regimens are highly toxic and alternative agents are available, we do not consider long-
term high-dose steroid monotherapy a treatment option.
Alkylating agents
Although the treatment of patients with MN is heavily debated, there is grade A level of 
evidence that alkylating agents are effective and can improve renal outcome in patients with MN 
(18). The efficacy of alkylating agents was proven in two randomized, controlled clinical trials. 
Ponticelli et al. recruited 81 patients with recent onset MN, nephrotic syndrome and normal 
renal function (19-21). Treatment consisted of an alternating schedule of monthly corticosteroids 
(i.v. methylprednisolone and oral prednisolone) and chlorambucil for a total treatment duration 
of six months (treatment schedules are given in Table 1). The intervention significantly increased 
remission rate and improved renal survival compared to standard treatment (Table 2). These data 
were confirmed in 2007, with the publication of a second randomized, controlled trial (22). This 
study included 93 patients with nephrotic syndrome of at least 6 months duration and normal 
renal function. A treatment schedule similar to the one of Ponticelli et al. was used, although 
chlorambucil was replaced by oral cyclophosphamide. The data were clear: immunosuppressive 
therapy increased remission rate and improved renal survival (Table 2). Of note, in both studies 
many untreated patients developed a spontaneous remission of proteinuria (Table 2).
Immunosuppressive therapy in idiopathic membranous nephropathy  |  131 
9
T
ab
le
 1
. T
re
at
m
en
t 
sc
he
du
le
s 
fo
r 
id
io
pa
th
ic
 m
em
br
an
ou
s 
ne
ph
ro
pa
th
y 
T
re
at
m
en
t
A
ge
n
ts
D
os
ag
e 
of
 t
h
er
ap
y
T
re
at
m
en
t 
p
er
io
d
C
hl
or
am
bu
ci
l c
yc
li
ca
l 
th
er
ap
y 
(1
9)
C
hl
or
am
bu
ci
l
P
re
dn
is
ol
on
e
M
et
hy
lp
re
dn
is
ol
on
e
0.
2 
m
g/
kg
/d
ay
0.
5 
m
g/
kg
/d
ay
1g
 i.
v.
M
on
th
s 
2,
4,
6
M
on
th
s 
1,
3,
5
3 
co
ns
ec
ut
iv
e 
da
ys
, a
t 
st
ar
t 
of
 m
on
th
s 
1,
3,
5
C
yc
lo
ph
os
ph
am
id
e c
yc
li
ca
l 
th
er
ap
y 
(2
9)
C
yc
lo
ph
os
ph
am
id
e
P
re
dn
is
ol
on
e
M
et
hy
lp
re
dn
is
ol
on
e
2.
0 
m
g/
kg
/d
ay
0.
5 
m
g/
kg
/d
ay
1g
 i.
v.
M
on
th
s 
2,
4,
6
M
on
th
s 
1,
3,
5
3 
co
ns
ec
ut
iv
e 
da
ys
, a
t 
st
ar
t 
of
 m
on
th
s 
1,
3,
5
C
yc
lo
ph
os
ph
am
id
e d
ai
ly
 
th
er
ap
y 
(2
4)
* 
C
yc
lo
ph
os
ph
am
id
e
P
re
dn
is
ol
on
e
M
et
hy
lp
re
dn
is
ol
on
e
1.
5 
m
g/
kg
/d
ay
0.
5 
m
g/
kg
/q
od
1g
 i.
v.
M
on
th
s 
1 
to
 6
M
on
th
s 
1 
to
 5
, t
he
n 
ta
pe
r
3 
co
ns
ec
ut
iv
e 
da
ys
, a
t 
st
ar
t 
of
 m
on
th
s 
1,
3,
5
C
yc
lo
sp
or
in
e (
42
) 
**
C
yc
lo
sp
or
in
e
P
re
dn
is
ol
on
e
St
ar
t 
w
it
h 
3.
5 
m
g/
kg
/d
ay
, 
ac
hi
ev
e 
le
ve
l 1
25
-2
25
 μ
g/
L
0.
15
 m
g/
kg
/d
ay
, m
ax
. 1
5m
g
M
on
th
s 
1 
to
 6
, t
he
n 
ta
pe
r 
by
 2
5%
 p
er
 m
on
th
;
co
nt
in
ue
 t
re
at
m
en
t 
at
 5
0%
 o
f d
os
e 
un
ti
l 1
2 
m
on
th
s,
th
en
 t
ap
er
 t
o 
lo
w
es
t 
po
ss
ib
le
 m
ai
nt
en
an
ce
 d
os
e*
**
M
on
th
s 
1 
to
 6
, t
he
n 
ta
pe
r
Ta
cr
ol
im
us
 (
48
,4
9)
 *
*
Ta
cr
ol
im
us
P
re
dn
is
ol
on
e
St
ar
t 
w
it
h 
0.
05
 m
g/
kg
/d
ay
, a
ch
ie
ve
 le
ve
l 7
-9
 µ
g/
L 
in
 fi
rs
t 
3 
m
on
th
s,
 a
nd
 le
ve
l 5
-9
 µ
g/
L 
af
te
rw
ar
ds
 
m
on
th
s 
3-
6
0.
15
 m
g/
kg
/d
ay
M
on
th
s 
1 
to
 1
2,
 t
he
n 
ta
pe
r 
to
 lo
w
es
t 
po
ss
ib
le
 
m
ai
nt
en
an
ce
 d
os
e*
**
M
on
th
s 
1 
to
 6
, t
he
n 
ta
pe
r
R
it
ux
im
ab
 (
52
,5
4,
55
)
R
it
ux
im
ab
10
00
 m
g 
i.v
.
37
5 
m
g/
m
2  i
.v
.
D
ay
s 
1 
an
d 
15
1-
4 
w
ee
kl
y 
do
se
s
* 
O
ri
gi
na
l s
tu
dy
 u
se
d 
cy
cl
op
ho
sp
ha
m
id
e 
fo
r 
12
 m
on
th
s.
 M
ea
nw
hi
le
, t
re
at
m
en
t 
pe
ri
od
 h
as
 b
ee
n 
re
du
ce
d 
to
 6
 m
on
th
s
**
 
It
 is
 n
ot
 k
no
w
n 
if
 p
re
dn
is
ol
on
e 
co
-a
dm
in
is
tr
at
io
n 
is
 n
ee
de
d.
 M
os
t 
st
ud
ie
s 
w
it
h 
cy
cl
os
po
ri
ne
 h
av
e 
us
ed
 p
re
dn
is
ol
on
e
**
* 
H
ig
h 
re
la
ps
e 
ra
te
, t
re
at
m
en
t 
m
us
t 
be
 c
on
ti
nu
ed
 in
 t
he
 m
aj
or
it
y 
of
 p
at
ie
nt
s
132  |  Chapter 9
T
ab
le
 2
. A
lk
yl
at
in
g 
ag
en
ts
 in
 id
io
pa
th
ic
 m
em
br
an
ou
s 
ne
ph
ro
pa
th
y:
 c
li
ni
ca
l t
ri
al
s 
T
re
at
m
en
t
T
yp
e 
of
 s
tu
d
y
P
at
ie
n
ts
Se
x
D
u
ra
ti
on
 M
N
sC
re
at
P
ro
te
in
u
ri
a
(n
)
(m
/f
)
(m
on
th
s)
(µ
m
ol
/L
)
(g
/2
4 
ho
ur
s)
P
on
ti
ce
ll
i (
21
)
C
hl
A
/s
te
ro
id
s
R
C
T
42
34
/8
6 
(1
-5
0)
94
±
22
6.
2±
3.
0
Su
pp
or
ti
ve
39
29
/1
0
5 
(1
-5
2)
93
±
25
5.
3±
2.
8
To
rr
es
 (
23
)
C
hl
A
/s
te
ro
id
s
C
oh
or
t
19
11
/8
14
±
19
¶
12
4±
62
8.
9±
3.
6
Su
pp
or
ti
ve
H
is
to
ri
ca
l c
on
tr
ol
s
20
15
/5
11
±
12
¶
12
4±
88
6.
9±
3.
1
du
 B
uf
 (
24
)
C
P
/s
te
ro
id
s
C
oh
or
t
65
55
/1
0
13
 (0
-2
80
)
17
1 
(1
06
-5
12
)
10
.0
 (2
.0
-2
3.
0)
#
Su
pp
or
ti
ve
H
is
to
ri
ca
l c
on
tr
ol
s§
24
20
/4
N
A
17
3 
(1
37
-3
60
)
8.
5 
(0
-1
9.
6)
Jh
a 
(2
2)
C
P
/s
te
ro
id
s
R
C
T
47
30
/1
7
11
±
8
10
8±
27
6.
1±
2.
5
Su
pp
or
ti
ve
46
27
/1
9
12
±
6
10
3±
20
5.
9±
2.
2
M
N
, i
di
op
at
hi
c 
m
em
br
an
ou
s n
ep
hr
op
at
hy
; s
C
re
at
, s
er
um
 c
re
at
in
in
e;
 C
hl
A
, c
hl
or
am
bu
ci
l; 
C
P,
 c
yc
lo
ph
os
ph
am
id
e;
 R
C
T,
 ra
nd
om
iz
ed
 c
on
tr
ol
le
d 
tr
ia
l; 
N
A
, d
at
a 
no
t 
av
ai
la
bl
e.
 D
at
a 
ar
e 
pr
es
en
te
d 
as
 n
um
be
r, 
m
ea
n±
 S
D
 o
r 
m
ed
ia
n 
(r
an
ge
).
¶
 d
ur
at
io
n 
M
N
 fr
om
 b
io
ps
y 
to
 a
pp
ea
ra
nc
e 
of
 r
en
al
 in
su
ffi
ci
en
cy
§ 
11
 p
at
ie
nt
s 
in
 t
he
 h
is
to
ri
ca
l c
on
tr
ol
 g
ro
up
 r
ec
ei
ve
d 
im
m
un
os
up
pr
es
si
ve
 t
re
at
m
en
t 
pr
ov
en
 in
ef
fe
ct
iv
e 
# 
pr
ot
ei
nu
ri
a 
in
 g
/1
0m
m
ol
 c
re
at
in
in
e
T
ab
le
 2
. C
on
ti
nu
ed
T
re
at
m
en
t
F
ol
lo
w
-u
p
R
em
is
si
on
 r
at
e*
R
el
ap
se
 r
at
e*
*
R
en
al
 f
u
n
ct
io
n
 e
n
d
p
oi
n
t
(m
on
th
s)
(%
)
(%
)
P
on
ti
ce
ll
i (
21
)
Tr
ea
tm
en
t
12
0
83
26
D
ia
ly
si
s 
fr
ee
 1
0 
yr
-s
ur
vi
va
l: 
92
%
C
on
tr
ol
12
0
38
N
A
D
ia
ly
si
s 
fr
ee
 1
0 
yr
-s
ur
vi
va
l: 
60
%
To
rr
es
 (
23
)
Tr
ea
tm
en
t
52
±
37
42
25
D
ia
ly
si
s 
fr
ee
 7
 y
r-
su
rv
iv
al
: 9
0%
C
on
tr
ol
47
±
38
0
-
D
ia
ly
si
s 
fr
ee
 7
 y
r-
su
rv
iv
al
: 2
0%
du
 B
uf
 (
24
)
Tr
ea
tm
en
t
51
 (5
-1
32
)
86
20
D
ia
ly
si
s 
fr
ee
 5
 y
r-
su
rv
iv
al
: 8
6%
C
on
tr
ol
48
 (1
2-
65
)
20
50
D
ia
ly
si
s 
fr
ee
 5
 y
r-
su
rv
iv
al
: 3
2%
Jh
a 
(2
2)
Tr
ea
tm
en
t
13
2 
(1
26
-1
44
)
72
24
D
ia
ly
si
s 
fr
ee
 1
0 
yr
-s
ur
vi
va
l: 
89
%
C
on
tr
ol
13
2 
(1
26
-1
44
)
35
25
D
ia
ly
si
s 
fr
ee
 1
0 
yr
-s
ur
vi
va
l: 
65
%
N
A
, d
at
a 
no
t 
av
ai
la
bl
e.
 D
at
a 
ar
e 
pr
es
en
te
d 
as
 n
um
be
r, 
m
ea
n±
 S
D
 o
r 
m
ed
ia
n 
(r
an
ge
) 
* 
de
fin
it
io
ns
 o
f r
em
is
si
on
 a
s 
us
ed
 b
y 
th
e 
au
th
or
s
**
  
re
la
ps
e 
ra
te
: p
er
ce
nt
ag
e 
of
 r
el
ap
se
s 
in
 p
at
ie
nt
s 
w
it
h 
pr
ev
io
us
 r
em
is
si
on
 
Immunosuppressive therapy in idiopathic membranous nephropathy  |  133 
9
The first reports of the randomized trial in the period 1984-1989 by Ponticelli et al. paved 
the way for intensive immunosuppressive therapies in patients with MN. Many physicians 
adopted the so-called Ponticelli regimen for the treatment of their patients with MN. However, 
most authors advised to restrict treatment to patients with evidence of renal insufficiency or 
deteriorating renal function, i.e. patients at highest risk for ESRD. Obviously, their major 
concern was the unnecessary use of alkylating agents in up to 40 - 50% of patients who would 
develop a spontaneous remission of proteinuria and thus were not at risk to develop ESRD. This 
was particularly relevant in view of the side effects that are associated with alkylating agents.
In the eighth and ninth decade of the past century, renal insufficiency was the best predictor of 
ESRD. The advice to restrict immunosuppressive therapy to patients with reduced eGFR was not 
evidence based since the abovementioned randomized controlled trials did not prove the efficacy 
of immunosuppressive therapy in patients with established renal insufficiency. Two prospective 
cohort studies have meanwhile provided strong support for such a strategy (23, 24). In these 
studies patients with MN and renal insufficiency were treated with a regimen containing either 
chlorambucil or cyclophosphamide. A historical control group was used as comparator. Both 
studies showed that renal survival was higher in the treated patients (Table 2), confirming that 
immunosuppressive treatment is also effective in high-risk patients.
Based on the latter studies treatment algorithms were developed that advised to restrict 
immunosuppressive therapy to high-risk patients. The efficacy of such a restrictive treatment 
policy was demonstrated by du Buf-Vereijken et al., who evaluated renal outcome in a cohort 
of 69 patients with MN and nephrotic syndrome (25). Patients were identified from the central 
pathology registry, thus including all patients diagnosed with MN and excluding any selection 
bias. Immunosuppressive therapy was only given to patients with renal insufficiency or patients 
with severe, longstanding nephrotic syndrome. Follow-up averaged 66 months. During this 
period of follow-up 22 of 60 patients developed a spontaneous remission, and 33 patients (48%) 
received immunosuppressive therapy, which consisted of the combination of an alkylating agent 
and prednisone in 28 patients. Patient survival after 7 years was 100% and renal survival 88%. 
This study thus indicated that a restrictive treatment strategy, which avoids unnecessary exposure 
to alkylating agents in approximately half of the patients, resulted in a favourable prognosis in 
patients with MN.
We recently provided additional evidence that the use of a restrictive treatment strategy and 
cyclophosphamide as alkylating agent alters outcome in patients with MN. In an epidemiological 
study, we analyzed the incidence of ESRD in the Netherlands and observed that the incidence 
of ESRD due to MN decreased in our region by 70% when comparing the period 1991-1995 
with the period 2000-2005 (26). By contrast, the incidence of ESRD due to MN had remained 
unchanged in other parts of the Netherlands. We confirmed that only 18% of patients with ESRD 
due to MN had received treatment with an alkylating agent. The Toronto group also confirmed 
that the more frequent use of immunosuppressive therapy has improved outcome of patients with 
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MN in the past decades. The benefits of immunosuppressive therapy were confirmed in a separate 
analysis (27). Using propensity scoring, 39 treated patients were matched with 39 untreated 
controls. Five year renal survival amounted 70% in the control group vs. >95% in the treated 
group. Of note, 32/39 treated patients had received cyclophosphamide.
Most studies have used either cyclophosphamide or chlorambucil. Uncontrolled data from our 
group suggested that cyclophosphamide was more effective and less toxic than chlorambucil (28). 
A review of the literature supported this conclusion, although we could not exclude that these 
differences in efficacy were caused by differences in treatment duration in the various studies (6). 
Ponticelli et al. performed a randomized trial (29). In this study 95 patients were included who 
were treated with either chlorambucil or cyclophosphamide. There were no differences in efficacy 
parameters such as remission rate (chlorambucil 82% vs. cyclophosphamide 93%), relapse rate 
(30% vs. 25%), or deterioration of renal function. Side effects and infectious complications were 
more frequent in the chlorambucil group. Thus, this study supported the use of cyclophosphamide 
as the preferred alkylating agent.
The use of immunosuppressive therapy in patients with renal insufficiency is not without 
problems. Most studies concluded that side effects of therapy were more severe and more frequent 
in patients with renal failure. In fact, in these patients the dose of the immunosuppressive agents 
needed to be reduced. Therefore, it was hypothesized that earlier start of immunosuppressive 
therapy, at a time point well before the onset of renal insufficiency, might be beneficial. It was 
expected that renal function would be better maintained and that higher doses of alkylating 
agents would be better tolerated if therapy was started in patients with normal renal function. 
To answer this question we performed a small randomized controlled trial (30). Patients with 
MN, a nephrotic syndrome and preserved renal function were randomized for immediate start 
of immunosuppressive therapy or for late start, i.e. start of therapy was initiated after onset of 
renal function deterioration. This study included 26 patients. Twelve patients were randomized 
for delayed start of therapy. Of these, only eight patients eventually needed immunosuppression. 
At the end of follow-up there were no significant differences in remission rate, renal function or 
proteinuria. Still, early start of therapy significantly reduced the period of nephrotic syndrome. 
Since a persistent nephrotic syndrome is associated with an increased risk of infections and 
thromboembolic events early start of therapy might still be advantageous, even without affecting 
the development of ESRD.
In conclusion: there is now grade A evidence that alkylating agents are effective in patients with 
MN and normal renal function. Additional data strongly suggest that treatment can be restricted 
to high-risk patients and that a restrictive treatment strategy carries a good prognosis. 
Azathioprine
Azathioprine is often used as replacement for cyclophosphamide. Indeed, azathioprine has been 
used successfully as maintenance therapy in patients with vasculitis or lupus nephritis. However, 
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there is no proof of its efficacy in MN and several studies have demonstrated no overall benefit 
(31, 32). Since the latter studies included patients with preserved renal function, and renal event 
rate was low, beneficial effects of azathioprine cannot be excluded. Indeed, two studies suggested 
that azathioprine improved renal outcome in patients with renal insufficiency (33, 34). In these 
studies a total of 34 patients with renal insufficiency were included. After start of therapy with 
azathioprine and prednisone renal function improved or stabilized in 28 patients, and proteinuria 
decreased to reach levels of a partial remission in the majority of them. However, treatment 
needed to be continued lifelong, since a relapse of proteinuria occurred during tapering of drug 
therapy in all but four patients. The most recent and largest uncontrolled trial of azathioprine 
was performed by Goumenos et al. (35). These authors included 33 patients who were treated 
with azathioprine and prednisone for a mean of 26 months, and 17 patients who received no 
immunosuppressive treatment. After a follow-up of 10 years, there were no differences in the 
end-points of doubling of serum creatinine (42 vs. 35%) and ESRD (21 vs. 18%) between the 
treated and untreated groups, respectively.
In conclusion: there is no consistent evidence that azathioprine has a favourable influence on the 
course of MN. We therefore do not advise its use.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is a relatively new immunosuppressive agent with mild side 
effects, certainly when compared to cyclophosphamide. The drug is used successfully in patients 
after kidney transplantation, and in patients with lupus nephritis or vasculitis. Case reports and 
small cohort studies supported the efficacy of mycophenolate mofetil in MN, and many physicians 
were eager to use this drug as replacement for cyclophosphamide. In a randomized study, MMF 
monotherapy was compared with placebo (36). Nineteen patients with MN were treated with 
MMF at a dose of 2000 mg/day and 17 patients were untreated (control group). Remission rate 
was only 37% in the MMF group, and not different from remission rate in the control group. 
Remission rate was even lower (13%) in a study of Miller et al. (37). This study included 16 
patients with MN, severe proteinuria and renal insufficiency. Previous treatment with alkylating 
agents had failed in six and cyclosporine had failed in five patients. MMF was given in doses of 
500-2000 mg/day, and five patients received additional steroids. The low response rate in the 
abovementioned studies might be the result of omitting steroids and the use of a relative low dose 
of MMF, and the inclusion of treatment resistant patients (6).
We prospectively treated 32 patients with MMF (2 g/day) and steroids (38). We selected patients 
who were at high risk for disease progression, based on our predictive models (see discussion about 
individualized therapy below). For comparison, we used data of matched historical controls who 
were treated with cyclophosphamide and a similar dose of steroids. There were no differences in 
the initial response rate, and the cumulative remission rate after 12 months was 66% in the MMF 
group and 72% in the historical controls. Two small, randomized studies reported similar results. 
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Nayagam et al. compared MMF and prednisone with alternating cycles of cyclophosphamide and 
prednisone (39). A total of 21 patients were included (11 MMF, 10 cyclophosphamide). Follow-
up was 17 months. Remissions occurred in seven patients treated with MMF and in 8 patients 
treated with cyclophosphamide. Chan et al. treated 11 patients with MMF and steroids and nine 
patients with chlorambucil according the Ponticelli regimen (40). Follow-up was 15 months. A 
remission occurred in seven and six patients, respectively.
Although these studies thus suggested that a MMF based regimen was as effective in inducing a 
remission as the standard regimen containing chlorambucil or cyclophosphamide, there are some 
concerns. First, we observed a higher rate of primary non-response with MMF (16% vs. 0% with 
cyclophosphamide; P =0.05). Primary treatment failure was even higher at 36% in the study 
of Chan et al. (40). Moreover, remissions were not sustained in the MMF treated patients. The 
cumulative relapse rate at two years after end of therapy was as high as 70% in the MMF group 
as compared to 20% in the cyclophosphamide group (38).
In conclusion: MMF monotherapy is not effective in MN. When used in combination with 
steroids, MMF induces remissions. However, the effect of short-term therapy is not sustained and 
it is likely that treatment must be continued for a long-term period. Studies that have evaluated 
long-term renal outcome are lacking.
Calcineurin inhibitors
The antiproteinuric effects of calcineurin inhibitors (CNI) have been extensively documented. 
The mechanisms have been debated. CNI do not affect antibody production. The antiproteinuric 
effect has been attributed to a decreased glomerular perfusion and altered T cell functioning. 
More recently, Faul et al. demonstrated that CNI could directly influence podocyte function (41). 
Table 3 summarizes the data of studies that have evaluated the effects of CNI on proteinuria. 
Many studies were uncontrolled, both cyclosporine (CsA) and tacrolimus have been used, and 
treatment regimes have been variable with respect to the duration of therapy and the concomitant 
use of corticosteroids.
Still, the effect of CNI on proteinuria is well established in randomized controlled trials. Cattran 
et al. studied 51 patients with steroid resistant MN, nephrotic range proteinuria and normal 
renal function (42). Twenty-eight patients were treated with CsA in a starting dose of 3.5 mg/
kg/day (target trough level 125-225 µg/L) and prednisone 0.15 mg/kg/day for 26 weeks. The 
control group (n =23) received only prednisone. Remission rate was significantly higher in 
the intervention group (at 26 weeks 75% vs. 22%, P <0.001). Others studies have confirmed 
these findings, with remission rates ranging from 71% to 88% (Table 3) (43-50). However, 
in most patients remissions were not sustained, which may not be unexpected in view of the 
abovementioned mechanisms. In the North American randomized controlled trial (42) a relapse 
occurred in almost 50% of the patients within 12 months after withdrawal of CsA. More recently, 
a Spanish group performed a multicenter randomized controlled trial comparing tacrolimus 
Immunosuppressive therapy in idiopathic membranous nephropathy  |  137 
9
monotherapy (n =25) to standard treatment (n =23) (48). The starting dose of tacrolimus (0.05 
mg/kg/day) was adjusted to achieve a through level of 3-5 μg/L, and 5-8 μg/L if a remission was 
not obtained after 2 months. Therapy was continued for 12 months and gradually tapered off for 
6 months. After 18 months, 94% of patients in the tacrolimus group were in remission compared 
to 35% in the control group. However, nearly 50% of patients treated with tacrolimus relapsed 
within 18 months after tacrolimus withdrawal. Other investigators have reported similarly high 
relapse rates (Table 3). There are some notable exceptions, with two studies reporting a relapse 
rate of less than 20% (45, 50). However, these data are biased. In one study patients were followed 
for only 12 months after start of therapy, and three months after withdrawal of tacrolimus (50). 
Such a short period of follow-up is insufficient for reliable conclusions on relapse rate. The study 
of Alexopoulos et al. is of interest (45). In this study patients were treated with either CsA 
monotherapy, or with a combination of CsA and prednisone for a period of 12 months. If a 
remission was achieved after 12 months, treatment was continued. The lowest relapse rate of 15% 
was noted during continued therapy with the combination therapy. Moreover, relapses occurred 
particularly in patients who received a lower daily CsA dose and had lower CsA trough levels.
In conclusion: CNI alone or in combination with prednisone reduce proteinuria and induce 
a remission of proteinuria in over 75% of patients. However, most patients will relapse after 
withdrawal, thus treatment with CNI needs to be continued for many years. To prevent relapses 
CsA should preferably be given with low-dose steroids, in an adequate daily dose. Although data 
are lacking, the same likely holds for tacrolimus. Although remission portends a good prognosis, 
there are no studies demonstrating improved outcome with respect to hard renal endpoints with 
the use of CNI.
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Rituximab
Rituximab has received great interest. This monoclonal antibody, which targets CD20-positive 
B cells, has become standard therapy in patients with malignant lymphomas. In recent years 
randomized trials have provided evidence for efficacy of rituximab in rheumatoid arthritis and 
vasculitis. Since MN is considered an antibody driven autoimmune disease, rituximab might 
be effective. Several uncontrolled studies have reported the outcome of rituximab therapy in 
MN (51-57). The drug was given in different dosing schedules, varying from one bolus of 
1 g or two biweekly doses of 1 g/day, to 4 weekly doses of 375 mg/m2. Results from recent 
clinical trials are given in Table 4. The use of rituximab was associated with a high incidence of 
remissions. Initial studies showed best outcome in female patients with normal renal function 
and moderate proteinuria (56, 57). These data suggested that rituximab may not be effective in 
high-risk patients. However, a recent cohort study in 20 patients with MN, which included 11 
patients who had failed prior immunosuppressive therapy, showed a remission rate of 89% (52). 
The Bergamo group recently presented the outcome of 100 consecutive patients treated with 
rituximab. There were 69 males, mean age was 51 years, serum creatinine 1.4 mg/dL, serum 
albumin 22 g/L and proteinuria 10.6 g/24 hours (55). Almost one third of patients had been 
treated previously with immunosuppressive therapy. Proteinuria decreased from 10.6 g/24 hours 
to 4.7, 3.0 and 2.0 g/24 hours at 1, 2, and 3 years after rituximab, respectively. The cumulative 
incidence of remission was reported and amounted 94%. Relapses occurred in approximately one 
quarter of patients. Segarra et al. have reported beneficial effects of rituximab in patients with 
dependence of CNI (53). They included 13 patients with at least four CNI-responsive relapses 
of nephrotic proteinuria who received 4 weekly doses of rituximab at 375 mg/m2. Mean follow-
up after rituximab treatment was 35 months. CNI were succesfully withdrawn in all patients, 
accompanied by an improvement in eGFR and reduction of proteinuria. Three patients had a 
relapse after rituximab, which was succesfully treated with a second course of rituximab.
In conclusion: rituximab therapy is associated with a high remission rate. Relapse rate is relatively 
low, and comparable to relapse rate with cyclophosphamide. The efficacy on renal outcome is not 
proven in randomized trials.
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Adrenocorticotropic hormone
Several studies showed beneficial effects of synthetic adrenocorticotropic hormone (ACTH) 
in patients with MN (58-60). The proposed mechanism of action is through activation of the 
melanocortin receptor MCR1 in podocytes, leading to reduction of oxidative stress and proteinuria 
and improved podocyte morphology (61). In a randomized controlled trial synthetic ACTH 
proved to be as effective as combined cytotoxic agent/steroid therapy in inducing a remission, 
and was associated with very few side effects (60). A recent retrospective case series of 11 patients 
with MN that were treated with the natural highly purified ACTH gel formulation showed a 
remission rate of 82% in patients who had previously failed a mean of 2.4 immunosuppressive 
therapies (62). 
In conclusion: Although promising, we argue against the use of ACTH in view of the lack of 
sufficient evidence, the short follow-up in the reported studies and the lack of data on hard renal 
endpoints. Furthermore, the ACTH gel brings enormous costs.
Immunosuppressive therapy in idiopathic membranous nephropathy: toward individualized therapy
Although early start of immunosuppressive therapy did not improve outcome with respect to 
eGFR and proteinuria, it resulted in a more rapid onset of remission and a shorter duration of 
the nephrotic syndrome (30). This may certainly be beneficial in individual patients. For the 
physician taking care of patients with MN it is important to discuss treatment options with 
individual patients in view of the potential benefits and risks. Treatment carries risks, however also 
the nephrotic syndrome is associated with risks such as infection, thrombosis, or cardiovascular 
events.
We have provided an overview of the literature on immunosuppressive therapy in MN. 
It is evident that immunosuppressive therapy is effective: in randomized clinical trials 
immunosuppressive therapy has increased remission rate and reduced the incidence of ESRD. 
The use of immunosuppressive therapy has changed the natural history of MN, with currently 
less than 10% of patients progressing to ESRD. 
Still, how can we incorporate all information in the daily care of patients with MN? Clinical 
trials are important, however the conclusions are not always applicable to the individual patient. 
Moreover, there are virtually no trials that have compared benefits and risks of the various 
immunosuppressive regimens. Also, cost-efficacy has not been properly addressed. Based on the 
literature data and our experience, we suggest that patients with MN need more individualized 
therapy. 
All patients with MN and proteinuria should receive optimal conservative therapy, targeting 
blood pressure, cholesterol, and risk of thrombosis. Although early start of cyclophosphamide 
therapy did not significantly improve outcome with respect to eGFR and proteinuria, we caution 
against routinely delaying the start of immunosuppressive therapy until renal failure is evident. 
Early start of therapy resulted in a more rapid onset of remission and a shorter duration of the 
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nephrotic syndrome. This may certainly be beneficial in individual patients, in view of the risks 
associated with nephrotic syndrome such as infection, thrombosis, or cardiovascular events. 
Moreover, some agents may be less effective (rituximab) or more difficult to manage (CNI) when 
started in patients with renal failure. Thus, when taking care of patients with MN it is important 
to discuss the benefits and risks of the various treatment options. 
Individualized patient care necessitates an accurate prediction of prognosis. We consider the 
use of toxic, immunosuppressive agents in patients who will develop a spontaneous remission 
unjustified. Preferably, treatment should be started in an early phase of disease in patients who 
will progress to ESRD. To this end it is important to predict prognosis with high accuracy (30, 
63). Several predictors have been proposed. Cattran et al. demonstrated that prognosis can be 
predicted by the magnitude and duration of proteinuria (64). In a follow-up study they validated 
a risk score that incorporated the level of maximum proteinuria, baseline creatinine clearance 
and the change of creatinine clearance over a 6-month period of maximum proteinuria (65). 
Bazzi et al. and our group have focused on urinary protein patterns (66, 67). Urinary excretion of 
low-molecular-weight proteins predicted outcome with reasonable accuracy (80%). We recently 
compared the risk score and urinary low-molecular-weight proteins in 104 patients with MN, 
a nephrotic syndrome and preserved renal function. There were no differences, with area under 
the receiver operating characteristic curves averaging 0.80 (68). Polanco et al. recently reported 
the outcome in a Spanish cohort of patients with MN. A decrease of proteinuria >50% in the 12 
months after renal biopsy proved a strong, independent prediction of spontaneous remission (69). 
Although the Toronto risk score, the measurement of the urinary excretion of low-molecular-
weight proteins, and the initial change of proteinuria can all be used to predict prognosis, in the 
individual patient benefits and risks must be weighed, since accuracy of these predictive markers 
is at best 80-90%. 
We suggest that in high-risk patients and certainly in patients with established renal insufficiency 
immunosuppressive therapy should be considered. Based on the available evidence we prefer 
alkylating agents as first line therapy, particularly in patients with reduced eGFR. Alternative 
treatment modalities are CNI and rituximab. These agents have fewer side effects, and induce 
remission of proteinuria. Still, their efficacy in improving renal outcome must be proven in 
randomized trials. In this respect we welcome the European Renal Association-European Dialysis 
and Transplant Association-approved “Sequential treatment with TAcrolimus-Rituximab versus steroids 
plus cyclophosphamide in patients with primary MEmbranous Nephropathy (STARMEN)” study (70). 
The discovery of PLA
2
R as a major antigen in MN may change treatment in the near future. 
We showed that anti-PLA
2
R titers correlate with clinical disease activity (71). Furthermore, the 
disappearence of circulating anti-PLA
2
R preceded the remission of proteinuria (72). Qin et al. also 
found an association between anti-PLA
2
R titers and outcome in Chinese patients (73). Patients 
with low titers had a shorter time to remission (6.6 vs. 14.5 months). These studies will stimulate 
further research into the role of anti-PLA
2
R antibody levels in the prediction of prognosis and the 
guidance of therapy (5).  
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ABSTRACT
Background: Urinary excretion of alpha-1-microglobulin (α1m) and beta 2-microglobulin 
(β2m) reflects tubular damage and predicts outcome in patients with idiopathic membranous 
nephropathy (MN) with reasonable accuracy. Urinary kidney injury molecule-1 (KIM-
1) and neutrophil gelatinase-associated lipocalin (NGAL) are novel biomarkers of tubular 
damage. We investigated if these markers could improve the prediction of outcome in MN. 
Methods: We measured KIM-1 and NGAL in urine samples from patients with MN, who had 
nephrotic proteinuria and normal renal function. Excretion of α1m and β2m had been measured 
previously. Progression was defined as a serum creatinine rise >30%, a rise in serum creatinine 
to an absolute value of ≥135 µmol/L, or a clinical decision to start immunosuppressive therapy. 
Remission was defined as proteinuria <3.5 g/24 hours and >50% reduction from baseline.
Results: Sixty-nine patients were included. Median follow up was 35 months (interquartile range 
18-63 months). Progression occurred in 30 patients (44%), and spontaneous remission in 36 
(52%). KIM-1 and NGAL excretion were significantly correlated with each other, and with α1m 
and β2m. The areas under the receiver operating characteristic curves for progression were 0.75 
(0.62-0.87) for KIM-1 and 0.74 (0.62-0.87) for NGAL. In multivariate analysis with either α1m 
or β2m, KIM-1 and NGAL did not independently predict outcome. 
Conclusion: KIM-1 and NGAL excretion rates correlated with excretion rates of other tubular 
damage markers and predicted outcome in patients with MN. They did not add prognostic value 
compared to measurement of either α1m or β2m.
Urinary KIM-1 and NGAL in idiopathic membranous nephropathy  |  151 
10
BACKGROUND
Idiopathic membranous nephropathy (MN) is a leading cause of nephrotic syndrome in Caucasian 
adults (1). Natural history studies with follow-up of at least three years indicate that approximately 
50% of patients with nephrotic MN develop renal failure (2-4). It has been demonstrated that 
a restrictive treatment strategy which limits immunosuppressive treatment to patients with 
established renal insufficiency results in good long term renal survival (5, 6). Although this 
strategy assures that patients who will develop spontaneous remission do not unnecessarily 
receive toxic therapy, it delays its use in others (7). Preferably, immunosuppressive treatment 
should be initiated at an early stage and only in patients who will otherwise develop progressive 
disease. This requires a highly accurate method to identify high-risk patients.
High urinary concentrations of proteins that reflect tubular or glomerular damage precede a 
decline in estimated glomerular filtration rate (eGFR) in patients with MN (8-11). We have 
previously validated a prognostic model to predict disease progression in patients with MN and 
preserved renal function using urinary beta-2-microglobulin (β2m) and IgG excretion rates (12). 
However, a recent evaluation of the data indicated that a substantial proportion of patients are 
still misclassified when urinary β2m or the closely resembling biomarker α1-microglobulin 
(α1m), or IgG are used as predictors (3). 
Kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are 
novel and early markers of tubular damage, which have mainly been studied in the context of 
acute kidney injury (13-16). There is increasing evidence for a prognostic value of KIM-1 and 
NGAL in patients with glomerular disease (17-20). Neither were strongly correlated with β2m 
excretion in proteinuric patients with IgA nephropathy (17). The aim of the study was to evaluate 
the prognostic value of urinary KIM-1 and NGAL excretion in patients with MN.
METHODS
Subjects
The present study cohort represents a subgroup from a previously described cohort of 129 patients 
with biopsy-proven MN designed to re-evaluate the prognostic value of urinary low-molecular 
weight proteins α1m and β2m (3). Patients who were referred to our clinic for a timed urinary 
protein measurement between 1995 and 2009 had been included. Other inclusion criteria 
were preserved renal function (defined by a serum creatinine <135 µmol/L), proteinuria ≥3.0 
g/10mmol creatinine, and absence of prior immunosuppressive therapy. Patients were excluded 
if follow-up was <1 year, or if time between renal biopsy and measurement was >3 years. In the 
present study we included all patients from this cohort who had available stored urine samples 
for measurement of KIM-1 and NGAL. Patients were followed until a pre-defined end point (see 
below) was reached or until June 2011. 
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Methods
Patients with MN were evaluated using a standardized protocol, which includes a timed 
measurement of urinary proteins including β2m and α1m (12). Patients were instructed to take 
sodium bicarbonate on the night before urinary measurement to obtain a urinary pH >6.0, which 
is mandatory for reliable measurement of β2m. Timed urine samples were collected, and blood 
samples were obtained. Urinary β2m was measured by an in-house developed ELISA (detection 
limit of 0.002 mg/L, interassay variation coefficient of 5.7%), and urinary α1m was measured by 
immunonephelometry on a BNII nephelometer (Behring, Marburg, Germany; detection limit for 
urinary α1m was 2 mg/L, and interassay variation coefficient was 4.7%) (12, 21). A portion of the 
timed urine sample was centrifuged (10 min, 3000 r/min) and stored at -80°C. Urinary KIM-1 
and NGAL concentration was measured after overnight thawing of frozen stored samples using 
human-specific enzyme-linked immunoassay kits (R&D, Minneapolis, MN) (17). Detection limit 
for KIM-1 was 0.02 µg/L, for NGAL 0.66 µ/L. All measurements were performed in duplicate.
 
Outcome
Progression was defined as (a) a ≥30% rise in serum creatinine, (b) a rise in serum creatinine to 
an absolute value ≥135 µmol/L, or (c) other clinical indications for starting immunosuppressive 
therapy established by the treating nephrologist. Complete remission was defined as proteinuria 
reduction to <0.2 g/10mmol creatinine. Partial remission was defined as proteinuria <3.5 
g/10mmol creatinine with reduction of >50% from baseline in the presence of stable renal 
function (22). 
Statistical analyses
Median values and interquartile range are reported for non-normally distributed values. Statistical 
differences between groups were assessed with χ2 or Mann-Whitney U test. Correlations between 
parameters were calculated with Spearman’s correlation coefficient. Areas under the receiver 
operating characteristic curves (ROC-AUC) were used to assess prognostic performance of 
respective biomarkers. For all biomarkers, the optimal cut-off level was determined where the 
most patients were correctly classified. The discriminatory capacity for progression and remission 
of respective biomarkers at optimal cut-off levels was compared using the net reclassification 
improvement (NRI). Calibration of biomarkers was plotted using the Hosmer-Lemeshow 
goodness-of-fit test, which compares expected versus observed progression across deciles of risk. 
We used logistic regression models to evaluate combinations of biomarkers. Statistical analyses 
were performed with SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM 
Corp.) and GraphPad Prism (GraphPad Prism version 5.03 for Windows, GraphPad Software, 
San Diego California USA, www.graphpad.com). P-values <0.05 were considered to reflect 
statistical significance. 
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RESULTS
From the described cohort of 129 patients with MN included in the prognostic study of urinary 
α1m and β2m, 69 (53%) had available stored urine samples for measurement of KIM-1 and 
NGAL (3). Four patients had missing values for β2m because urinary pH was below 6.0 (β2m 
is unstable at these pH levels). Two of these patients developed progressive disease. The large 
majority (96%) of patients reached an endpoint during follow-up (Table 1). 
Table 1. Clinical characteristics of patients with idiopathic membranous nephropathy included in the 
analysis (urine available for KIM-1/NGAL measurement) 
Variable Patients with MN (n =69)
Gender (male/female) 41/28
Age at biopsy (yr) 51 (39-61)
Interval between biopsy and referral (months) 2.3 (1.2-5.1)
MAP (mmHg) 98 (84-105)
Serum creatinine (μmol/L) 80 (60–102)
eGFR (mL/min/1.73m2) 79 (62–100)
Serum albumin (g/L) 24 (19-29)
Proteinuria (g/10mmol creatinine) 8.4 (5.8-11.1)
β2m excretion (µg/min) 0.9 (0.2-4.5)
(n =65)
α1m excretion (µg/min) 39.0 (20.7-85.0)
KIM-1 excretion (ng/min) 1.7 (0.3-3.4)
NGAL excretion (ng/min) 17.8 (11.0–57.2)
Follow-up in months, median (IQR) 35 (18–63) *
Progression, n (%) 30 (44) 
    >30% creatinine rise 25
    Creatinine ≥135 µmol/L 2
    Clinical decision (n) 3
Remission, n (%) 36 (52) 
    Partial (n) 24
    Complete (n) 12
No endpoint reached, n (%) 3 (4) 
MN, idiopathic membranous nephropathy; IQR, interquartile range; MAP, mean arterial blood pressure; 
eGFR, estimated glomerular filtration rate; β2m, beta-2-microglobulin; α1m, alpha-1-microglobulin; 
KIM-1, kidney injury molecule-1; NGAL, neutrophil gelatinase-associated lipocalin.  
Data are expressed as median (interquartile range). eGFR was calculated with the abbreviated Modification 
of Diet in Renal Disease formula.
* Follow-up until endpoint was reached. 
Excretion of KIM-1 and NGAL
KIM-1 excretion was 1.7 ng/min (IQR 0.3-3.4 ng/min) and NGAL excretion was 17.8 ng/min 
(IQR 11.0-57.2 ng/min) during timed urinary measurement. For comparison, median KIM-
1 excretion was 0.6 (IQR 0.4-0.9 ng/min), and median NGAL excretion was 15.6 ng/min 
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(IQR 10.4-19.9 ng/min) in 65 healthy adult controls (17). Excretion rates of both KIM-1 and 
NGAL correlated significantly with each other, and excretion rates of α1m and β2m (Table 2). 
Furthermore, excretion rates of KIM-1 and NGAL correlated significantly with proteinuria and 
eGFR (Table 2). 
Table 2. Correlations of KIM-1 and NGAL urinary excretion with other parameters
Variable              KIM-1               NGAL
rho P -value rho P -value
Age .14 .25 .10 .43
MAP - .10 .40 .06 .61
Serum albumin - .31 .009 -.17 .15
Serum cholesterol .02 .98 .03 .83
eGFR - .53 < .001 -.32 .007
Urinary protein .53 < .001 .49 < .001
Urinary β2m .67 < .001 .55 < .001
Urinary α1m .47 < .001 .52 < .001
Urinary KIM-1 - - .72 < .001
Urinary NGAL .72 < .001 - -
MAP, mean arterial blood pressure; eGFR, estimated glomerular filtration rate; β2m, beta-2-microglobulin; 
α1m, alpha-1-microglobulin; KIM-1, kidney injury molecule-1; NGAL, neutrophil gelatinase-associated 
lipocalin.  
Correlation was calculated with Spearman’s rank correlation coefficient. 
Prediction of outcome
ROC curves for progression and remission, and optimal cut-off values of respective biomarkers are 
shown in Figure 1 and Table 3. The NRI values show that there is no significant improvement in 
outcome prediction of KIM-1 or NGAL compared to α1m or β2m (Figure 2). Hosmer-Lemeshow 
goodness-of-fit tests were non-significant for all biomarkers, indicating good model calibration 
(Figure 3). In the backward stepwise logistic regression models, KIM-1 and NGAL did not reach 
statistical significance as independent predictors.
Reclassifications using KIM-1 and NGAL in patients misclassified by β2m 
Prognostic misclassifications by β2m cut-off levels were studied in detail in order to detect a 
potential benefit of KIM-1 and NGAL in certain subgroups. Seven patients with β2m <1.0 µg/
min progressed (Table 4). A common characteristic in most of these patients was performance of 
urinary measurement relatively early after biopsy. Three patients were reclassified using KIM-1 
and two by NGAL prognostic cut-off levels as described above. Nine patients with β2m ≥1.0 µg/
min did not progress (Table 4), and all reached remissions. Four of them were correctly reclassified 
with NGAL and three by KIM-1 using the described cut-off values. 
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Figure 1. Receiver operating characteristic curves for prognostic accuracy of kidney injury molecule-1 
(KIM-1; AUC 0.75 [95% CI 0.62-0.87]), neutrophil gelatinase-associated lipocalin (NGAL; AUC 0.74 
[95% CI 0.62-0.87]), β-2-microglobulin (β2m; AUC 0.79 [95% CI 0.69-0.91]), and α-1-microglobulin 
(α1m; AUC 0.79 [AUC 0.68-0.89]) in the prediction of disease progression.
A. KIM-1 versus β2m. NRI progression 3.5% (95% CI -12.1%-19.5%); NRI remission -8.6% (95% CI 
-23.4 – 6.2%); overall NRI -5.0% (95% CI -26.7%-16.6%).
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B. NGAL versus β2m. NRI progression -10.7% (95% CI -31%-9.1%); NRI remission 8.6% (95% CI 
-4.0%-21.1%); overall NRI -2.1% (95% CI -24.5-20.2%).
C. KIM-1 versus α1m. NRI progression 10.0% (95% CI -7.3%–27.3%); NRI remission -13.9% (95% CI 
-31.9%-4.2%); overall NRI -3.9% (95% CI -28.9%-21.1%).
D. NGAL versus α1m. NRI progression 3.3% (95% CI -11.2% - 17.9%); NRI remission 0 
(-16.0%-16.0%); overall NRI 3.3% (95% CI -17.5%–24.1%)
Figure 2. Reclassifications using prognostic cut-off values for urinary neutrophil gelatinase-associated 
lipocalin (NGAL; 30 ng/min) or kidney injury molecule-1 excretion (KIM-1; 1.6 ng/min) versus beta-2-
microglobulin (β2m; 1.0 µg/min) or alpha-1-microglobulin (α1m; 50 µg/min), respectively. Urinary β2m 
was measured in 65 patients
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Figure 3. Calibration of biomarkers.
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DISCUSSION
Our study clearly demonstrates that the recently identified urinary biomarkers NGAL and KIM-
1 predict outcome in patients with MN and preserved renal function. However, overall they did 
not have additional prognostic value beyond established markers α1m and β2m.
NGAL is a low-molecular weight protein of approximately 25 kDa. It is expressed on neutrophils, 
and also on inflamed epithelia including kidney tubules (23, 24). In experimental acute kidney 
injury, tubular NGAL expression and urinary NGAL excretion occur within two hours, before 
β2m is observed in the urine (24). Increased urinary NGAL excretion is also observed in 
glomerular disease. A strong correlation between proximal tubular NGAL expression and urinary 
NGAL has been found in patients with IgA nephropathy, suggesting that tubular cells actively 
produce NGAL (25).
KIM-1 is a transmembrane glycoprotein, which is not expressed in the normal kidney. It is 
strongly upregulated by proximal tubular epithelial cells after toxic or ischemic acute kidney 
injury (26). Cleavage of KIM-1 by MAP-kinases results in urinary excretion of its 90 kDa soluble 
ectodomain (27). There is a strong relationship between tubular expression and urinary excretion 
of KIM-1 (28). It is not produced by other cells to an extent that can account for urinary levels 
that are observed in patients with kidney disease (29). 
Thus, urinary NGAL and KIM-1 are specific markers of tubular cell injury. In contrast, the 
low-molecular weight proteins α1m and β2m only reflect a reduction in tubular reabsorptive 
capacity. We hypothesized that KIM-1 and NGAL may be more specific markers of tubular 
injury and thus better predictors of outcome than α1m and β2m. Evidently, neither KIM-1 nor 
NGAL showed improved overall prognostic accuracy. By contrast, we have identified KIM-1 as 
an independent predictor of end-stage renal disease in IgA nephropathy, where α1m and β2m 
did not predict outcome (17). There were strong significant correlations between the respective 
proteins in MN, which were absent in IgA nephropathy. Tubular dysfunction may progress faster 
in the heavily nephrotic patients with MN. We hypothesize that elevated NGAL and/or KIM-1 
may have preceded elevated α1m and β2m in patients with progressive MN. The data of patients 
with progression in the presence of β2m below prognostic cut-off support this hypothesis. Indeed, 
urinary measurement was performed shortly after biopsy in most of these patients. Thus, KIM-1 
and NGAL may have added prognostic value in the earliest stages of MN.
The definition for progression used in our study may be criticized. Assuming an initial normal 
kidney function, a rise to a serum creatinine ≥135 µmol/L indicates a serious deterioration which 
is associated with progression to end-stage renal disease (5, 30). The other criteria for progression 
are in conformity with current guidelines for treatment of MN (31). 
The present cohort comprises a subgroup from a larger study that was conducted to evaluate 
prognostic accuracy of urinary α1m and β2m in MN (3). Although optimal prognostic cut-off 
values of urinary α1m and β2m were unchanged in this subgroup, the smaller number of patients 
limits the accuracy of the estimated predictive values of KIM-1 and NGAL excretion.
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In conclusion, we have shown that urinary KIM-1 and NGAL are elevated in many patients with 
nephrotic MN and preserved renal function. However, KIM-1 and NGAL measurement did not 
improve prognostic accuracy when compared or combined with established markers. Our data 
suggest that these markers may have added value in the earliest stages of the disease. Additional 
studies with longitudinal follow-up of these urinary markers are warranted to investigate their 
potential benefit in MN.
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Three main histological patterns of glomerular injury are associated with idiopathic nephrotic 
syndrome (iNS) in adults: minimal change disease (MCD), focal segmental glomerulosclerosis 
(FSGS) and membranous nephropathy (MN). Podocyte injury, reflected by foot process effacement 
on electron microscopic examination, is common in all of these conditions. The pathological 
findings are important, because they guide further work-up and initial treatment. In addition, 
clinical characteristics such as proteinuria and baseline renal function have prognostic significance. 
Still, outcome may be highly variable between patients with similar pathological findings and 
presenting features. For example, a patient presenting with nephrotic syndrome, normal renal 
function and a histological appearance of MCD may enter complete proteinuria remission without 
immunosuppressive treatment, may develop a relapsing disease course necessitating repeated 
immunosuppressive treatment, or may manifest steroid-resistant proteinuria and develop 
progressive renal failure associated with FSGS on repeated biopsy. A similarly variable course 
is observed in patients with FSGS and MN, although there are differences in the percentages of 
patients with spontaneous remission and treatment responsiveness. This clearly demonstrates 
that the underlying etiologies of podocyte damage in iNS are poorly understood. In idiopathic 
MN a causative role for circulating antibodies against the phospholipase A2 receptor has been 
firmly established. In MCD and idiopathic FSGS causative circulating glomerular permeability 
factors are strongly suspected, but their identities remain unknown. 
In this thesis, we investigated prognosis and outcome of iNS in adults, and evaluated potential 
new biomarkers associated with etiology and outcome.
FSGS can recur after transplantation, which is characterized by rapid onset of nephrotic range 
proteinuria. A history of post-transplant FSGS recurrence is a strong predictor of recurrence in 
subsequent grafts. No factors have been identified that were highly predictive of recurrence in 
patients who received a first kidney graft. We conducted a retrospective study of 94 patients with 
biopsy-proven FSGS who received a first kidney graft in our center (Chapter 2). The aim of the 
study was to evaluate if clinical criteria can identify patients at high risk for post-transplant FSGS 
recurrence. Patients were divided into three groups: familial/genetic FSGS (n =18), secondary FSGS 
(n =10), and idiopathic FSGS (n =66). Post-transplant disease recurrence was exclusively observed 
in patients with idiopathic FSGS (42%). In univariate analysis the interval between presentation 
and biopsy as well as serum albumin, proteinuria, and estimated glomerular filtration rate (eGFR) 
at diagnosis were associated with recurrence. In the multivariate analysis, serum albumin at 
diagnosis was the only independent predictor. The highest recurrence rate of 78% was observed 
in patients with a baseline serum albumin level <25 g/L. Recurrence did not occur in patients 
with serum albumin >35 g/L, suggesting that these patients had unidentified secondary forms 
of FSGS. In conclusion, patients with a high risk of FSGS recurrence after transplantation could 
be identified using clinical criteria that are readily available in clinical practice. In another single 
center study, Hickson et al. observed post-transplant FSGS recurrence in 14/30 (47%) patients 
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with idiopathic FSGS based on strict criteria (1). Compared to patients with non-recurrent FSGS, 
their patients with post-transplant recurrence had higher peak proteinuria before transplantation. 
These data support our observation that FSGS typically recurred in patients with more severe 
nephrotic syndrome. Since our retrospective study spanned a long inclusion period, genetic 
testing was not uniformly performed. FSGS recurrence has been observed in <5% of patients with 
a genetic diagnosis (2). Targeted sequencing of 27 podocyte-associated genes resulted in a genetic 
diagnosis in almost 30% of children with steroid-resistant nephrotic syndrome, including many 
patients with a negative family history (3). These findings were extended to young adults (age 
19-25 years), who had a single-gene cause in 21% of cases. Thus, next-generation sequencing 
strategies for genetic testing may lead to further improvement in the prediction of outcome after 
transplantation.  
The morphology of FSGS lesions is diverse. A pathological classification has been designed to 
standardize the morphological description of FSGS (4). The classification consists of five mutually 
exclusive variants described as collapsing, tip, cellular, perihilar, and not otherwise specified, 
respectively. Previous studies have shown that all variants were associated with potential post-
transplant FSGS recurrence (5-7). We hypothesized that there should be concordance between 
the variant in the native kidney and the variant in the kidney graft with disease recurrence if 
the classification reflects different underlying etiologies. In Chapter 3, we compared the FSGS 
pathological variants before and after transplantation in patients who developed post-transplant 
proteinuria recurrence. In addition, we investigated the morphological evolution of lesions in 
available samples of repeat biopsies. Morphological classification of native and graft kidneys were 
concordant in only 4/17 cases (24%). Of note, the initial graft biopsy did not reveal FSGS lesions 
in the majority of cases. If these biopsies (which were classified as “minimal lesions”) were regarded 
as an intermediate stage in the development of FSGS lesions, morphological concordance between 
native and graft kidneys was present in 4/9 cases (44%). In repeat biopsies many transitions were 
observed, but the not otherwise specified variant consistently appeared as a final stage associated 
with advanced disease. A recent study of repeat native kidney biopsies in patients with FSGS 
also demonstrated transitions from other variants into the “not otherwise specified” subtype 
(8). In conclusion, it was unlikely that the pathological variants represent different etiologies. 
Rather, the variants appeared to reflect the level of severity and chronicity of lesions (Figure). 
This concept is supported by animal models showing that progressive podocyte loss resulted 
in mesangial expansion (0-20% depletion), glomerular adhesion and FSGS lesions (20-40% 
depletion) and finally global glomerulosclerosis (>40% depletion) (9). Baseline podocyte number 
and loss during the disease process may hold prognostic relevance in iNS. In patients who had 
apparent MCD on the initial biopsy, subsequent development of FSGS lesions in the repeat 
biopsy could be predicted by a larger glomerular tuft area on the initial biopsy (10). A recent 
study of kidney autopsy specimens from patients without kidney disease has linked glomerular 
hypertrophy to decreased podocyte density (11). It was hypothesized that these hypertrophic 
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glomeruli are susceptible to pathology. New methods have been described to study the process of 
podocyte loss in patients with glomerular disease. It was suggested that podocyte density could 
be reliably estimated in a single histological section (12). Podocyte depletion has been monitored 
longitudinally by non-invasive measurement of cell-specific mRNAs in urinary sediments. One 
or more measurements of podocin mRNA were performed in an observational study including 
patients with different types of glomerular disease (13). In patients with iNS, the highest levels 
of urinary podocin mRNA (100-fold increase above control) were associated with progression to 
end-stage renal disease. Patients who did not progress might have such high values at some point, 
but proteinuria remission reduced urinary podocin mRNA levels to normal. Thus, we suggest 
that future studies should evaluate the prognostic significance of podocyte depletion markers, 
which are ultimately responsible for the observed morphological alterations. 
Figure. Schematic illustration of the concept that FSGS variants represent activity and chronicity of the 
disease process
In 2011, the soluble urokinase plasminogen activator receptor (suPAR) was proposed as the 
circulating factor that caused idiopathic FSGS and was also responsible for post-transplant 
proteinuria recurrence. The claim was based on a translational study that included measurement 
of serum suPAR in patients with FSGS and controls using a commercially available assay (14). 
A serum suPAR concentration ≥3000 pg/mL was suggested as the cut-off level to diagnose 
idiopathic FSGS. Patients who developed post-transplant FSGS recurrence had even higher 
suPAR concentrations. In Chapter 4 we investigated whether suPAR may be used in routine 
clinical practice as (i) a diagnostic marker of idiopathic FSGS versus secondary FSGS and MCD 
(ii) a prognostic marker of the response to corticosteroids in idiopathic FSGS/MCD and (iii) a 
biomarker for post-transplant FSGS recurrence in patients with end-stage renal disease. Median 
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serum suPAR concentration was not different between idiopathic FSGS (2392 pg/mL; n =11), 
secondary FSGS (2716 pg/mL; n =5), and MCD (2482 pg/mL; n =7), nor did it predict steroid 
responsiveness in patients with idiopathic FSGS/MCD. We observed a significant negative 
correlation between serum suPAR concentration and eGFR. We additionally measured serum 
suPAR concentrations in eight dialysis patients, including three patients with a history of biopsy-
proven FSGS in their native kidney and recurrent FSGS in one or two kidney allografts. All of 
these patients had serum suPAR levels ≥3000 pg/mL, and levels were not higher in patients with 
FSGS compared to non-FSGS dialysis controls. 
In Chapter 5 we further studied the relationship between eGFR and suPAR in a cohort of 
476 non-FSGS controls from the Leuven mild-to-moderate CKD study and 54 patients with 
biopsy-proven idiopathic FSGS (44 with active disease and 10 in remission). Median eGFR was 
significantly higher in patients with FSGS compared to controls. In the control group, eGFR 
was the strongest determinant of suPAR concentration. The proposed diagnostic threshold 
concentration for idiopathic FSGS (3000 pg/mL) was exceeded in 17%, 39%, 88%, and 95% 
of controls with eGFR levels >60, 45–60, 30–45, and <30 ml/min per 1.73m2, respectively. 
Patients with biopsy-proven FSGS and controls were subsequently plotted on suPAR against 
eGFR graphs. At no eGFR did suPAR concentrations in patients with idiopathic FSGS exceed 
suPAR concentrations in controls. Two other independent cohorts failed to identify serum suPAR 
as a biomarker for FSGS and confirmed the negative association between eGFR and suPAR (15, 
16). The results strongly argue against the use of serum suPAR levels to diagnose idiopathic 
FSGS. In addition, they point to the pitfalls when using biomarkers that are highly dependent 
on eGFR.    
In Chapter 6, we reviewed the existing knowledge with regard to the roles of the membrane-
bound urokinase plasminogen activator receptor (uPAR) and its soluble forms (suPAR) in FSGS. 
Tissue expression of uPAR has been associated with tissue remodeling and increased cell motility. 
Recent experimental studies suggested that uPAR may be involved in the pathogenesis of 
proteinuria and FSGS. The proposed mechanism involved uPAR-mediated activation of podocyte-
associated β3-integrin (17). Enzymatic cleavage of uPAR at one or two sites results in the release 
of suPAR fragments of variable length. Subsequent studies addressed the inferred hypothesis 
that suPAR was a permeability factor that caused FSGS. Indeed, animal studies demonstrated 
that suPAR caused proteinuria, while in vitro studies showed that sera from patients with post-
transplant recurrence activated podocyte β3-integrin (14). As described above (Chapter 4) the 
pathogenic role of suPAR in FSGS was further supported by human data. However, these studies 
did not adjust for reduced eGFR in the FSGS patients, while subsequent studies demonstrated 
an inverse relationship between elevated suPAR levels and eGFR. When adjusted for eGFR, 
suPAR levels did not differentiate between FSGS and other kidney diseases. Of note, high serum 
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suPAR levels have been reported in various conditions that are not associated with proteinuria. 
In conclusion, there is no proof that any known form of suPAR constitutes the responsible 
circulating factor in human FSGS. Furthermore, measurement of suPAR with the assays currently 
available is of no clinical value in patients with FSGS. Meanwhile, the pathogenic role of suPAR 
was further questioned by two independent groups who were unable to demonstrate suPAR-
induced proteinuria in mouse models (18, 19).
Hypotheses supporting the existence of glomerular permeability factors in MCD and FSGS were 
first described in the 1970s (20, 21). After forty years of research these factors remain elusive. In 
Chapter 7, we reviewed the history of the search for circulating glomerular permeability factors 
in MCD and FSGS. Multiple candidate proteins have been proposed, but none were validated 
(Table). We described potential reasons for the lack of success. Different experimental models were 
used, with few investigators using more than one model at a time. Importantly, many studies that 
used patient samples included badly phenotyped patients. An example is provided by the pivotal 
study that proposed suPAR as the causative permeability factor. This study included patients 
with so-called idiopathic FSGS, however a critical look at the data showed that most patients 
must have had secondary FSGS. In order to guide future research, we defined four conditions that 
should be met before a permeability factor can be considered pathogenic:
1. The permeability factor must have biologic effects in vitro and in vivo, and be confirmed in 
validation studies
2. The permeability factor must be identified in well-phenotyped patients but not in controls, 
and validated in independent patient cohorts
3. There must be a temporal relation between the presence or level of the permeability factor and 
disease activity
4. Specific removal of the permeability factor in vivo blocks the biologic effect i.e. leads to 
remission of disease activity
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Table. Putative permeability factors in MCD and FSGS.
Putative permeability 
factors
Molecular 
weight
Comments
MCD
GPF-NOS (22)
Hemopexin (23)
IL-13 (24)
60-160 kDa
80-85 kDa
16 kDa
Obtained from T cell hybridoma made from patients with MCD
Induced proteinuria when injected into rats
Permeability factor has not been further characterized
Both recombinant and human hemopexin induced reversible 
proteinuria accompanied by FPE in rats
Decreased serum hemopexin with increased protease activity in 
MCD in relapse
Induced nephrin-dependent cytoskeletal rearrangements 
and increased albumin permeability across monolayers of 
glomerular endothelial cells
No validation studies have been performed
Increased expression of mRNA and cytoplasmic IL-13 in CD4+/
CD8+ T cells from children with SSNS
Stimulated podocyte protein trafficking and proteolysis in vitro
Overexpression of IL-13 in rats induced MCD- like disease
No clinical studies 
FSGS
CLC-1 (25)
suPAR (14)
22-25 kDa
20-50 kDa
Increased glomerular permeability
Decreased nephrin expression in cultured podocytes
Antibody to CLC-1 reversed the permeability effect of FSGS sera
Concentrations up to 100 times higher in recurrent FSGS
Results are preliminary, only published in abstract form 
Activated podocyte β3 integrin, resulting in reorganization of the 
actin cytoskeleton of podocytes
High dose recombinant mouse suPAR induced proteinuria, 
increased podocyte β3 integrin activity and foot process 
effacement in mice lacking the gene for uPAR but not in wild 
type mice
Experimental data were not supported by clinical data: 
−	 When adjusted for renal function suPAR levels did not 
differentiate between FSGS and other kidney diseases
−	 No correlation between serum suPAR and degree of 
proteinuria
−	 Higher serum or plasma levels of suPAR were also reported 
in patients with cancer, sepsis, atherosclerosis and PNH 
without FSGS
FSGS, focal segmental glomerulosclerosis; GPF-NOS, glomerular permeability factor not otherwise 
specified; MCD, minimal change disease; PNH, paroxysmal nocturnal hematuria; CLC-1, cardiotrophin-
like cytokine-1; SSNS, steroid-sensitive nephrotic syndrome; (s)uPAR, (soluble) urokinase plasminogen 
activator receptor 
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Few clinical studies have been performed in adult-onset MCD. Therefore, treatment is mainly 
based on data obtained in children. Chapter 8 describes the results of a retrospective cohort 
study including 125 patients with adult-onset MCD who were treated in 10 Dutch centers. 
Median duration of follow-up was 4.9 years. Patients generally had severe nephrotic syndrome at 
presentation. Onset of nephrotic syndrome was associated with acute kidney injury in 50 patients 
(40%). One of these patients died, the others had recovery of renal function. Venous or arterial 
thrombosis occurred in 11 patients, mostly within 2 weeks after first onset or relapse of nephrotic 
syndrome. The majority of patients (84%) received initial treatment with high-dose oral 
prednisone. Cumulative remission rate after 16 weeks was 88%. Thirteen patients (10%) reached 
remissions without immunosuppressive treatment. Most of these patients had a progressive rise in 
serum albumin after biopsy confirmation of MCD, indicating clinical improvement. Five patients 
never reached proteinuria remission during follow-up. One of these patients died of acute kidney 
injury and infection. Three progressed to end-stage renal disease, which was associated with FSGS 
on repeat biopsy. Overall, 62% of patients initially treated with prednisone relapsed. Nineteen 
patients (15%) developed steroid dependent or frequently relapsing MCD. Cyclophosphamide 
resulted in long-term stable remissions in 57% of patients with relapses. Patients with relapses 
after cyclophosphamide were mostly treated with calcineurin inhibitors or repeated courses of 
prednisone. At the end of follow-up, 94% of patients were alive with preserved renal function. 
The steroid-induced remission rates and time to remission in our study were comparable with 
previous series of predominantly Caucasian patients with adult-onset MCD (26-29). The study 
clearly demonstrated that MCD is not a benign disease. Almost 20% experienced life-threatening 
events such as severe acute renal failure and venous or arterial thrombosis, which occurred mostly 
early after presentation. Many patients needed prolonged and repeated immunosuppressive 
treatment, which was associated with severe complications. The results highlight the unmet 
need for less toxic treatment with rapid and long-lasting efficacy. Rituximab may be an attractive 
alternative for current immunosuppressive treatment in MCD. Recently, efficacy of rituximab 
for maintenance of remission was proven for the first time in a randomized controlled study of 
children with relapsing iNS (30). Studies into effective and efficient use of rituximab in adult 
patients with iNS will be performed in the near future.
In Chapter 9 we reviewed the efficacy of various immunosuppressive treatment regimens for 
patients with idiopathic MN. Three randomized controlled trials have proven that a combination 
of cytotoxic drugs (cyclophosphamide or chlorambucil) and corticosteroids improved renal 
outcome (31-33). Calcineurin inhibitors with or without low-dose corticosteroids were associated 
with improved remission rates in two randomized controlled trials, but no evidence is available 
with respect to hard renal endpoints (34, 35). Mycophenolate in combination with corticosteroids, 
as well as rituximab were associated with high remission rates in uncontrolled studies (36, 
37). Again, data on hard renal endpoints are lacking. However, all immunosuppressive drugs 
174  |  Chapter 11
have been associated with serious complications. Of note, almost 50% of patients will reach 
remissions without immunosuppressive treatment. Delayed treatment with cytotoxic drugs and 
corticosteroids also results in good outcome, but this approach also increases the duration of 
nephrotic syndrome (38). Two risk models for disease progression have been validated. One risk 
model relied on measurement of urinary proteins that reflect tubular damage, such as alpha-
1-microglobulin (α1m) and beta-2-microglobulin (β2m) (39). The other model used levels of 
sustained proteinuria and repeated measurement of creatinine clearance over a period of at least 6 
months (40). Both models predicted outcome with reasonable accuracy (AUC of approximately 
0.80) (41). Based on the available data, we proposed an individualized treatment protocol for 
patients with idiopathic MN.   
More accurate risk stratification for disease progression is needed to justify early start of 
immunosuppressive treatment in patients with idiopathic MN. Urinary kidney injury molecule-1 
(KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are early markers of tubular 
injury. In Chapter 10, we tested if these markers may improve prediction of outcome, alone or in 
combination with α1m or β2m. We measured KIM-1 and NGAL in a cohort of 69 patients with 
idiopathic MN and preserved renal function. Excretion of α1m and β2m had been previously 
measured. Progression occurred in 30 patients (44%), and remission in 36 (52%). Both KIM-
1 and NGAL predicted progression with AUCs of 0.75 and 0.74, respectively. However, in 
multivariate analysis with either α1m or β2m, KIM-1 and NGAL did not independently predict 
outcome. Subgroup analysis suggested that patients misclassified by low excretion of β2m early 
after biopsy may be correctly reclassified by KIM-1 or NGAL. This needs to be validated in larger 
studies. To our knowledge, no studies have been performed into the prognostic role of KIM-1 in 
idiopathic MN, whereas one previous study evaluated urinary NGAL (42). These investigators 
found that patients with NGAL excretion >350 ng/mL had a 3.36 fold increased risk of ≥50% 
eGFR decrease after one year compared to patients with lower NGAL excretion. However, the 
study included patients with impaired renal function at baseline who have a high risk of disease 
progression regardless of NGAL excretion. 
Clearly better predictors are needed. We expect that the use of untargeted proteomics techniques 
may lead to the discovery of more accurate biomarkers. The use of urinary exosomes may offer 
advantages, and techniques for the isolation of urinary exosomes for nephrotic urine are now 
available (43). 
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Het nefrotisch syndroom wordt veroorzaakt door nierziekten die leiden tot beschadiging van de 
glomeruli (nierfilters), en wordt gekenmerkt door meer dan 3,5 gram proteïnurie (eiwit in de 
urine) per 24 uur, een verlaagde serumconcentratie van het eiwit albumine (<30 g/L) en oedeem. 
Mogelijke complicaties van het nefrotisch syndroom zijn verslechtering van de nierfunctie, 
bacteriële infecties en veneuze of arteriële trombose. Een nefrotisch syndroom kan worden 
veroorzaakt door systeemziekten die zich ook in andere organen manifesteren zoals diabetes 
mellitus, amyloïdose en systemische lupus erythematosus. Indien er geen onderliggende oorzaak 
van het nefrotisch syndroom kan worden vastgesteld, wordt bij volwassen patiënten een nierbiopt 
verricht. Er is sprake van een idiopathisch nefrotisch syndroom indien de glomeruli in het 
nierbiopt geen tekenen van ontsteking vertonen. Het idiopathisch nefrotisch syndroom bestaat 
hoofdzakelijk uit drie beelden: minimal change disease (MCD), focale segmentale glomerulosclerose 
(FSGS) en membraneuze nefropathie. Een gemeenschappelijk kenmerk van deze beelden is een 
aantasting van de normale celstructuur van de podocyten, die onderdeel uitmaken van de 
glomeruli. 
Het onderscheid tussen MCD en FSGS is niet scherp. Patiënten met een beeld van MCD in 
het nierbiopt kunnen met name bij aanhoudende proteïnurie FSGS ontwikkelen. Bovendien is 
het idiopathisch nefrotisch syndroom niet de enige oorzaak van FSGS. Er bestaan bijvoorbeeld 
erfelijke vormen van FSGS die worden veroorzaakt door aangeboren afwijkingen in eiwitten 
die een rol spelen in de bouw of functie van de podocyt. Ondanks deze kanttekeningen is 
het pathologisch onderzoek van het nierbiopt bij patiënten met een idiopathisch nefrotisch 
syndroom van belang voor de behandeling en prognose. Ook de nierfunctie en ernst van de 
proteïnurie hebben prognostische waarde. Het ziektebeloop kan bij de individuele patiënt met 
deze parameters echter onvoldoende worden ingeschat. Als voorbeeld nemen we een patiënt met 
een idiopathisch nefrotisch syndroom, een normale nierfunctie en in het nierbiopt een beeld 
van MCD. Mogelijke scenario’s van het ziektebeloop zijn spontane remissie (verdwijnen van de 
proteïnurie zonder afweeronderdrukkende behandeling), frequente recidieven van het nefrotisch 
syndroom ondanks langdurige afweeronderdrukkende behandeling, en therapieresistente 
proteïnurie met progressieve nierschade en FSGS in een tweede nierbiopt. Het beloop van 
FSGS en membraneuze nefropathie is eveneens variabel, en er zijn verschillen in de kans op 
een remissie met of zonder afweeronderdrukkende behandeling. De onvoorspelbaarheid van het 
beloop weerspiegelt het gebrek aan kennis over de oorzaken van de verschillende vormen van het 
idiopathisch nefrotisch syndroom. Er zijn sterke aanwijzingen dat het idiopathisch nefrotisch 
syndroom wordt veroorzaakt door “circulerende factoren” die de podocyten beschadigen en 
proteïnurie veroorzaken. De identiteit van deze factoren is bij MCD en FSGS echter onbekend. 
Een doorbraak in het onderzoek naar de oorzaken van het idiopathisch nefrotisch syndroom 
was de ontdekking van antistoffen tegen de op de podocyt aanwezige fosfolipase-A2 receptor bij 
patiënten met een membraneuze nefropathie.  
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In dit proefschrift onderzochten wij de prognose en het beloop van het idiopathisch nefrotisch 
syndroom bij volwassen patiënten, en de waarde van een aantal nieuwe biomarkers voor de 
diagnostiek en prognose.
FSGS kan leiden tot eindstadium nierfalen, waardoor patiënten zijn aangewezen op dialyse of 
niertransplantatie. Patiënten die vanwege FSGS een niertransplantatie ondergaan kunnen een 
recidief van de oorspronkelijke ziekte in de transplantaatnier ontwikkelen. Een kenmerkend 
verschijnsel is acute forse proteïnurie, die meestal kort na de niertransplantatie optreedt. Een 
FSGS recidief vereist een intensieve behandeling die niet altijd succesvol is. Het is daarom van 
belang om patiënten nauwkeurig te kunnen informeren over het risico. Indien een FSGS recidief 
eenmaal is opgetreden zal dit bij een volgende niertransplantatie vrijwel zeker opnieuw gebeuren. 
Bij de eerste niertransplantatie ligt het risico volgens eerder onderzoek tussen 15 en 52%. Om 
dit risico nauwkeuriger vast te stellen hebben wij de gegevens onderzocht van 94 patiënten met 
FSGS die voor het eerst een transplantaatnier ontvingen (Hoofdstuk 2). De patiënten werden 
verdeeld in drie groepen: erfelijke FSGS (n =18), FSGS door andere onderliggende oorzaken (n 
=10) en idiopathische FSGS (n =66). Een ziekterecidief werd enkel vastgesteld in de groep met 
een idiopathische FSGS (42%). Binnen deze groep bleek de serumconcentratie van het albumine 
ten tijde van de diagnose de belangrijkste voorspeller van een recidief. Patiënten met een serum 
albumine <25 g/L hadden het hoogste risico (78%), terwijl een FSGS recidief nooit optrad indien 
het serum albumine >35 g/L was. Samenvattend levert dit onderzoek een methode om het risico 
op een FSGS recidief op eenvoudige wijze te voorspellen. 
De morfologie (vorm) van FSGS bij microscopisch onderzoek van de glomeruli is heterogeen. In 
2004 hebben pathologen een classificatie van FSGS opgesteld waarin de volgende varianten worden 
onderscheiden: collaberend, tip, cellulair, perihilair en niet anderszins omschreven. Het onderscheid is 
puur gebaseerd op het histologisch onderzoek. Het is onbekend of deze varianten het gevolg zijn 
van verschillende onderliggende oorzaken van FSGS. Wij vergeleken de morfologische varianten 
in de eigen nieren en de transplantaatnieren van patiënten die FSGS recidieven doorgemaakt 
hadden (Hoofdstuk 3). Indien de verschillende morfologische varianten een gevolg zijn van 
verschillen in de oorzaak van FSGS, verwachtten wij dat dezelfde variant consequent aanwezig 
moest zijn in de eigen nieren en de transplantaatnieren. In slechts 4 van de 17 onderzochte 
transplantaatnieren (24%) bleek er overeenstemming met de morfologische variant in de eigen 
nier (zie Hoofdstuk 3, Figuur 1). Wij onderzochten in herhaalde biopten tevens hoe de FSGS 
varianten zich in de loop van de tijd ontwikkelden. In het eerste biopt van de transplantaatnieren 
was ten tijde van het ontstaan van proteïnurie vrijwel nooit FSGS zichtbaar en leek het beeld 
eerder op MCD. FSGS varianten waren alleen zichtbaar indien de proteïnurie tenminste een maand 
bestond of regelmatig terugkeerde na behandeling. Bij vergelijking van opeenvolgende biopten 
zagen wij de niet anderszins omschreven variant telkens als eindstadium van ernstige nierschade. Wij 
concludeerden dat de morfologische varianten niet wijzen op de oorzaak van FSGS, maar meer een 
reflectie zijn van de ernst en de duur van het idiopathisch nefrotisch syndroom.
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In 2011 verscheen een publicatie waarin geconcludeerd werd dat het eiwit soluble urokinase 
plasminogen activator receptor (suPAR) een circulerende factor is die idiopathische FSGS veroorzaakt. 
In dit onderzoek werd een hogere suPAR-concentratie gemeten in het serum van patiënten met 
FSGS ten opzichte van controlegroepen met onder meer MCD en membraneuze nefropathie. 
Een serumconcentratie hoger dan 3000 pg/mL werd voorgesteld als diagnostisch voor FSGS. 
Patiënten die na transplantatie een FSGS recidief ontwikkelden hadden nog hogere suPAR-
waarden. In Hoofdstuk 4 onderzochten wij of suPAR in de praktijk kan worden toegepast als 
(i) diagnostische marker voor idiopathische FSGS, (ii) marker voor de respons op behandeling 
met prednison bij FSGS en MCD, (iii) marker voor een FSGS recidief na niertransplantatie. 
Wij bepaalden de suPAR-concentraties in de sera van 11 patiënten met idiopathische FSGS 
(mediaan 2392 pg/mL), 5 patiënten met andere oorzaken van FSGS (mediaan 2716 pg/mL) en 
7 patiënten met MCD (mediaan 2482 pg/mL). De verschillen tussen de groepen waren niet 
significant. De suPAR-concentratie voorspelde evenmin de respons op prednisonbehandeling. Er 
was een negatieve correlatie tussen serum suPAR en de nierfunctie (zie Hoofdstuk 4, Figuur 
2). Het suPAR werd tenslotte gemeten in de sera van 3 dialysepatiënten die in het verleden een 
FSGS recidief hadden ontwikkeld (en daarmee een zeer hoog risico op een toekomstig recidief 
in een volgende transplantaatnier) en 5 andere dialysepatiënten die geen FSGS hadden. Alle 
dialysepatiënten hadden waarden hoger dan 3000 pg/mL en deze waren niet hoger bij patiënten 
met FSGS ten opzichte van andere dialysepatiënten. Samenvattend bleek de serum suPAR-
concentratie in onze handen geen bruikbare biomarker voor patiënten met FSGS. 
In Hoofdstuk 5 onderzochten wij de relatie tussen de nierfunctie en de serum suPAR-concentratie 
in een grotere groep patiënten. Wij maakten gebruik van bloedmonsters van 54 patiënten met 
idiopathische FSGS, en van 476 patiënten met andere nieraandoeningen (de controlegroep). De 
eerder vastgestelde afkapwaarde van suPAR voor de diagnose idiopathische FSGS (3000 pg/
mL) werd in de controlegroep frequenter overschreden naarmate de nierfunctie slechter was (zie 
Hoofdstuk 5, Figuur 1a). Ook werd de negatieve correlatie tussen de suPAR-concentratie en 
de nierfunctie bevestigd. De serum suPAR-concentraties van patiënten met FSGS waren niet 
verhoogd ten opzichte van patiënten in de controlegroep met een vergelijkbare nierfunctie 
(zie Hoofdstuk 5, Figuur 1b). Wij concludeerden dat suPAR niet gebruikt kan worden als 
diagnostische marker voor FSGS. Ons onderzoek wijst ook op de beperkingen van het gebruik 
van biomarkers die sterk worden beïnvloed door de nierfunctie.
In Hoofdstuk 6 gaven wij een overzicht van de actuele kennis over de rol van het celmembraan 
gebonden eiwit urokinase plasminogen activator receptor (uPAR) en de vrij circulerende vormen 
van dit eiwit (suPAR) bij FSGS. In 2008 werden onderzoeksresultaten gepubliceerd waarin 
beschreven wordt hoe expressie van uPAR op de podocyten leidt tot proteïnurie. De effecten van 
uPAR kwamen tot stand door activatie van het eiwit β3-integrine en intracellulaire eiwitten die 
de opbouw van het celskelet veranderen. Enzymen kunnen het uPAR op verschillende plekken in 
het eiwit losknippen van de celmembraan (zie Hoofdstuk 6, Figuur 1), waardoor verschillende 
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suPAR-fragmenten ontstaan. De kennis over uPAR gaf aanleiding tot vervolgonderzoek naar de 
rol van het circulerende suPAR bij het ontstaan van proteïnurie en FSGS. Muizen die intensief 
blootgesteld werden aan suPAR ontwikkelden proteïnurie, en serum van patiënten met een FSGS 
recidief veroorzaakte activatie van β3-integrine op humane podocyten in vitro. Zoals beschreven 
(Hoofdstuk 4) werden metingen in het serum van patiënten verricht om aan te tonen dat suPAR 
gebruikt kan worden als biomarker voor FSGS. De resultaten werden echter vertekend door het 
effect van de nierfunctie op de suPAR-concentratie. Na correctie voor de nierfunctie bleek het 
suPAR bij patiënten met FSGS niet hoger dan bij patiënten met andere nierziekten. Bovendien 
kunnen diverse ontstekingsziekten en kwaadaardige ziekten ook gepaard gaan met hoge suPAR-
concentraties in het serum. De conclusie was dat het meten van suPAR met de beschikbare 
methoden geen meerwaarde heeft voor patiënten met (een vermoeden op) FSGS.
De hypothese dat MCD en FSGS worden veroorzaakt door circulerende factoren bestaat al sinds 
de jaren 70 van de vorige eeuw. Ruim 40 jaar later zijn deze factoren nog steeds niet gevonden. 
In Hoofdstuk 7 beschreven wij de geschiedenis van de zoektocht naar circulerende factoren 
bij patiënten met MCD en FSGS. In het verleden is meermaals beweerd dat de circulerende 
factor gevonden was, maar nooit werd dit definitief bevestigd. Wij beschreven mogelijke 
oorzaken voor het gebrek aan succes. Er zijn verschillende experimentele modellen gebruikt om 
de ziekteactiviteit van de circulerende factoren te meten, maar zelden werd meer dan één model 
tegelijk gebruikt. Een belangrijk probleem is dat de klinische kenmerken van de patiënten in 
het onderzoek vaak niet goed omschreven zijn. Om toekomstig onderzoek te sturen stelden wij 
voorwaarden op waar het onderzoek naar een circulerende factor die een idiopathisch nefrotisch 
syndroom veroorzaakt aan moet voldoen:
1. Biologische effecten moeten worden aangetoond in vitro en in vivo, en bevestigd worden 
door meerdere onderzoekers
2. De factor is enkel aanwezig bij patiënten met een idiopathisch nefrotisch syndroom; dit 
moet bevestigd worden in meerdere onderzoekspopulaties
3. De ernst van de ziekteverschijnselen moet parallel verlopen met de aanwezigheid of 
activiteit van de factor
4. Verwijdering van de factor leidt tot remissie van de proteïnurie 
Er is weinig onderzoek naar MCD bij volwassenen verricht. Om het ziektebeloop en de 
resultaten van de behandeling bij volwassenen met MCD in kaart te brengen verrichtten 
wij een retrospectief onderzoek in een groep van 125 patiënten (Hoofdstuk 8). De mediane 
duur van de observatieperiode was 4,9 jaar. Maar liefst 50 patiënten (40%) ontwikkelden 
een acute verslechtering van de nierfunctie als gevolg van het nefrotisch syndroom. Eén van 
deze patiënten overleed als gevolg van complicaties, maar alle anderen hadden herstel van de 
nierfunctie. Elf patiënten ontwikkelden een veneuze of arteriële trombose. De meeste patiënten 
(84%) werden behandeld met prednison. Het remissiepercentage was 88% na 16 weken 
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prednisongebruik. Dertien patiënten hadden een spontane remissie. Zij kregen geen prednison 
bij een geleidelijke stijging van het serumeiwit albumine als teken van herstel. Vijf patiënten 
hadden therapieresistente proteïnurie. Hun nierfunctie ging geleidelijk achteruit, en bij een 
tweede nierbiopt werd telkens FSGS geconstateerd. Herhaaldelijke recidieven van het nefrotisch 
syndroom kwamen voor bij 15% van de patiënten die in eerste instantie een remissie hadden na 
prednison. Het cytotoxische middel cyclofosfamide was langdurig effectief in het voorkomen van 
ziekterecidieven. Aan het eind van de observatieperiode was nog 94% van de onderzoeksgroep in 
leven met behoud van nierfunctie. Het onderzoek maakt duidelijk dat MCD een ernstige ziekte 
is met potentieel levensbedreigende complicaties. Bovendien waren er veel complicaties van de 
afweeronderdrukkende behandeling. Voorlopige resultaten van de behandeling met rituximab 
suggereren dat dit middel effectief en veilig is voor patiënten met MCD. Op basis van deze 
gegevens zullen gerandomiseerde gecontroleerde onderzoeken met rituximab verricht worden.
In Hoofdstuk 9 gaven wij een overzicht van het onderzoek naar de effectiviteit van diverse 
afweeronderdrukkende medicamenten bij patiënten met een idiopathisch nefrotisch syndroom 
ten gevolge van membraneuze nefropathie. In gerandomiseerde gecontroleerde onderzoeken is 
aangetoond dat een behandeling met cytotoxische middelen (cyclofosfamide en chloorambucil) 
leidt tot een remissie van het nefrotisch syndroom en een veel lagere kans op bereiken van het 
eindstadium nierfalen op de lange termijn. De middelen ciclosporine en tacrolimus, al dan niet 
in combinatie met prednison, hebben ook een gunstig effect op de proteïnurie en het behoud van 
de nierfunctie. Het is echter niet definitief bewezen dat deze middelen het eindstadium nierfalen 
voorkomen. Hetzelfde geldt voor mycofenolzuur en rituximab. Alle genoemde medicamenten 
kunnen ernstige bijwerkingen en complicaties teweeg brengen. Op termijn gaat het nefrotisch 
syndroom bij de helft van de patiënten met een membraneuze nefropathie spontaan in remissie 
en blijft de nierfunctie behouden. Bij de andere helft zal een aanhoudend nefrotisch syndroom 
zonder afweeronderdrukkende behandeling uiteindelijk leiden tot het eindstadium nierfalen. Het 
streven is om de twee groepen in een vroeg stadium te onderscheiden en alleen de patiënten met 
een hoog risico op het eindstadium nierfalen te behandelen met afweeronderdrukkende middelen. 
Dit zal leiden tot een maximaal behoud van de nierfunctie bij alle patiënten, een kortere duur 
van het nefrotisch syndroom, en vermijden van overbehandeling met afweeronderdrukkende 
middelen. Er zijn twee prognostische modellen ontwikkeld om de uitkomst van membraneuze 
nefropathie te voorspellen. Eén model is gebaseerd op meting van eiwitten in de urine die wijzen 
op schade aan de niertubuli (nierbuisjes), zoals alfa-1-microglobuline (α1m) en beta-2-microglobuline 
(β2m). Het andere model is gebaseerd op herhaalde metingen van de nierfunctie en de totale 
hoeveelheid proteïnurie gedurende een periode van tenminste 6 maanden. Het is aangetoond dat 
beide modellen de uitkomst redelijk nauwkeurig voorspellen. Verbetering van de prognostische 
modellen is echter nodig om een vroege start van afweeronderdrukkende behandeling te 
rechtvaardigen. De urine eiwitten kidney injury molecule-1 (KIM-1) en neutrophil gelatinase-
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associated lipocalin (NGAL) zijn vroege markers van schade aan de niertubuli. In Hoofdstuk 10 
onderzochten wij de afzonderlijke en toegevoegde waarde van deze markers ten opzichte van het 
model met α1m- en β2m-bepalingen. De uitscheiding van KIM-1 en NGAL werd gemeten in 
de urine van 69 patiënten met membraneuze nefropathie en een normale nierfunctie. Eerder was 
de uitscheiding van α1m en β2m al gemeten. Progressie van de ziekte trad op bij 30 patiënten 
(44%), en spontane remissie bij 36% (52%). Zowel KIM-1 als NGAL voorspelden ziekteprogressie 
met AUC-waarden onder de ROC-curves van respectievelijk 0.75 en 0.74. Dit betekent dat het 
redelijke voorspellers zijn. KIM-1 en NGAL verbeterden de bestaande predictiemodellen met 
α1m of β2m echter niet. Een subgroepanalyse suggereerde dat meting van KIM-1 en NGAL kort 
na het stellen van de diagnose mogelijk wel meerwaarde heeft. Dit moet in een groter onderzoek 
worden aangetoond. Naast de bepaling van eiwitten in de urine zal meting van antistoffen tegen 
de fosfolipase A2 receptor in de toekomst waarschijnlijk een belangrijke rol gaan spelen bij de 
diagnose en behandeling van membraneuze nefropathie.
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